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SUMMARY
Biosynthesis of the complement regulatory proteins Cl-INH, 
C4-bp, factor H, factor I, S protein, SP-40,40, DAF, MCP, CD59 and CR1 
has been investigated in synovial membrane tissue cultures obtained 
from normal individuals, and patients with osteoarthritis (OA) and 
rheumatoid arthritis (RA) by a combination of immunological and 
molecular biological techniques. Normal, OA and RA synovial membranes 
were capable of synthesizing this battery of regulatory complement 
proteins. The abundances of the mRNAs encoding the classical and 
alternative pathway secreted proteins were elevated in RA synovium as 
was that of CD59 mRNA. However, tissue samples were small and they 
may not reflect the whole situation in RA joints.
The cells present in synovial membrane, endothelial cells,
monocytes, synovial fibroblasts and peripheral blood lymphocytes, were
cultured and investigated in order to find which cell types provide which
regulatory proteins detected in synovial membrane. Cell-specific
differences were observed in the regulatory complement proteins
synthesized. ELISA, immunohistochemical staining, Northern blot and
doubling-dilution dot-blot analysis showed that both monocytes and
fibroblasts expressed nine, endothelial cells expressed eight and
lymphocytes expressed six of the eleven components under standard
culture conditions. All of the cell types investigated synthesized factor H,
DAF, MCP, CD59 and MIP. Endothelial cells and fibroblasts did not
synthesize C4-bp and CR1. Also cell-specific differences/observed in the _ . Lwere.
amounts of secretion for some proteins.
Furthermore, cell specific differences were, observed for the 
expression of different mRNA species of DAF, MCP and CD59 between 
endothelial cells and fibroblasts.
The effect of a cytokine, interferon-y (IFNy), on the synthesis of 
these complement regulatory proteins was also investigated. Treatment 
of endothelial cells with IFNy caused an increase of transcription rate of 
DAF, MCP and CD59 but this did not correlate with the protein levels on 
the cell surface detected by flow cytometry.
This study indicated that complement regulatory protein synthesis 
is constitutive and varies between the different types of cells in synovial 
membrane. To some extend, the amounts of some complement regulatory 
proteins is regulated by IFNy.
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ABBREVIATIONS USED IN THIS THESIS
C l First component of complement
C lq , C lr, C ls Sub-components of C l
Cl-INH Inhibitor of activated C l
C2 Second component of complement
C2a, C2b Fragments of C2
C3 Third component of complement
C3a Anaphylatoxin fragment of C3
C3b Largest fragment of C3
C3bi Inactivated C3b
C3c, C3d, C3e Fragments of C3
C3dg C3bi fragment produced by control proteins
C4 Fourth component of complement
C4a, C4b Fragments of C4
C4bp C4 binding protein
C5 Fifth component of complement
C5a Anaphylatoxin fragment of C5
^ d e s  Arg Desarginyl derivative of C5a
C5b Largest fragment of C5
C6 Sixth component of complement
C7 Seventh component of complement
C8 EightWomponent of complement
C9 Ninth com. ponent of complement
DAF Decay accelerating factor
MCP Membrane cofactor protein
HRF Homologous restriction factor
M IP Membrane inhibitory protein
CR1 Complement receptor type 1 
(binds C3b and C4b)
CR2 Complement receptor type 2
(binds C3d, C3dg and C3bi)
CR3 Complement receptor type 3 
(binds C3bi)
CR4 Complement receptor type 4
CR5 Complement receptor type 5
H Factor H
I Factor I
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D Adipsin
S S Protein or vitronectin
SP-40,40 Clustrin
IgA Immunoglobulin class A
IgG Immunoglobulin class G
IgM Immunoglobulin class M
MHC Major histocompatibility complex
DNA Deoxyribonucleic acid
cDNA Complementary DNA
RNA Ribonucleic acid
mRNA Messenger RNA
tRNA Transfer RNA
rRNA Ribosomal RNA
SCR Short consensus repeat
RCA Regulators of complement activation
kb Kilobases
kD a Kilodalton
HSA Human serum albumin
PMN Polymorphonuclear leucocyte
RA Rheumatoid arthritis
OA Osteoarthritis
IFNy Interferon gamma
IFN a Interferon alpha
EL-1 Interleukin one
IL-6 Interleukin six
MOPS Sodium morpholino propanesulphonic acid
T ris Tris hydroxymethyl-methylamine
w/v Weight per volume
v/v Volume per volume
FCS Foetal calf serum
HUVEC Human umbilical vein endothelial cells
PHA Phytohaemagglutinin
PWM Pokeweed mitogen
Con A Concafl&stoliflA
CHX Cycloheximide
PCR Polymerase chain reaction
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CHAPTER 1. INTRODUCTION
1.1 INFLAMMATION
1.1.1. Definition of Inflammation
Inflammation is defined as a localized protective event, elicited by 
injury, which serves to destroy, dilute or wall off both injurious agent and 
the injured tissues. It involves a complex series of events, including 
dilatoW* of arteries, capillaries and venules, with increased blood flow and 
vascular permeability and exudation of body fluids and plasma proteins. 
These processes are often rapidly followed by the adhesion of leucocytes 
to the vascular endothelium with a subsequent influx of the cells into the 
surrounding tissues.
The various mediators which regulate local blood flow and the cells 
of the inflammatory response are discus^d below.
1.1.2. Inflammatory Mediators
The components which mediate inflammatory reactions are derived 
from the complement system, lymphocytes, granulocytes, mast cells and 
platelets, causing an increase in blood flow and vascular permeability.
The immune system can initiate acute inflammatory reactions 
either via the classical complement pathway which is activated by 
antigen-antibody complexes containing IgG or IgM antibodies, or by 
recruiting mast cells by sensitizing them with IgE so that they are 
triggered following contact with antigen. The anaphylatoxins C3a, C4a 
and C5a also trigger mast cells and basophils. C5a is chemotactic for, and 
activates, neutrophils and macrophages. Eicosanoids released from the 
mast cells affect the local vasculature, and leukotriene B4 (LTB4) is itself 
chemotactic. Additional eicosanoids are produced by the macrophages
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themselves, as well as by the local endothelium. Once present at the site 
of inflammation, inflammatory cells (granulocytes, macrophages, 
lymphocytes) come under the additional controls of cytokines including 
interferon y (IFNy), tumor necrosis factor (TNF) and interleukin-1 (IL1). 
Macrophages and lymphocytes are of particular importance in chronic 
inflammatory reactions. The mediators of inflammation are summarized 
in Table 1.1.
According to its duration, inflammation is classified as acute or 
chronic.
1.1.3. Acute Inflammation
There are three main events in the acute inflammatory process.
1) Vasodilatation and changes in the blood flow: a transient 
vasoconstriction of the arterioles occurs immediately after the injury and 
is followed by vascular dilatation affecting arterioles mainly but also to a 
lesser extent the venules and the capillaries. Blood flow through the 
injured tissue is increased immediately after the injury, but is followed by 
slowing of blood flow and stasis. Decreased blood flow is thought to be due 
to increased blood viscosity.
2) Exudation of plasma: contraction of the endothelial cells 
increases vascular permeability. This permits large molecules to traverse 
the endothelium and allow? the soluble plasma mediators of immunity 
(e.g. complement, antibody) to reach the damaged tissue.
3) Emigration of neutrophil leucocytes: increased migration of cells 
from the blood vessels into the affected area occurs following their 
adhesion to endothelial cells, their emigration out of the vessel by 
insinuating themselves between the endothelial cells and finally, their 
movement through the tissues to the site of inflammation along a
3
Table 1.1. MEDIATORS OF INFLAMMATION
Mediator Sources Activators Principle effects
Bradykinin High mol
weight
kininogen
Factor XHa
kallikrein
proteases
vasodilatation
increased
vascular
permeability,pain
Histamine mast cell,
basophil,
granules
IgE,antigen 
anaphylatoxin
vasodilatation
increased
vascular
permeability,
spasmogenic
chemokinesis
C3a,C5a complement
system
C3 and C5 
convertases
proteases
mast cell
degranulation
chemotaxis
increased
vascular
permeability.
Platelet
Activating
Factor
(PAF)
basophils
neutrophils
macrophages
depends on 
cell type
platelet factor
release,spasmogen
neutrophil
activation
increased
vascular
permeability
Eicosanoids 
(see below)
macrophages 
monocytes 
endothelial cell 
mast cell 
basophils.
many inducers modulate effects 
of other mediator 
vasoactive
p g e 2 cyclo-
oxygenase
pathway
many inducers vasodilatation 
potentiates LTB4, 
C5a, bradykinin, 
5-HT effects
PGI2 cyclo-
oxygenase
pathway
many inducers vasodilatation 
blocks platelet 
aggregation 
broncho- 
constriction
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Table 1.1. MEDIATORS OF INFLAMMATION (continued)
Mediator Sources Activators Principle effects
TxA2
LTB4
LTD4
Interleukin 1 
(IL-1)
Interferony
(IFNy)
Tumour
Necrosis
Factor
(TNFa,p)
cyclo- many inducers
oxygenase
pathway
lipo- many inducers
oxygenase
pathway
lipo- many inducers
oxygenase
pathway
macrophages macrophage 
activators 
(e.g. C5a)
T cells antigen
macrophages bacteria 
lymphocytes protozoa
some tumour 
cells
vasoconstriction
platelet
aggregation
broncho-
constriction
chemotaxis
modulates
increased
vascular
permeability
spasmogen 
increa se 
vascular 
permeability 
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chemical gradient, a process called chemotaxis. Activation of the 
neutrophils facilitates phagocytosis, bacterial killing and the degradation 
of phagocytosed material.
Acute inflammatory foci contain mostly polymorphonuclear 
leucocytes, whereas regions of chronic inflammation contain a high 
proportion of lymphocytes and macrophages, and possibly epith'i Mold and 
giant cells.
1.1.4. Chronic Inflammation
Inflammation is said to be chronic when its duration is relatively 
prolonged for months or years. The tissues are infiltrated by several types 
of cells such as mononuclear phagocytes, lymphoid cells, fibroblasts, and 
endothelial cells. In addition there may be granulocytic leucocytes, 
particularly eosinophils. Mononuclear phagocytes are present as 
macrophages, epithelioid cells, or multinucleated giant cells. Lymphoid 
cells are present as lymphocytes, plasma cells or immunoblasts. 
Fibroblasts produce collagen and ground substance and proliferate to 
form more fibroblasts. Endothelial cells migrate and proliferate forming a 
rich neovascular network necessary for the maintenance of the 
inflammatory response. One of the most important components of chronic 
inflammation is the macrophage' and its derivatives. They recognize 
material to be phagocytosed by means of their surface receptors which 
include the complement receptors C3b and iC3b and the Fc portion of 
IgG. By facilitating recognition and phagocytosis, complement acts as an 
opsonin. Macrophages also present antigen to lymphocytes. Finally, they 
have potential microbial effector mechanisms such as reactive oxygen 
intermediates (.OH, O*, O2" and H2O2), toxic oxidants produced by 
interaction of H2O2 on halides in the presence of peroxidase catalase,
6
phagosome acidification, lysosomal enzymes and growth inhibitors,
including lactoferrin and arginase. Necrosis is a common feature of
chronic inflammation which may be associated with the formation of
granulation tissue and fibrous tissue. A proliferative type of lesion may 
tr
result and is called "granuloma".
Rheumatoid arthritis is an example of CV chronic inflammatory 
disease and it is discussed in more detail below.
1.1.5. Rheum atoid A rth ritis
Rheumatoid arthritis is a chronic progressive inflammatory 
arthritis of unknown aetiology which affects principally the joints and is 
characterized by the tendency to spontaneous remissions and subsequent 
relapses. It is two to three times more frequent in females and usually 
involves the small joints of the hands and feet.
1.1.5.1. Pathologic anatom y
The basic tissue changes of rheumatoid disease are not specific but 
in combination they give a fairly typical and diagnostically suggestive 
picture. Several features which characterize the rheumatoid lesion are as 
follows.
1. Diffuse or focal infiltration of the tissue by lymphocytes or 
plasma cells or both, with the development of lymphoid follicles.
2. Vasculitis with endothelial proliferation, narrowing or occlusion 
of the lumen^brinoid change or necrosis of the walls and perivascular 
aggregation of lymphocyteSand plasma cells.
3. The rheumatoid granuloma, a focal lesion with an amorphous 
center composed of necrotic tissues.
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1.1.5.2. Immunogenetics in rheum atoid arth ritis
Susceptibility to rheumatoid arthritis (RA) is linked to genes 
within the major histocompatibility complex (Payami et al., 1986). 
Patients with classical or definite disease, 70% eitoW- either HLADR4 or 
DR1 (Nepom et al., 1989; Wordsworth et al., 1989).The high association 
with RA appears to reside in the specific sequences in the third 
hypervariable region of the HLA-DR (31 chain (Wordsworth et al., 1989). 
However this association is not absolute since there are some patients 
who lack DR4 or DR1. Wordsworth et al. (1991) have shown a significant 
association with DRwlO in the DR4/DR1 negative RA group.
Evidence that immune processes are important in the development 
of the rheumatoid lesion can be summarized as follows.
1) The presence of IgG, IgA, IgM in synovial fluid, in synovial 
lining cells and in the articular cartilage.
2) The presence of antigen-antibody complexes in synovial fluid 
and synovial tissue.
3) The presence of rheumatoid factor (RF), IgM antibody reactive 
the Fc portion of IgG, in the plasma cells in synovial tissue.
4) The presence of activated complement components in synovial 
fluid, in synovial tissue, in macrophages, in the interstitial connective 
tissue and synovial lining cells. This is asssociated with decreased levels 
of complement components in the synovial fluid.
In addition, the presence of other autoantibodies in the sera of 
patients (e.g. antinuclear antibodies and antibodies to type II collagen) is 
fu rtb1 r evidence that autoimmune processes are involved in the 
pathogenesis of RA.
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1.1.6. Osteoarthritis
Osteoarthritis (OA) is a non-inflammatory disorder of the synovial 
joints. OA characterized by the degenerative changes in articular 
cartilage and by overgrowth of subchondral and juxta-articular bone and 
intra-articular soft tissues.
The aetiology of osteoarthritis is multifactorial. But primary and 
secondary osteoarthritis must be distinguished although morphologically, 
the two types are indistinguishable. Secondary osteoarthritis is often 
post-traumatic in origin due to malalignment of a joint due to congenital 
malformations, fractures or the deposition of extraneous injurious 
material within the articular tissues. Genetic (increased familial 
incidence), hormonal (increased severity of OA associated with 
acromegaly and diabetes) and nutritional factors (frequent coexistence of 
OA and obesity) and age have been shown to determine the susceptibility 
of the articular cartilage to becoming arthritic (Altmann et al., 1986).
1.2. THE COMPLEMENT SYSTEM
The initial discoveries leading to the understanding of complement 
were made about a century ago. Grohman (reviewed by Colten, 1976) 
reported that cell-free blood was capable of destroying bacteria in vitro. 
This lytic activity was shown to be lost when the blood was stored at room 
temperature, incubated at 55 °C, or dialysed against distilled water. At 
the same time, progress was made leading to the discovery of serum 
antibodies and the subsequent division of bactericidal activity of serum 
into two factors: 1) a heat-stable factor confined to immune sera and 2) a 
heat-labile factor constituting the bactericidal entity itself (quoted by
9
Morgan, 1990). The sequential nature of the two factors was elucidated 
by Erlich and Morgenroth (Bouldan, 1910), whose studies led to the 
concept that a specific antibody reacted with a target acceptor and than 
activated the lytic activity of the second factor. They first termed the 
second factor "alexin" but later introduced the term "complement" as it 
complemented antibody function. Over the next few years an intense 
debate developed concerning the nature of complement and its interaction 
with antibodies, the main protagonists being Bordet and Erlich 
(reviewed in Morgan, 1990).
The complement system has evolved as the major humoral defense 
mechanism against infection, and complement activation products 
mediate many of the processes of inflammation. These include 1) the 
binding of fragments of the third component (C3) to the surfaces of the 
microorganisms or other antigens targets them to cells expressing C3 
receptors {e.g. phagocytes); 2) chemotactic factors (C5a and C5a^es ^.g) 
recruit phagocytic cells to the area where complement activation takes 
place; 3) cell killing is mediated through the formation of the C5b-9 
membrane attack complex.
An essential requirement for such a destructive capacity to exist in 
vivo is the existence of stringent control mechanisms. Multiple inhibitory 
and control proteins influence virtually every stage of the complement 
system, preventing excessive activation and damage to host cells.
1.2.1. Nomenclature
The proteins of the classical activation pathway and the membrane 
attack pathway are called "components" and are symbolized by the letter 
"C" followed by a number, e.g. Cl, C4, C2, C3, C5, C6 , C7, C8 , C9.
The proteins of the alternative activation pathway are termed 
"factors" and are symbolized by letters, e.g. B, D, P.
The control proteins are referred to with contraction of their trivial 
names e.g. C l inhibitor (Cl-INH), C4-binding protein (C4-bp).
The enzymically active form of components are denoted by a bar 
over the number i.e. Cl. Cleavage fragments are denoted with suffixed 
lower case letters e.g. C3a, C3b, C3c, C3d. Polypeptide subunit chains are 
suffixed with Greek letters starting with the largest chain, e.g. C3a and 
C3p.
1.3. THE ACTIVATION OF COMPLEMENT SYSTEM
The complement system consists three interacting pathways:
1) the classical pathway;
2) the alternative pathway;
3) the membrane attack sequence.
1.3.1. The Classical Pathway
Immune complexes containing antibodies of either IgG (subclasses 
IgGl, IgG2 and IgG3) or IgM initiate classical pathway activation (Figure 
1.1). The classical pathway consists of four plasma proteins, C l, C4, C2 , 
C3 (Table 1.2).
The first component of complement is a large Ca^+-dependent 
complex composed of one molecule of Clq and two molecules each of C lr 
and Cls (Lepow et al., 1963).
Clq, the recognition unit of the classical pathway, is a multichain 
molecule consisting of a central stem which separates into six fibrillar
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stalks each of which terminates in a globular head, giving it the 
appearance of a bunch of tulips (Knobel et al., 1975). The globular head 
region of Clq binds to specific sites in the Fc region of the IgG and IgM. 
IgG3 is the IgG subclass which binds Clq most efficiently, followed by 
IgGl and IgG2 (Lucisano-Valim and Lachmann, 1991). IgG4 does not 
appear to bind Clq. Complexes of polycations with polyanions such as 
protamine with heparin, or C polysaccharide with C-reactive protein 
(CRP), bacterial lipopolysaccharide and myelin are also capable of 
binding Clq and activating C l (Claus et al., 1977).
Binding of Clq to immunoglobulins or other activators classical 
pathway initiates conformational changes within both C lq and C lr, 
resulting in the expression of neoantigens on Clq and of proteolytic 
activity by Clr. Activated C lr (Clr) activates C ls by producing a single 
proteolytic cleavage (Arlaud et al., 1987) (Figure 1.1).
Activated C ls (Cls) cleaves C4 at a single site in the a  chain, 
thereby releasing a 77 amino acid (8 kDa) N-terminal fragment, C4a, 
(Gorski et al., 1979) which is a weak anaphylatoxin. The remaining 
fragment, C4b, contains an internal thiolester group in the a  chain which 
is exposed during Cls cleavage. This thiolester provides a binding site 
permitting the covalent binding of C4b to surfaces. The thiolester is 
extremely labile, being active for only a few microseconds and decays as a 
result of hydrolysis if C4b does not encounter a suitable surface. Only 
about 5% of C4b actually becomes bound to the activating surface, and 
the distribution is limited to a small area around the activating C l 
complex.
C4 occurs in two structurally and functionally distinct isotypes, 
C4A and C4B, each of which are encoded by distinct genes (Carroll et al., 
1984). C4A reacts preferentially with amino groups, C4B with hydroxyl 
groups.
1 3
IMMUNE COMPLEXES
C1q C3+ +
Ca
C1r C1r 
C1 s —^  C1 s
C4b2aC4b C2
C4
□
C2b
C3b
C2C4a
Figure 1.1! Sum m ary of the classical pathw ay. Binding of Clq to 
immune complexes activates C lr and Cls. CJTs cleaves C4a from C4 
which binds C2 in the presence of Mg++. Cls cleaves C2b from this 
complex to leave a classical pathway C3 convertase (C4b2a) (Adapted 
from Roitt et al., 1990).
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C2 binds to C4b and subsequently becomes a substrate for Cls. It 
is cleaved into two fragments C2a (85 kDa) and C2b (35 kDa) (Polley and 
Muller-Eberhard, 1968). Although C l can cleave free C2 , the efficiency of 
cleavage is greatly enhanced when C2 is bound to an adjacent C4b 
molecule. C2a associates with C4b to form the C4b2a complex, the 
classical pathway C3 convertase. C2b may be released into fluid phase or 
it may remain loosely attached to the C4b2a complex (Ziccardi and 
Cooper, 1980; Gigli and Austen, 1969) (Figure 1.1).
C3 is the complement component which is present in highest 
concentration in plasma (1.5 mg/1) and is of central importance. It is 
involved in both classical and alternative pathways. Both the classical 
and the alternative pathway C3 convertases (C4b2a and C3bBbP) 
respectively cleave C3 in the fluid-phase. This cleavage releases a small 
N-terminal fragment, C3a (9kDa), which is an important anaphylatoxin, 
and a large fragment, C3b, which has°thiolester group which can bind the 
hydroxyl or amino groups on surfaces, forming ester or amide bonds 
respectively (Law and Levine, 1977) (Figure 1.1). The thiolester has an 
extremely short life (approximately 60 ms) and if it does not bind to a 
surface by that time, the thiolester bond undergoes hydrolysis and C3b 
becomes inactive fluid-phase C3b. Thus, although each C4b2a complex 
can activate several hundred C3 molecules, only approximately 10% of 
C3b molecules bind to surfaces. C3b which binds to C4b in C4b2a alters 
the specificity of the enzyme to that of a C5 convertase (C4b2a3b). This 
occurs because C3b in C4b2a3b act as a receptor for C5 and presents C5 
to C2a for activation (Medicus et al., 1976).
1.3.2. The A lternative Pathway
The addition of polysaccharides such as the yeast cell wall extract,
congenitally deficient of either C4 or C2 leads to cleavage of C3 and to the 
assembly of the membrane attack complex by a mechanism tha t is 
independent of the classical activation pathway. IgA is also thought to be
the activator o ternative pathway. IgG2 is the best IgG subclass for 
alternative pathway activation but requires high epitope density and 
equivalence or antibody excess (Lucisano-Valim and Lachmann, 1991). 
This pathway comprises six plasma proteins (Table 1.3), three of 
which form the C3 and C5 convertases (C3, factor B and factor D) while 
properdin has a positive regulatory property (Gotze and Muller Eberhard, 
1974) and factor H and I are negative regulators (Whaley and Ruddy, 
1976; Pangburn et al., 1977). Phylogenetically the alternative pathway is 
older than the classical pathway.
The alternative pathway continuously undergoes low-grade 
spontaneous non-enzymatic activation (Lachmann and Hughes-Jones, 
1984). This activation occurs because of spontaneous hydrolysis of the 
internal thiolester of C3 to form a C3 derivative molecule, C3(H2 0 ). 
Apart from its inability to bind covalently to surfaces, C3(H2 0 ) is 
functionally equivalent to C3b. In the presence of magnesium ions, 
C3(H2 0 ) binds to B in the fluid-phase, rendering it susceptible to 
cleavage activation by D and thereby forming a low efficiency fluid phase 
C3 convertase C3(H2 0 ), Bb (Fearon et al., 1974; Pangburn and Muller- 
Eberhard, 1984) (Figure 1.2). Unlike C3b, C3(H20) is relatively resistant 
to the control proteins, H and I.
Factor B is the alternative pathway homologue of C2. Upon 
binding to activated C3, it is rendered susceptible to cleavage by factor D,
zymosan or Gram-negative bacterial endotoxin to the serum of animals
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Mg.. I
AC3b B J i
t
©
A
C3
Mg
\ J
C 3 b B b
C3b
E>
Figure I.2.* A lternative pathway. In the presence of Mg++ ions C3b 
binds to B, rendering it susceptible to cleavage by factor D and thereby 
forming an alternative pathway C3 convertase (C3bBb). Properdin binds 
to C3bBb and stabilizes the C3 convertase (Adapted from Roitt et al., 
1990).
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exist in plasma as an active serine protease present in its active state in 
the fluid phase. Cleavage of B releases a 33 kDa fragment, Ba, which may 
have mitogenic activity. The Bb, 60 kDa fragment has serine protease 
activity and like C2 is capable of cleaving C3 and C5 (Lambris and 
Muller-Eberhard, 1984).
The spontaneously generated fluid-phase convertase C3(HaO)Bb 
cleaves C3 in precisely the same way as the C4b2a complex, releasing 
the anaphylatoxin C3a and exposing the thiolester binding site on C3b. 
C3b formed in this way binds to any surface it encounters during the 
lifetime of its binding site. Thus, C3b is deposited continuously in a 
random and nonspecific way on the surfaces of host cells and pathogenic 
organisms alike. C3b which is bound to nonactivating surface {e.g. host 
cells) is rapidly inactivated by the control proteins H and I (Figure 1.3), 
whereas C3b bound to an activating surface is protected from these 
factors (H and I) and therefore persists and binds B to form a membrane 
bound C3bBb (Fearon and Austen, 1977; Pangburn and Muller-Eberhard, 
1978). The bound C3bBb complex can then cleave more C3, initiating a 
positive feedback cycle which rapidly amplifies the amount of C3 bound to 
the activator and the amount of anaphylatoxin generated. The control of 
such a potentially explosive cycle is achieved by the spontaneous decay of 
C3bBb complex (half-life of seconds at 37 °C) and by the action of control 
proteins H and I.
Although C3b is already present in the C3 convertase C3bBb a
second C3b must bind to the original C3b to form a C5 convertase. This
second C3b in "C3bBbC3b" acts as the C5 receptor and presents C5 for
the activation by Bb (Medicus et al., 1976; Schreiber et al., 1975).
>
C3bBbC3b cleaves C5 Exactly the same site as does C4b2a3b.
C3
iC3b
C3b C3b
NON-ACTIVATOR SURFACE
C3bBb
C3b
ACTIVATOR SURFACE
Figure 1.3: R egulation of the am plification loop. C3b which has 
bound to an activator surface binds factor B and an alternative pathway 
C3 convertase (C3bBb) is generated. C3b which has bound to self surfaces 
promote the binding of factor H rather than  factor B, thus C3b becomes 
inactivated by factor I (Adapted from Roitt et al., 1990).
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Properdin binds to C3bBb and stabilizes the alternative pathway 
C3 and C5 convertases by slowing the rate of decay of Bb from the 
complex (Fearon et al., 1975; Czop et al.,1978).
1.3.3. The Membrane Attack Sequence
The membrane attack sequence compromises of five complement 
components C5, C6, C7, C8 and C9 (Table 1.4). Cleavage of C5 by the 
convertases of either pathway is the final enzymatic step in the 
complement activation cascade.
C5 consists of two disulphide-linked polypeptide chains. C2a in the 
C4b2a3b complex, Bb in the C3BbC3b complex cleave C5 at a single site 
in its a-chain, releasing a 74 amino acid N-terminal fragment, C5a 
(12kDa), which has important anaphylactic and chemotactic activities. 
The major cleavage product C5b expresses a labile membrane binding 
site which is not present on native C5. This allows C5b to bind weakly 
and reversibly to cell membranes. Another binding site recognizes C6 
which, if it binds within a few minutes, stabilizes the low affinity 
membrane binding site. However, as the membrane binding site is of low 
affinity, the C5b6 complex may be released into the fluid-phase and binds 
to cell membranes distal to the site of complement activation. As the 
haemolytic potential of complex is preserved, damage to cells outside the 
area of the original injury may occur (reviewed by Muller, 1986).
Binding of C6 creates a stable complex with weak membrane 
binding properties and the capacity to bind C7, a single chain protein of 
110 kDa. Binding of C7 causes a major conformational change; in the 
complex, which effects its release from the C5 convertase and exposes a 
hydrophobic membrane binding site. If the C5b67 does not encounter a 
membrane rapidly, it self-aggregates and interacts with inhibitory
21
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proteins (S protein and SP-40,40) in the fluid-phase so that membrane 
insertion cannot occur (Podack et al., 1978, 1984; Kirszbaum et al., 1992) 
(Figure 1.4).
As mentioned earlier, C5b6 can dissociate from the target cells and 
bind to host cells. The subsequent binding of C7, C8 and C9 leads to 
"bystander lysis". Alternatively, C7 may bind to C5b6 in the fluid-phase 
and then bind to cells in the immediate vicinity. The subsequent binding 
of C8 and C9 leads to "reactive lysis" (Lachmann and Thompson, 1970). 
Once inserted into the membrane, the C5b-7 complex becomes a stable 
membrane protein although cytolysis does not occur until C8 and C9 have 
been incorporated (Figure 1.4).
C8 comprises three polypeptide chains a, P, y. The a  and y chains 
are disulphide-linked, while the p chain is noncovalently bound. C8 binds 
to C5b67 complex via a binding site in the C8 p chain. The incorporation 
of the C8 to the C5b67 complex causes the complex to become more deeply 
embedded in the membrane making it slightly leaky. The leak may be 
sufficient to cause slow lysis of metabolically inert targets like aged 
erythrocytes but actively metabolizing cells are resistant by virtue of 
their ion pumps (reviewed in Morgan, 1990).
C9 consists of a single polypeptide chain. Binding of C9 to the a- 
chain of C8 initiates a major conformational change in C9 allowing it to 
insert deeply into the membrane (Stewart and Sodetz, 1985). Once the 
first molecule of C9 has bound to C5b-8, a second molecule binds and 
undergoes the same conformational change. This process continues until 
a complete cylinder of poly-C9 (containing between 12 and 18 molecules) 
has been formed (Stanley, 1988) (Figure 1.5). This cylinder traverses the 
cell membrane and has an everted lip at its outer aspect. In anuclear 
cells, the formation of transmembrane channels occurs through the centra 
of the cylinder and the passage of water and electrolytes ensures that cell
23
CLASSICAL PATHWAY ALTERNATIVE PATHWAY
C l, C4, C2, C3 C3, B, D, P
 ^ 4
S P rote inC7
C6 SP40-40
C9
C5b
C8
C6C6 C6
C5b C5b C5b
C7 C7 C7
C8C8
C5b67 C5b678
Figure 1.4: G eneration of m em brane a ttack  complex. The major 
cleavage product of classical and alternative pathway C5 convertases 
(C4b2aC3b and C3bBbC3b respectively) is C5b. Binding of C5b to C6 
than Cl exposes a hydrophobic membrane binding site on C5b67 complex. 
The subsequent binding of C8 and C9 leads to formation of 
transmembrane channels. If the C5b67 does not encounter a membrane 
rapidly, it interacts with inhibitory proteins S protein and SP-40,40 in the 
fluid phase so that membrane insertion cannot occur (Adapted from Roitt 
et al., 1990).
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C9 UNFOLDING AND INSERTION
FORMATION OF MAC BY POLYMERIZATION OF C9
Figure 1.5! Polym erization of C9. Binding of C9 to the a-chain of C8 
initiates a major conformational change in C9 allowing it to insert deeply 
into the membrane. Once the first molecule of C9 has bound to C5b-8, a 
second molecule binds and this process continues until a complete 
cylinder of poly C9 has been formed (Adapted from Meri et al., 1990)
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death occurs by osmotic lysis. In nucleated cells the mechanism of lysis is 
less well understood. Multiple molecules of poly-C9 damage the 
membrane directly, but in addition influx of Ca^+ and ATP depletion 
occur, suggesting that cell death may be a metabolically active process 
(Morgan, 1989).
1.4. THE BIOLOGICAL ACTIVITIES OF COMPLEMENT SYSTEM
1.4.1. Cytolysis
Membrane attack complex polymerized C9 forms cylindrical 
structures. The insertion o f  large number of membrane attack complexfe 
into cell membranes disrupts the membrane and eventually uncontrolled 
electrolytes and water flux results in osmotic swelling and subsequent 
lysis.
1.4.2. Increased Vascular Perm eability
The anaphylatoxins C4a, C3a and C5a increase vascular 
permeability, C5a being the most potent and C4a the least. C3a and C5a 
act on mast cells to release histamine (Johnson et al., 1975). However, as 
C5a induces smooth muscle contraction independently of histamine 
release (Regal et al., 1980), it is possible that it also has a direct effect on 
the endothelial cells of the microcirculation. Additionally, the contraction 
of the endothelial cells opens up the intercellular gaps which increases 
plasma exudation.
1.4.3. Neutrophil Adhesiveness
In order to emigrate through blood vessel walls to the sites of 
inflammation, neutrophils must first adhere to the vascular endothelium. 
It has been shown that C5a and desarginyl dervative of C5a, CSa^g ^ .g , 
act on neutrophils and promote their adherence to endothelial cells. It is 
possible that the diffusion of C5a and or CSa^gg p^g products through the 
walls of the microcirculation during vascular stasis results in the 
aggregation of neutrophils and their adherence to the vascular 
endothelium which is a prerequisite for their emigration (Tonnesen et al.,
1984)
1.4.4. Chemotaxis
The loss of C-terminal residue of C5 following cleavage by 
carboxypeptidase B produces C5a^eg pj.g which posess relative stability 
and it can diffuse long distances from the inflammatory site recruiting 
inflammatory cells from a wide area. Thus C5a and CSa^eg are 
potent chemotactic agents which attract neutrophils, eosinophils and 
monocytes at site of inflammation (Damerau et al., 1978; Fernandez et 
al., 1978).
1.4.5. Leucocytosis
A peptide derived from the a  chain of C3 causes an initial 
leucopenia followed by leucocytosis. This peptide, termed C3e, appears to 
be produced as a result of proteolytic cleavage of C3c by an unidentified 
plasma protease (Ghebrehi v it and Muller-Eberhard, 1979). Another 
fragment of C3 (C3d-K) which is produced by the proteolysis of iC3b by
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kallikrein also releases leucocytes from the bone marrow and inhibits T- 
cell proliferative responses. Although it is almost identical to C3dg, its N- 
terminal sequence of nine amino acids are not a part of the C3dg 
molecule. The C3e fragment probably contains the same sequence, which 
explains why they are both able to induce leucocytosis (Hoeprich et al.,
1985).
1.4.6. Phagocytosis
Microorganisms or antigen-antibody complexes coated with C3b 
are able to bind to the cells which possess receptors for this ligand. The 
C3b receptors on phagocytic cells promote phagocytosis and killing of 
microorganisms and the internalization and the degradation of immune 
complexes (Gigli and Nelson, 1968). CR1 is a receptor which is present on 
many blood cells and binds C3b. Erythrocyte CR1 may be involved in the 
removal of complement-coated antigen-antibody complexes from the 
circulation.
1.4.7. Lymphocyte Function
The presence of complement receptors on lymphocytes suggeststhat 
C3 cleavage products might influence immune responses. Studies on mice 
which had been complement depleted by the administration of cobra 
venom factor revealed that thymus-dependent antibody responses and 
the generation of B memory cells were impaired (Pepys, 1974; Klaus and 
Humphrey, 1976).
1.5. THE REGULATION OF THE COMPLEMENT SYSTEM
The control of complement activation is achieved by a combination 
of regulatory proteins and the spontaneous decay of active factors.
Regulatory proteins may act in the fluid-phase (Table 1.5) to 
prevent spontaneous or abortive activation; or on cell membranes (Table 
1.6) to protect host cells from the destructive action of complement. Some 
of the membrane proteins with regulatory activities may also act as 
receptors for complement activation products enabling the cell to respond 
to complement-coated particles (CR1) (Table 1.6).
Within the last decade, the amino acid sequences of the majority of 
the complement components and control proteins have been determined. 
This has provided new insights into the way the proteins interact with 
one another and, moreover, has revealed that homology exists within the 
system, which enables the components to be categorized according to 
their functional and structural similarities. In addition, the chromosomal 
localization of many of the genes has shown that genes encoding proteins 
with similar functions occur in groups. For example, pulse-field gel 
electrophoresis has recently revealed that MCP, CR1, CR2, and DAF as 
well as a  and p subunits of C4-bp are encoded by a 900 kb segment in 
order of MCP-CRl-CR2-DAF-C4-bp a-C4-bp p while the factor H gene is 
located at a distance of more than 500 kb from this group (Rey-Campos et 
al., 1988; Carrol et al., 1988; Bora et al., 1989; Pardo-Manuel et al., 1990). 
All of the members of this group are called "Regulators of Complement 
Activation" (RCA). They share short consensus repeats(SCRs) of 60 amino 
acids, characterized by a framework of four very highly-conserved 
cysteines and several other residues (reviewed by Klickstein et al., 1987). 
The number of the SCRs in each component varies: 4 for DAF and MCP, 8 
for C4-bp, 16 for CR2, 20 for factor H and 30 for CR1 (Figure 1.6).
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Figure 1.6f Regulators of com plem ent activation. All the members 
of this group share short consensus repeat (SCRs) of 60 amino acids 
characterized by a frame-work of four very highly conserved cystein and 
proline, glycin, phenylalanine and tryptophan residues. The num ber of 
the SCRs in each component varies: 4 for decay accelerating factor (DAF) 
and membrane cofactor protein (MCP), 8 for C4 binding protein (C4-bp), 
16 for CR2, 20 for factor H and 30 for CR1. TM, transm em brane domain; 
CYT, cytoplasmic domain; ST, serine/threonine-enriched area; G, 
glycolipid anchor; U, domain of unknown functional significance 
(Adapted from Hourcade et al., 1989).
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Although many of the members of the RCA group share the function of 
binding to C3, the SCRs are not directly homologous with this function. 
They are also found in other complement proteins, including C2 and B 
(three each) and C lr and Cls (two each), as well as in |5-2 glycoprotein I, 
a protein of unknown function, the IL-2 receptor, the leucocyte common 
antigen and factor XIII of the clotting system.
The functional, biochemical and genetic properties of the 
regulatory fluid-phase and the regulatory membrane proteins are 
discussed below (sections 1.5.1 and 1.5.2.).
1.5.1. Functional and  Genetic F eatu res o f th e  F luid-phase 
Regulatory P ro te ins
1.5.1.1. C l-inhibitor
Cl-INH is a member of the SERPIN superfamily of serine protease 
inhibitors (Table 1.5). It is able to inactivate several plasma serine 
proteases, including C lr and Cls. Cl-INH also inhibits certain enzymes 
in the coagulation, kallikrein and plasmin systems (Levy and Lepow, 
1959; Ratnoff et al., 1969).
Cl-INH binds covalently to the enzymatic site of C lr and Cls. The 
resultant Clr:Cls:Cl-INH complex (ratio 1:1:2) dissociates from the C l 
molecule, leaving Clq attached to the immune complex. This restricts the 
half-life of activated Cl to only about 20 seconds at physiological 
concentrations. Cl-INH also prevents spontaneous activation of fluid- 
phase C l probably by combining loosely with the molecule in plasma 
(Ziccardi, 1985).
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Genomic clones for Cl-INH have been isolated and characterized. 
The gene is 17 kb long with eight exons and seven introns and localized 
on chromosome 11 ( Davis et al., 1986; Carter et al., 1988).
Northern blot analyses of mRNA demonstrate a major 2.1 kb band 
(Bock et al., 1986).
1.5.1.2 . C4-binding pro tein
C4-bp is a glycoprotein (Table 1.5) composed of seven identical 
disulphide-linked 70 kD subunits (a chains) (Dahlback and Stenflo, 1981; 
Gigli et al., 1979). Each 70 kD unit of C4-bp which contains 48 kD 
chipiotryptic fragment possessCithe C4b binding and factor I cofactor 
activity (Nagasava et al., 1982; Fujita et al., 1985). C4-bp also contains a 
unique 45 kD P chain. It is disulphide-linked to the central core and 
contains a binding site for the vitamin K-dependent protein S (Hillarp 
and Dahlbach, 1988)
C4-bp regulates the classical pathway by acting as a cofactor to 
factor I in the degradation of C4b and by accelerating the decay of the C3 
convertase C4b2a (Fujita et al., 1978; Gigli et al., 1979). The major 
physiological role of C4-bp and factor H appears to be the inhibition of C3 
and C5 convertases in the fluid-phase, although these proteins 
undoubtedly contribute to the inhibition of C3b and C4b which are 
attached to the cell surfaces (Cooper, 1975).
The cDNA sequence studies demonstrated tha t the a  chain of 04- 
bp contains 549 amino acid residues (Chung et al., 1985). The N-terminal 
491 amino acids of C4-bp can be divided a t into eight internal homologous 
regions each approximately 60 amino acids long (SCRs) (Figure 1.6). 
Mouse C4-bp is 51% homologous to human counterpart although it lacks 
the equivalents of the human SCRs 5 and 6 . Since the mouse protein
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binds to human C4b as well as to mouse C4b and as it is an active 
cofactor in the cleavage of human C4-bp mediated by mouse I (Hourcade 
et al., 1989), it is unlikely that human SCR 5 and 6 are required to the 
expression of these activities.
Northern blot analysis indicated that the mRNA for C4-bp is 
approximately 2.5 kb long (Chung et al., 1985).
Recently Hillarp and Dahlback (1990) isolated and characterized 
full length cDNA clones for the ($ chain. The (3 chain contains five 
potential N-linked glycosylation sites. Northern blot analysis of human 
liver mRNA using P chain cDNA as a probe demonstrates a major mRNA 
species of approximately 1.0 kb (Hillarp and Dahlback, 1990). From the 
N-terminus, the p chain contains three tandem repeat units (60 amino 
acids long) which are homologous to those present in the a  chain. The O  
terminal region which is unrelated to the tandem repeats demonstrates 
sequence similarity with the corresponding region of the a  chain. In both 
a  and P chains these regions contain two cysteine residues which 
probably form the interchain disulphide bridges (Hillarp and Dahlback, 
1990).
1.5.1.3. Factor H
Factor H (formerly called piH) is a single-chain plasma and 
membrane-bound glycoprotein (Whaley and Ruddy, 1976) (Table 1.5). On 
limited digestion with trypsin, H is cleaved in a specific manner to give 
35 kDa (N-terminal) and 120 kDa (C-terminal) fragments (Alsenz et al., 
1984). The N-terminal 35 kDa fragment shows co-factor activity in the 
factor I-mediated conversion of C3b to iC3b while the remainder of the 
molecule is inactive in this respect (Alsenz et al., 1984). Factor H binds to 
C3b and prevents the binding of B and C5. As the affinity for C3b is
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higher than that of B, the formation of the alternative pathway C3 and 
C5 convertases is restricted (Figure 1.3). In addition, H will bind to C3b 
which is present in the C3 and C5 convertases of the alternative pathway 
and accelerate their decay by displacing Bb (Whaley and Ruddy, 1976).
The signal sequence of human factor H is similar to that of mouse 
factor H (Kristensen and Tack, 1986), having 11 out of 18 identities and 
three conservative replacements. The factor H amino acid sequence is 
arranged in 20 homologous repeating units based on a frame work of four 
invariant cysteine residues and highly-conserved acidic proline, 
asparagine, glycine, tyrosine, phenylalanine and tryptophan residues 
(Ripoche et al., 1988).
Three different species of human factor H mRNA (4.3 kb; 1.8 kb; 
1.4 kb) are expressed abundantly in the liver. The 4.3 kb mRNA which 
encodes the major factor H serum protein of 150 kDa was sequenced 
completely by Ripoche et al. (1988). The sequence of 1.8 kb mRNA shows 
that this species is largely identical to the 5' portion of the 4.3 kb mRNA 
and it appears that these two mRNAs arise by alternative splicing from a 
single gene (Schwaeble et al., 1991). Schwaeble et al. (1991) have also 
shown that the 1.4 kb factor H mRNA is the product of a distinct gene.
1.5.1.4. Factor I
Factor I is a serine proteinase, although it is not inhibited by di- 
isopropylfluorophosphonate, a general inhibitor of this class of enzyme 
(Table 1.5). Unlike the majority of plasma serine proteinases, factor I 
does not appear to have a circulating proenzyme form.
Human factor I is responsible for the cleavage of the a  chains of 
C4b and C3b in the presence of the cofactors such as H, C4-bp, CR1, CR2 
and MCP.
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The a  chain of C4b is cleaved by factor I at two sites resulting in 
the formation of C4d, an a  chain fragment which is covalently linked to 
the activating surface because it contains the thiolester and C4c, the 
fluid-phase fragment of a  chain, and the intact P and y chains (Pangburn 
et al., 1977). The first two cleavages of C3b by factor I liberates a 2 kDa 
C3f fragment and yields iC3b (Figure 1.7). Further cleavage of iC3b by 
factor I occurs, releasing a large fragment C3c, while a smaller piece, 
C3dg remains attached to the membrane (Lachmann et al., 1982).
Northern blot analysis of human liver mRNA probed with factor I 
cDNA indicated that the mRNA is about 2.4 kb (Catteral et al., 1987).
1.5.1.5. S  Protein
S Protein (vitronectin) (Table 1.5) is a plasma protein functioning 
as a regulator of the membrane attack complex (Podack et al., 1978).
Vitronectin binds to the exposed hydrophobic region of the newly 
formed C5b-7 complex to form the water-soluble SC5b-7 complex (Figure 
1.4). The SC5b-9 complex is incapable of membrane insertion and is 
therefore not cytolytic. C9 polymerization does not occur in SC5b-9 
(Podack et al., 1978; 1984; Podack and Muller-Eberhard, 1979; Bhakdi 
and Tranum-Jensen, 1982).
Recent studies strongly suggested that ionic interactions between 
the negatively charged "class A" cysteine-rich domain of terminal 
complement proteins and the heparin-binding region of S protein trigger 
the binding of S protein to nascent terminal complement complexes 
(Tschopp et al., 1988).
S protein may also have a regulatory role in the coagulation system 
(Podack and Muller-Eberhard, 1979). S Protein can be observed in a
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C3f C3c
C3b
CR1H MCP or CR1 jC3b
C3d,g
F igure 1.7: D egradation  o f C3b by factor  I. Factor H, m em brane 
cofactor protein (MCP) and complement receptor 1 (CR1) are cofactors for 
factor I mediated cleavage of C3b to iC3b. CR1 involves fu rther cleavage 
of iC3b to C3d,g and C3c (Adapted from Roitt e t al., 1990).
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complex with thrombin in serum after coagulation but not in plasma. 
This complex contains antithrombin III (Jenne et al., 1985).
S protein and the serum-spreading factor, vitronectin, are 
identical. The human vitronectin gene (4.5-5 kb) consists of eight exons 
and seven introns (reviewed in Preissner, 1991). The S protein amino acid 
sequence can be divided into five regions with different functional 
significance (Suzuki et al., 1985) as follows.
(1) The first 44 residues of S protein (somatomedin B) contains four 
disulphide bonds and have the appearance of an independently-folding 
cysteine-rich domain. No homology was observed between this region and 
high cysteine region of complement component C9.
(2) Adjacent to the somatomedin B domain, there is a three amino 
acid (Arg-Gly-Asp) motif which is shared by several molecules exibiting 
cell attachment activity (Hayman et al., 1985).
(3) This is followed by a proline-rich region (residues 48-347) which 
contains three possible sites for attachment of N-linked oligosaccarides, 
but shows no amino acid homology with collagen or fibronectin.
(4) The following 32 residues of the molecule contain 14 positive 
charges, no negative charges and only two hydrophobic residues. This 
region has been identified as a heparin-binding site (Suzuki et al., 1984). 
This site could also be involved in the binding of S protein to the terminal 
components of complement pathway since it has been observed that 
polylysine can block the inhibition of C5b-7 by serum factors.
(5) Following the heparin-binding region is the C-terminal region 
which is found to be partially cleaved in plasma and which is cleaved 
rapidly when purified S protein is treated with trypsin (Podack and 
Muller-Eberhard, 1979). Endogenous proteolytic cleavage of this carboxy- 
terminal fragment accounts for the two molecular weight forms of both S 
protein and vitronectin.
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Vitronectin gene has been mapped to the centromeric region of the 
long arm of chromosome 17 at 17qll (Fink et al., 1992).
1.5.1.& SP-40,40
SP-40,40 (clusterin) is a heterodimeric structure (Table 1.5). It has 
two chains which are of a similar size (40 kD). The amino terminal 
sequences of the chains are unrelated to one another (Murphy et al., 
1988).
SP-40,40 acts as a control protein of the membrane attack complex 
of complement. Recent studies have shown tha t SP-40,40 potentially 
inhibits C5b-6 initiated lysis, by preventing the hydrophilic-amphilic 
transition of C5b-C7 complex during the assembly of the lytic pore C5b-9 
complex (Kirszbaum et al., 1992) (Figure 1.4).
The cDNA sequence encoding the SP-40,40 was reported by 
Kirszbaum et al. (1989). The two chains of SP-40,40 are coded in a single 
open reading frame on the same mRNA molecule indicating the existence 
of a biosynthetic precursor protein which matures postsynthetically by 
proteolysis (Kirszbaum et al., 1990). The coding order of SP-40,40 chains 
upon the mRNA is p, a. The precursor contains six N-linked glycosylation 
sites which are distributed equally between the two chains. The sequence 
of the SP40,40 bears a 77% identity to a ra t sulphated glycoprotein-2 
(SGP-2, clusterin) which is the major secreted product of Sertoli cells 
(Jenne and Tschopp, 1989). SP-40,40 and SGP-2 are the serum and 
seminal forms of the same protein. A sequence of 23 amino acids within 
the P chain of SP-40,40 exhibits significant homology to corresponding 
segments located within complement components C7, C8 and C9. This 
short, cysteine-containing motif represents the only evidence of a possible
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vestigial relationship between SP-40,40 and other complement 
components.
Northern blot analysis showed that a single species of mRNA 
(approximately 2 kb) is normally present in various tissues (Collard and 
Griswold, 1987; Bettuzi et al., 1989).
1.5.2. Functional and G enetic Features o f the Membrane 
Regulatory Proteins
1.5.2.1. Decay Accelerating Factor (DAF)
DAF is a protein (Table 1.6) anchored in the cell membrane by a 
covalently-linked glycolipid (Medof et al., 1987; Davitz et al., 1986) rather 
than by a transmembrane anchor. This non-amino acid structure consists 
of a phospholipid-containing fatty acid, glycerol and inositol linked to an 
oligosaccaride-containing non-acetylated glucosamine and ethanolamine 
(Medof et al., 1987). The presence of glycophospholipid anchor in DAF 
increases its mobility. This increased mobility could enhance the ability of 
a limited number of DAF molecules to contact a large number of C3b and 
C4b fragments on the cell surface (Thomas et al., 1987). Other possible 
roles for the glycophospholipid anchor include serving as a means to 
release the protein from the cell membrane and transducing an 
intercellular signal (Lublin and Atkinson, 1989). Although DAF is 
present in plasma and in other body fluids, it is not known whether it 
arises frpm the membrane by endogenous phospholipases.
The initial purification of DAF was based on its ability to 
accelerate the spontaneous decay of preformed classical C3 convertase 
C4b2a (Nicolson-Weller et al., 1982). It has also been shown that DAF 
prevents the assembly of C3 and C5 convertases of the classical and
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alternative pathways (Figure 1.8). But Fujita et al. (1987) showed that 
DAF does not prevent the initial binding of C2 or B to the cells containing 
C4b or C3b respectively, but rather, it rapidly dissociates C2a or Bb from 
their binding sites, thus preventing the assembly of the C3 convertase. It 
has no effect on the structures of C3b and C4b (Medof et al., 1985) and 
thus its effect is reversible. DAF lacks cofactor activity for factor I- 
mediated cleavage of C3b and C4b (Pangburn et al., 1983).
DAF cDNA has been fully sequenced and the data show that DAF 
mRNA encodes a protein of 347 amino acids preceded by a hydrophobic 
rich stretch of amino acids characteristic of an NH2 terminal leader 
sequence. It has a single N-glycosylation site at position 61 and multiple 
potential O-glycosylation sites in the serine-threonine-rich region. There 
are four contiguous SCR repeats of internal homology of approximately 
61 amino acids (Figure 1.6). DAF SCRs 1, 2 and 4 are encoded by a single 
exon, while SCR 3 is encoded by two exons (Rodrigez de Cordoba et al., 
1985).
DAF cDNA hybridises to two major mRNA species of ~2.7 kb and 
~2 kb and a minor mRNA species of ~3.1 kb.
Recently the DAF gene promoter region has been characterized 
(Ewulonu et al., 1991). The DAF gene promoter possesses a region with 
the negative regulatory activity and responds to PMA and cAMP 
induction presumably PRE and CRE like elements (Ewulonu et al., 1991). 
The physiological function of the negative regulatory sequence in DAF's 
promoter could maintain the markedly divergent levels of DAF 
expression found in different cell types (Cheung et al., 1988).
The 35 kb long DAF gene is flanked upstream by the genes for 
complement receptors CR1 and CR2 and downstream by the genes for C4- 
bp other C3/C4 regulatory proteins (Lublin et al., 1987).
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A B C
C3bC3bC3b
DAF DAF
CR1
F igure  1.8: R egulation  of C3 convertases. Decay acceleration factor 
(DAF) and CR1 inhibit the association between C3b and B and promote 
dissociation of the C3bBb complex. CR1 also promotes the factor I 
mediated cleavage of C3b (Adapted from Roitt et al., 1990).
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I.5.2.2. Membrane cofactor protein  (MCP)
MCP was first identified as an iC3/C3b-binding membrane protein 
(Cole et al., 1985) (Table 1.6). It was subsequently purified and shown to 
be a potent cofactor for factor I mediated cleavage of fluid-phase C3b 
(Seya et al., 1986). This protein does not accelerate the decay of the C3 
convertases, therefore its functional profile is complementary to that of 
DAF. Like DAF, MCP is widely distributed and it is found on epithelial, 
endothelial cells, fibroblasts (McNearny et al., 1989) and all peripheral 
blood cells except for erythrocytes (Seya et al., 1988). Moreover, the 
structures of MCP and DAF are similar, consisting of four short 
consensus repeat (SCRs), altough MCP is a transmembrane protein 
wheras DAF possesses a glycolipid anchor (Figure 1.6) (Lublin et al., 
1988).
The cDNA sequence encoding the MCP has been reported by 
Lublin et al. (1988). The 1.5 kb cDNA encodes a protein of 384 amino 
acids with three sites for N-linked glycosylation. Following the SCR 
domains there is a segment of 29 amino acids enriched in serine, 
threonine and proline residues which are likely to be a site of heavy 0- 
linked glycosylation.
On Northern blot analysis, the cDNA for MCP detects a major and 
a minor mRNA of 4.2 and 4.8 kb (Lublin et al., 1988). Analysis of 
alternative splicing sites of MCP mRNA demonstrates the existence of 14 
transcripts generated by the alternative splicing of five exons (Figure 
1.9). Splicing of one exon is controlled by sequences within or near the 
MCP gene and is thus genetically determined. Splicing of other exons is 
regulated by tissue-specific factors or activation events (Russell et al., 
1992).
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STP A STP B STP C
GPRPTYKPPVSNYPVLPPSSTKPPALSHS VSTSSTTKSPASSAS
UTUT
\
L SCR STP TM CYT
TM B CYT A
W GVA V ICW PY  RYLQRRKKK GTYLTDETHREVKFTSL 
W G VA V ICW PY  RYLQRRKKK 
DIFKGGRRK
CYT B
KADGGAEYATYQTKSTTPAEQRQ
GKQMVELNMPLTRLNQPLQQSREAE
GKQMVELNMPLTRLNQPLQQSREAE
Figure 1.9: Exon structure o f m em brane cofactor protein . White 
boxes represent exons th a t undergo alternative splicing. Letters under 
enlarged boxes indicate amino acid sequence of isoforms from 
alternatively spliced transcripts; spaces in amino acid sequences indicate 
deletion of exons (Adapted from Russel et al., 1992).
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A yeast artificial chromosome (YAC) clone identified an MCP-like 
genetic element which is 93% and 84% homologous to MCP, at the 
nucleotide and amino acid levels, respectively. It is not known if this 
homologue is transcribed or is a pseudogene (Liszewski et al., 1991).
I.5.2.3. C D 5 9
CD59 [also known as protectin, membrane inhibitor of reactive 
lysis (MIRL) or homologous restriction factor 20 (HRF20)] is a membrane 
protein (Table 1.6) (Zalman et al., 1986). CD59 is a powerful inhibitor of 
complement cytolysis and exerts its activity by limiting the 
polymerisation of C9 in membrane C5b-9 complex (Meri et al., 1990) 
(Figure 1.10).
Phosphatidylinositol-specific phospholipase C digestion of the 
protein abolished 50% of its C5b-9 inhibitory activity and removed 
approximately 15% of the protein from the human erythrocytes (Rollins 
and Sims, 1990). This suggests that CD59 is linked to the cell surface by 
means of a glycolipid anchor. Thus CD59 antigen is absent from the 
surface of the affected erythrocytes of patients suffering from paroxysmal 
nocturnal haemoglobinuria (PNH) as such cells lack proteins that use a 
glycolipid anchor like DAF and HRF (Okada et al., 1987; 1989).
The cDNA sequence of CD59 is 1154 bp, and encodes a precursor 
polypeptide of 128 amino acids. The sequence shows that CD59 does not 
resemble any other complement component or regulatory protein, but 
shows 26% amino acid identity with that of murine LY-6 antigen (Davies 
et al., 1989).
Northern blot analysis revealed four species of CD59 mRNA, 
approximately 0.6 kb, 1.2 kb, 1.9 kb and 2.2 kb, which are present at 
varying amounts in different cells (Davies et al., 1989).
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F igure 1.10: In h ib ition  o f C9 p o lym eriza tion  by CD59. In the
presence of CD59 the initial binding of C9 to C5b-8 occurs but the 
subsequent insertion of C9 is prevented (Adapted from Meri et al., 1990)
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I.5.2.4. Homologous restriction factor (HRF)
HRF [also known as C8-binding protein (C8-bp) or Membrane 
Inhibitory Protein (MIP)] is a membrane protein which is highly effective 
in inhibiting complement-mediated cytolysis (Table 1.6). Like CD59, it 
recognizes the C5b-8 membrane attack complex, and prevents C9 
polymerization (Zalman et al., 1986; Schonermark et al., 1986). HRF 
possesses a glycophosphatidylinositol anchor and paroxysmal nocturnal 
haemoglobinuria (PNH) erythrocytes are lacking in this protein (Zalman 
et al., 1987). Amino acid and cDNA sequences of MIP are not available.
I.5.2.5. Complement receptor 1 (CR1)
Human CR1 is a glycoprotein that exibits genetically regulated 
structural and quantitative polymorphism (Table 1.6).
CR1 is mainly expressed on cells in the blood, whereas DAF and 
MCP are more widely distributed. Like DAF, CR1 accelerates the decay of 
the classical and alternative pathway C3 and C5 convertases. Moreover, 
like MCP, CR1 act as a co-factor for factor I to mediate inactivation and 
degradation of C3b and C4b (Figure 1.6). Thus CR1 possesses the 
properties of both DAF and MCP (Ahearn and Fearon, 1989). CR1 on 
erythrocytes can bind immune complexes bearing C3b/iC3b and may be 
important in the clearance of such complexes from the blood (Wong and 
Fearon, 1985).
Wong et al. (1985) identified a cDNA for CR1. This cDNA 
hybridized with mRNA species of 9 and 11 kb.
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I.5.2.6. Complement receptor 2 (CR2)
CR2 is a complement protein that serves as a receptor (Table 1.6) 
for C3dg (Ross et al., 1982) and for the Ebstein-Barr virus (Fingeroth et 
al., 1984; Nemerow et al., 1985). CR2 is a cofactor for factor I in the 
conversion of C3b to iC3b (Mitomo et al., 1987).
Human lymphocyte CR2 is known to act as an alternative pathway 
activator on which homologous C3 is deposited. This CR2 activity can not 
be suppressed by the DAF and MCP on the cell membrane.
1.6. RECEPTORS OF THE COMPLEMENT SYSTEM
Complement receptors and their ligands, in addition to CR1 and 
CR2, are summarized in Table 1.7.
1.7. BIOSYNTHESIS OF COMPLEMENT PROTEINS
1.7.1. In Liver
In 1911, Muller (reviewed by Colten, 1976) found that perfusion of 
liver with serum led to an increase in complement activity in the effluent, 
and concluded that complement synthesis occured in the liver. Alper and 
coworkers (1969) also confirmed this observation and showed that the 
liver was the major site of serum complement synthesis. The liver is the 
main site of synthesis of almost all of the serum complement proteins 
except Clq, D and properdin and hepatocytes are the main cell type
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responsible. Kupffer cells are probably a rich source of C4 and C2. Table 
1.8 shows the complement proteins secreted by the liver.
1.7.2. By Extrahepatic Sources
Complement proteins of the classical, alternative and membrane 
attack pathways are synthesized in several cell types in various tissues 
(Table 1.8).
Mononuclear phagocytes are widely distributed in tissues and their 
circulating precursors, monocytes, are able to be recruited rapidly into 
inflamed tissue. Endothelial cells are present throughout the body since 
they line the blood vessels. Fibroblasts are widespread in the connective 
tissues. In culture in vitro all three cell types synthesize complement 
proteins under basal conditions. Other cells which synthesize complement 
include astrocytes (Gasque et al., 1992), alveolar type II epithelial cells 
(Strunk et al., 1988) and intestinal epithelial cells (Colten, 1976).
Stimulation of these cells by mediators of inflammation (i.e. 
cytokines) changes the pattern of the secretion rates of the complement 
proteins. For example, IL-1, IL-6 and TNF all stimulate alternative 
pathway activating components (Katz & Strunk, 1989b); IFNy increases 
synthesis of Cl-INH, factor H, C2, factor B and C4-bp by monocytes, 
endothelial cells and skin fibroblasts (Lappin et al., 1992).
1.7.2.1. Mononuclear phagocytes
Monocytes mature to macrophages once they leave the blood 
stream. Together with the neutrophils, macrophages are the main 
phagocytes in the mammalian organism. Mononuclear phagocytes are the 
single richest source of complement proteins with synthesis of all the
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activator and inhibitor proteins in both activation pathways (Littman and 
Ruddy, 1977; Whaley, 1980; Hetland et al., 1986; Lappin et al., 1990). 
Complement proteins synthesized by mononuclear phagocytes are listed 
in Table 1.8.
1.7.2.2. Fibroblasts
Tissues are not solely composed of cells. A substantial amount of 
their volume is the extracellular space, which is largely filled by an 
intricate network of macromolecules constituting the extracellular 
matrix. In most connective tissues, these macromolecules such as 
collagen, elastin, fibronectin and laminin are secreted by fibroblasts. 
Recent studies demonstrated that fibroblasts also synthesize some 
complement proteins and cytokines. Thus, they actively contribute to 
local inflammatory response. The pattern of complement protein 
synthesis (Table 1.8) under resting conditions favours inhibition of both 
pathways. Rates of synthesis of inhibitors (Cl-INH, factor H) are greater 
than those of activators in fibroblasts (Katz and Strunk, 1988a; 1989a). 
Under stimulatory conditions by mediators of inflammation, this pattern 
changes with an increase in the rates of synthesis of activators being 
greater than those of inhibitors (Katz and Strunk, 1988b).
1.7.2.3. Endothelial cells
All tissues depend on blood supply and blood supply depends on 
the endothelial cells. They create an adaptable life support system 
extending into every region of the body. If there were no endothelial cells 
extending and remodeling the network of the blood vessels, tissue growth 
and repair would be impossible. Endothelial cells play a vital role by
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allowing white cells to migrate into the inflami _ed area and also allowing 
the exudation of plasma into the inflam: ed region. They also synthesise 
some complement proteins (Colten, 1976; Ripoche et al, 1988) (Table 1.8).
I.7.2.4. O ther cell types
Epithelial cells, alveolar type II epithelial cells (Strunk et al., 
1988), astrocytes (Gasque et al., 1992), intestinal epithelial cells (Colten, 
1976), are also capable of synthesizing some complement proteins (Table 
1.8).
1.8. COMPLEMENT DEFICIENCIES
Congenital and/or acquired deficiencies of the complement proteins 
have been described in man. With the exception of Cl-INH deficiency 
(autosomal dominant) and properdin deficiency (X-linked recessive), 
deficiencies of all complement components are autosomal recessive.
Cl-INH deficiency may result from the failure to secrete protein 
due^an abnormal gene or because the transcript of the abnormal gene 
encodes a functionally inactive protein. Hereditary angioedema (HAE) is 
a disease which results from inherited Cl-INH deficiency and is 
characterized by recurrent episodes of subcutaneous and submucosal 
oedema (Davies, 1988).
Complete deficiencies of either factors H or I result in uncontrolled 
turnover of the alternative pathway with secondary deficiencies of C3 and 
B due to depletion. These patients also have a high incidence of immune 
complex diseases and severe systemic bacterial infections (reviewed in 
Morgan and Walport, 1991).
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Deficiency of C4-bp has been reported in association with B elie fs  
syndrome and angioedema (Trapp et al., 1987).
Deficiency of DAF (Nicholson-Weller et al., 1983), HRF (Zalman et 
al., 1987) and CD59 (Holguin et al., 1989) occurs in patients with 
paroxysmal nocturnal haemoglobinuria. In this acquired clonal disorder 
of bone marrow cells, GPI-anchored proteins cannot be inserted
in the cell membrane so that they are susceptible to complement lysis.
The features of deficiencies of the other complement components 
are listed in Table 1.9.
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1.9. THE AIM OF THE PRESENT STUDY
Rheumatoid arthritis (RA) is a disease characterized by chronic 
inflammation of the synovium which leads to the destruction of cartilage 
and bone. The formation of immune complexes within the articular and 
peri-articular tissues is thought to play a major role in its pathogenesis. 
Complement system is activated by immune complexes. Detection of 
^^decreased levels of complement components and the presence of 
activation products (anaphylatoxins, SC5b-9, MAC, C3dg) in the synovial 
fluid provide strong evidence for intra-articular complement activation 
in RA. Activated complement components can become anchored to host 
cells as well as to the target organisms. Various types of cells such as 
fibroblasts, endothelial cells, macrophages, adipocytes, and synoviocytes 
(type A and type B, macrophages-like and fibroblast-like, respectively) 
are all found in the synovial membrane. In this potentially cytotoxic 
environment, the host cells should be protected from the destructive 
capacity of complement by fluid-phase and membrane-bound regulatory 
proteins.
Therefore, the aim of this project was firstly, to investigate which 
fluid-phase and membrane-bound proteins are synthesized in the 
synovial membrane from patients with RA and OA, and from normal 
individuals who did not have the diseases.
It was secondly, to examine the expression of the genes encoding 
the complement regulatory proteins in some of the cell types which are 
present in the synovial membrane {i.e., endothelial cells, monocytes, 
lymphocytes and fibroblasts fc&m RA, OA patients and from normal 
individuals).
And finally, it was to investigate the effects of cytokines {e.g. IFNy) 
on the expression of some of these complement components.
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CHAPTER 2. MATERIALS AND METHODS
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2.1. REAGENTS
The following reagents were purchased from the sources shown.
Flow Laboratories, Rickm ans worth, Herefordshire, England
Linbro multiwell tissue culture dishes, Linbro 75 cm^ tissue culture 
flasks, trypsin EDTA solution in Pack’s saline (trypsin/EDTA), Dulbecco's 
modified Eagle's medium (DMEM), RPM I1640.
GIBCO BRL, Paisley, Renfrewshire, Scotland
Foetal calf serum (FCS), penicilline-streptomycin, amphotericin solution, 
L-glutamine, Hank's balanced salt solution (HBSS), Dulbecco's Modified 
Eagle Medium (DMEM), trypsin-EDTA, nonessential amino acids, 
Nunclon tissue culture flasks 25 cm^; 75 cm^; 175 cm^, Taq DNA 
polymerase, sodium bicarbonate, fungizone, DNA ladder (1 kb), RNA 
ladder (0.24-9.5 kb), low melting temperature agarose.
Boehringer Mannheim, Mannheim, FRG
Random primed DNA labelling kit, DNAase I (ENAase free), RNAase 
inhibitor, restriction endonucleases (EcoRl, Hindlll, BamH I).
SIGMA Chemical Co., Poole, Dorset, England
Diethylpyrocarbonate, gelatin 2% solution, endothelial cell growth 
supplement, collagenase type II, collagenase type I, trypsin type II, 
deoxyribonuclease 1, Concanavalin A, phytolacca Americana (pokeweed 
mitogen), cycloheximide, extra avidin biotin staining kit mouse, polaroid 
photography film type 57, lysozyme, 3-N-morpholino propane sulfonic 
acid sodium salt (MOPS), hexadecyl trimethyl ammonium bromide
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(CTAB), spermidine free base, anti-mouse IgG FITC conjugate, Triton X 
100, Tween X 20 .
Biogenesis, Bournemouth, England
RNAzol, purified human alpha interferon (lymphoblastoid), purified 
human beta interferon (fibroblast), recombinant human interferon 
gamma.
British Biotechnology Ltd., Cowley, Oxford
Human interleukin 1(3 (recombinant), human interleukin 6, human TNF 
a  (recombinant), human TNF (3 (recombinant).
Amersham International, Bucks, England
Hybond-N nylon membranes, hyperfilm-MP (10x12") ZEPN 1680, a ^ P -  
dCTP, y^ P-ATP, a 32P-dUTP
Serotec, Oxford, England
Mouse monoclonal antibodies to human CR1 receptor, human membrane 
co-factor protein and human decay accelerating factor.
Atlantic Antibodies Incstar Ltd, Workingham, Berkshire
Goat anti-human Cl-INH, goat anti-human factor I, sheep anti-human 
C4-bp, goat anti-human factor H
Bioquotec Limited, 3 Mount Plaisant Court, West Yorkshire
Human vitronectin cDNA probe (1 kb)
6 0
BGRL Research Products BPL Commercial Department, Herts
Mouse monoclonal antibody to CD59.
DIFCO Labs, 146 Central Ave, East M olesley, Surrey
Bactotryptone, yeast extract,
Fluka Chemica, Peakodale Road, Glossop, D erbyshire
Formamide.
Welcome Diagnostic, Temple Hill, Dartford
Phytohaemagglutinin.
Me Quilkin Co., 21 Palm adif St., Glasgow, Scotland
Chloroform, propan-2 ol
Plasmids
The plasmid pCI (Cl-INH cDNA) was a gift from Dr Philip Carter, 
(Department of Biochemistry, University of Aberdeen; Carter et al., 
1988). The plasmid BP-8 C4bp (C4 binding protein cDNA) was a gift from 
Dr. K.B.M. Reid, (Immunochemistry Unit, Department of Biochemistry, 
University of Oxford; Chung et al., 1985). The plasmid B38-1 FH (factor 
H cDNA) and the plasmid pSp 64 (factor I cDNA) were gifts from Dr. R.B. 
Sim, (MRC Immonochemistry Unit, Department of Biochemistry, 
University of Oxford; Ripoche et al., 1988, Catteral et al., 1987). S protein 
(vitronectin) cDNA was purchased from Bioquote Ltd., (Ilkley, Yorkshire, 
England; Suzuki et al., 1985). The plasmid LK 107 (SP-40,40 cDNA) was 
a gift from Dr. Brendan Murphy, (St. Vincent's Hospital, Melbourne, 
Australia; Kirszbaum et al., 1989). The plasmid YTH 53.1/1 (CD59 cDNA) 
was a gift from Professor H Waldmann, (Department of Pathology,
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University of Cambridge, Cambridge, England; Davies et al., 1989). The 
plasmid pGEM DAF 2.1 (DAF cDNA) was a gift from Dr. E Medof, 
(Department of Pathology Casewestem Reserve University, Cleveland, 
Ohio, USA; Medof et al., 1987). The plasmid MCP-9 (MCP cDNA) was a 
gift from Dr. D.M. Lublin, (Washington University School of Medicine, St. 
Louis, Missouri,USA; Lublin et al., 1988). The plasmid pCRl.l (CR1 
cDNA) was a gift from Dr.D.T. Fearson, (Department of Medicine, Jonhs 
Hopkins University, Baltimore, Maryland, USA; Wong et al., 1985)
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2.2. BUFFERS
2.2.1. Preparation of Culture Media
2.2.1.1. Cell and  tissue culture m edia
Endothelial cell culture medium
Seventy mililitres RPMI 1640, 15 ml fetal calf serum (heat 
inactivated 2 hours at 56 °C), 10 ml human serum (heat inactivated 2 
hours at 56 °C), 1 ml glutamine (0.2 M) and 2 ml penicillin/streptomycin 
(5,000 units/ml; 5000 ng/ml), 1 ml endothelial cell growth supplement (3 
mg/ml), 1 ml heparin (1000 u/ml) were mixed together and stored at 4 °C 
up to two weeks.
Monocyte culture medium
Eighty-seven mililitres RPMI 1640, 10 ml human serum (heat 
inactivated 2 hours at 56 °C), 1 ml glutamine (0.2 M) and 2 ml 
penicillin/streptomycin (5,000 units/ml; 5000 |ig/ml) were mixed and 
stored at 4 °C. After the third day, instead of human serum, fetal calf 
serum (heat inactivated 2 hours at 56 °C) was added to the medium.
Synovial tissue and fibroblast cell culture medium
Twenty mililitres 10 x Dulbecco's Modified Eagle Medium 
(DMEM), 20 ml fetal calf serum (FCS, heat inactivated for 2 hours at 56 
°C), 8 ml sodium bicarbonate (7.5 %), 2 ml glutamine (0.2 M) and 2 ml 
penicillin/streptomycin (5,000 units/ml; 5000 |ig/ml) were mixed together 
and the volume made up to 200 ml with sterile water and stored at 4 °C 
for up to 2 weeks. The same medium was used for skin fibroblast cell 
culture.
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Transport medium
Sodium bicarbonate (70 mg), 20 ml 10 x Hank's solution, 4 ml FCS 
(heat inactivated for 2 hours at 56 °C), 10 ml penicillin/streptomycin were 
mixed and the volume made up to 200 ml with sterile water. The final 
solution was stored at -20 °C in aliquots of 10 ml.
Collagenase/DNase 1
Collgenase (100 mg), deoxyribonuclease 1 (10 mg) and sodium 
bicarbonate (35 mg) were dissolved in 10 ml 10 x HBSS and 2 ml 
penicillin/streptomycin. The volume was made up to 100 ml with sterile 
water. The final solution was divided into 25 ml aliquots and stored at - 
20°C.
Trypsin/EDTA
Trypsin (100 mg) and EDTA (40 mg) were dissolved in 20 ml 10 x 
phosphate-buffered saline and the volume was made up to 200 ml with 
sterile water. The final solution was stored at -20 °C as 25 ml aliquots.
2.2.1.2. Bacteria culture media
L-Broth
Bactotryptone (10 g), NaCl (10 g), yeast extract (5 g), were 
dissolved in water and the volume was made to 1 litre. The solution was 
sterilized by autoclaving and stored at room temperature.
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L-Broth Agar
Bactotryptone (10 g), NaCl (10 g), yeast extract (5 g), and bactoagar 
(20 g) were dissolved in water and the volume was made up to 1 litre. The 
solution was sterilized by autoclaving and stored at room temperature.
Lysosyme mix
Lysosyme was dissolved to a final concentration of 2 mg/ml in 
Tris.HCl (25 mM, pH 8.0) containing glucose (50 mM) and EDTA (10 
mM). The mixture was stored at 4 °C.
GTET
Glucose (8 g), 10 ml EDTA (0.5 M, pH 8.0), 10 ml Tris.HCl (0.5 M, 
pH 8.0) was added to 80 ml water. The solution was filtered through 0.2 
pm filter units, 100 ml Triton X 100 was added.
1 x Tris Borate EDTA (TBE)
Tris (10.8 g) and boric acid (5.5 g) were dissolved in 500 ml water 
after which 4 ml of EDTA (0.45 M) was added. The pH was adjusted to
8.0 before making the volume up 1 litre with water. The solution was 
stored at room temperature.
20 x Phosphate-Buffered Saline (PBS)
Sodium chloride (320 g), dipotassium hydrogen phosphate (48.4 g) 
and potassium dihydrogen phosphate (13.6 g) were dissolved in water and
yC
the volume was made up 2 litres and stored at room temperature.
65
2.2.2. Buffers for Nucleic Acid M anipulation
10 x MOPS
Sodium morpholino-propanesulphonic acid (42 g), sodium acetate 
(6.8 g) and EDTA (3.7 g) were dissolved in water and the pH was adjusted 
to 7.0 with glacial acetic acid. The volume was made up to 1 litre and the 
final solution was stored in the dark at room temperature.
20 x SSPE
Sodium chloride (3.6 M), sodium dihydrogen orthophosphate (0.2 
M) and EDTA (0.02 M), the pH was adjusted to 7.7 and the volume was 
made up to 1 litre and stored at room temperature.
20 x SSC
Sodium chloride (3 M) and trisodium citrate (0.3 M), the pH 
adjusted to 7.2 and the volume made up to 1 litre. The solution was 
stored at room temperature.
100 x Denhart's solution
Ficoll (2 g), polyvinyl pyrolline (2 g) and bovine serum albumin (2 
g) were dissolved in water, the volume was made up to 100 ml and the 
final solution was filtered through 0.2 pm filter units before dividing into 
1.25 ml aliquots which were stored at -20 °C.
Salmon sperm DNA (1 mg/ml)
Salmon sperm DNA (0.1 g) was added to 100 ml of water. The DNA 
was dissolved by autoclaving and the final solution was divided into 
aliquots and stored at -20 °C.
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Sample buffer (Northern blotting)
Formamide (250 pi), formaldehyde (80 pi) and 10 x MOPS (50 pi) 
were mixed in a microfuge tube and stored at -20°C.
Sample buffer (Slot blotting)
Formamide (250 pi), formaldehyde (80 p i)  and 20 x SSC (50 p i)  
were mixed in a microfuge tube and stored at -20 °C
Dye-mix
Two hundred and fifty microlitres of ethidium bromide (1 mg/ml), 
50 pi bromophenol blue (10 mg/ml) and 250 pi glycerol were mixed in a 
microfuge tube and stored at -20 °C.
TE buffer
Two mililitres of Tris.HCl (0.5 M, pH 8.0) and 20 ml EDTA (0.5 M, 
pH 8.0) were mixed and the volume was made up to 100 ml with water. 
The solution was filtered through 0.2 pm filter units and stored at room 
temperature.
Neutralising solution
Sodium chloride (1.5 M), Tris.HCl (0.5 M, pH 7.2) and EDTA (0.001 
M) were dissolved in one litre of water.
Lysis buffer
Tris.HCl (10 mM, pH 7.4), sodium chloride (10 mM), MgCl2 (3 mM) 
and Nonidet P-40 (5 %; v/v) were dissolved in water. The solution was 
stored at room temperature.
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Storage buffer
Tris.HCl (50 mM, pH 8.3), MgCl2 (5 mM), EDTA (0.1 M) and 
glycerol (40 %) were dissolved in one litre of water and filtered through 
0.2 pm filter.
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2.3. EUKARYOTIC CELLS AND TISSUE CULTURE
2.3.1. Endothelial Cells
Primary cultures of human umbilical vein endothelial cells 
(HUVEC) were prepared from freshly obtained umbilical cords from 
normal deliveries at the Royal Maternity Hospital, Glasgow, U.K. 
Umbilical cords were transferred to the laboratory in sterile 1 x HBSS. 
After catheterization, the vein was washed twice with 1 x HBSS. One end 
of the cord was tied with sterile clamp and then 10 ml collagenase 
solution (10 ml of 0.1 % w/v) was injected into the lumen of the vein. The 
cord was then incubated at 37 °C for 10 minutes. The collagenase was 
flushed into a sterile Falcon culture flask and the vein was further 
washed with 1 x HBSS in order to collect the remaining endothelial cells. 
The pooled cell suspension was centrifuged for 5 minutes at 1000 rpm at 
room temperature, the cell pellet was resuspended in RPMI 1640 medium 
(see section 2.2.1) and cultured at 37 °C, in a humidified atmosphere 
consisting of 5 % of CO2 in air (Jaffe et al., 1973). Cells were grown to 
confluence in 25 cm^ flasks coated with 1 % gelatin
Phase-contrast microscopy proved that at confluence, the cells 
formed a monolayer which had a uniform cobblestone appearance typical 
of endothelial cells (Figure 3.1).
Weibel-Palade bodies, rod-shaped organelles in endothelial cells, 
were detected by electron microscopy (Figure 3.2).
Clotting factor VIII antigen, which is considered to be the most 
reliable marker for endothelial cells, was detected when the cultured cells 
were stained with a monoclonal factor VIII antibody.
For all experimental work, the cells were used during their fourth 
passage.
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2.3.2. Monocytes
Human monocyte monolayers were prepared from the buffy coat of 
blood donations (Scottish Blood Transfusion Service, Law Hospital, 
Carluke, Scotland, U.K.). The buffy coat was centrifuged at 2,000 rpm for 
10 minutes which formed three phases.
The lower phase contained erythrocytes, the upper phase was 
plasma and the middle phase leukocytes. The leukocytes were aspirated 
and transferred to a fresh falcon tube, diluted with an equal volume of 
PBS and then layered onto a Ficoll-Hypaque gradient which was 
centrifuged at room temperature at 1,500 rpm for 30 minutes. The 
mononuclear cells at the interphase were transferred to a falcon tube, 
diluted with an equal volume of PBS and recentrifuged at 2000 rpm for 
10 minutes at room temperature. The supernatant was removed and the 
cells were resuspended (1 x 10^ cells per ml) in RPMI 1640 containing 
10% ABS (heat-inactivated 2 hours at 56 °C). The cells were placed into 
24 well Linbro dishes (1 ml per well), and cultured at 37 °C in a 
humidified 5% CC^/air atmosphere. The non-adherent cells were 
removed from the dishes following the five hours incubation. After 3 days, 
cells were washed extensively and the medium changed to RPMI 1640 
containing 20% FCS (heat-inactivated). The cells were incubated under 
the same conditions for another 24 hours before any experiments were 
performed.
The cells were found to consist of 95 % monocytes when assessed 
by phase-contrast and light microscopy (Figure 3.5), staining for non­
specific esterase and phagocytosis of latex particles.
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2.3.3. Peripheral Blood Lym_ "phocytes
Human Peripheral Blood Lynx phocytes were prepared from the 
buffy coat of blood donations (Scottish Blood Transfusion Service, Law 
Hospital, Carluke, Scotland, U.K.). The buffy coat was centrifuged at
2,000 rpm for 10 minutes formed three phases.
The lower phase contained erythrocytes, the upper phase was 
plasma and the middle phase leukocytes. The leukocytes were aspirated 
and transferred to a fresh falcon tube, diluted with an equal volume of 
PBS and then layered onto a Ficoll-Hypaque gradient which was 
centrifuged at room temperature at 1,500 rpm for 30 minutes. The 
lymphocytes a t the interphase were transferred to a falcon tube, diluted 
with an equal volume of PBS and recentrifuged at 2000 rpm for 10 
minutes at room temperature. The supernatant was removed and the 
cells were resuspended (1 x 10® cells per ml) in RPMI 1640 containing 15 
% FCS (heat-inactivated 2 hours at 56 °C). The cells were placed into 75 
cm^ flask, and cultured at 37 °C in a humidified 5 % CO^air atmosphere. 
The adherent cells, monocytes, were depleted from the culture by 
removing the non-adherent cells, lymphocytes, to a fresh flask following 
the three and five hours incubations.
2.3.4. Synovial Tissue Fibroblasts
Specimens of synovium were collected from the knees of 9 patients 
undergoing orthopaedic surgery in Gartnavel General Hospital, Glasgow, 
U.K.. Three patients were suffering from rheumatoid arthritis (RA), three 
from osteoarthritis (OA), and three patients from menisceal injuries. 
None of this last group had evidence of inflammatory joint disease or OA. 
Synovial tissue specimens were transported in Hank's transport medium.
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The tissues obtained were used for fibroblast cell cultures and for tissue 
cultures (see section 2.3.6).
Synovial fibroblasts were prepared according to the method of 
Dayer et al. (1976) except that the concentration of clostriopeptidase-A 
(crude bacterial collagenase type I) was 0.1% (w/v).
The specimen was washed twice with Dulbecco's calcium and 
magnesium-free phosphate buffered saline (PBS), and cut into 1-2 mm^ 
fragments in a large Petri dish containing Hank's transport medium. The 
tissue fragments were transferred to a 100 ml flask and allowed to settle 
for a few minutes before the supernatant was discarded. The tissue was 
then washed twice with PBS and the supernatant was discarded. The 
tissue was digested for 3.5 hours at 37 °C in a shaking water bath with 
25 ml Hank's balanced salt solution containing 0.1 % (w/v) collagenase 
and 0.01 % (w/v) deoxyribonuclease I. Cells and debris were removed by 
transferring the sample to a universal container which was centrifuged at 
400 g for 10 min at room temperature. After the supernatant was 
discarded, the cells and the tissue were washed into a conical flask used 
before with 50 ml Dulbecco's PBS containing 0.05 % trypsin and 0.02 % 
EDTA, and further incubated at 37 °C in a shaking water bath for 1 hour. 
The cells were separated from the undigested residue by allowing the 
residue to settle for 5 minutes, and then by pipetting off the supernatant 
containing the cells. The residue was then washed with 10 ml PBS, 
allowed to resettle and the supernatant was collected and pooled with the 
first supernatants. The cells were harvested from the supernatants by 
centrifugation at 400 g for 10 minutes at room temperature and the cell 
pellet washed three times with DMEM containing 10 % FCS (v/v), 
resuspeded in DMEM containing 10 % FCS and a cell count was 
performed. The cell suspension was adjusted to 2 x 10® cell/5 ml and 5 ml 
portions transferred to 25 cm^ flasks. The flasks were incubated at 37 °C,
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in a humid 5 % CC^/air atmosphere. Nonadherent cells were removed 
after 48 hours and culture of the adherent cells was continued after the 
addition of fresh medium (DMEM/FCS).
Fibroblasts were identified by their characteristic fusiform
morphology under light microscopy (Figure 3.3) and their specific
staining with anti-vimentin antibody (Figure 3.4). S ee,
^Or 4 4 ^  C O A + r o L
2.3.5. Harvesting Cells
Once the cells reached confluence in the 25 cm^ flasks, they were 
washed twice with PBS and harvested by trypsinisation with 
trypsin/EDTA solution. They were resuspended in 10 ml of fresh medium 
and transferred into 75 cm^ flasks. When the cells reached confluence in 
75 cm^ flasks they were trypsinised and cultured in 175 cm^ flasks until 
confluence was achieved. They were then divided into three 175 cm^ 
flasks and cultured until confluence when experiments were performed.
2.3.6. Synovial Membrane Tissue Culture
Specimens of synovium were collected at the time of surgery from 
the knee joints of three patients with rheumatoid arthritis (RA), three 
with osteoarthritis (OA) and three from individuals undergoing 
meniscectomy who did not have OA or any chronic inflammatory joint 
disease.
To allow optimal gas and nutrient exchange, gas-liquid interface 
technique was used. Medium (containing DMEM supplemented with 10 
% FCS) enough to wet filter was added to the dishes. The tissue was 
washed 3 times with Dulbecco's calcium and magnesium-free PBS. Tissue 
fragments (40-80 mg) were placed onto stainless steel grids with sterile
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filters in a humidified 5 % CO2 atmosphere. The culture medium was 
changed every second day.
2.3.7. Treatment of Cell Cultures
2.3.7.1. Cycloheximide
Three sets of HUVEC cultures, human synovial fibroblast cultures, 
and synovial membrane tissue cultures were treated with 2.5 |ig/ml of 
cycloheximide. Culture supernatants were collected at days 1, 3, 5 and 7 
in order to examine de novo synthesis of the complement components by 
ELISA, and total cellular RNA was isolated from the cells (section 2.8.).
2.3.7.2. Actinomycin D
Three sets of HUVEC cultures were exposed to actinomycin D (5 
fig/ml) in order to measure the stabilities of DAF, MCP and CD59 
mRNA. The total cellular RNA was isolated as described in section 2.8.1, 
at the time intervals of 0,1, 2, 4, 6, 8 and 24 hours. The isolated RNA was 
immobilized onto membranes as described in section 2.9.2 for further 
analysis.
2.3.7.3. Cytokines
Three sets of human endothelial cell cultures were incubated with 
two different concentrations of (0.1, and 10 ng/ml) IFNy, INFa, IL-1 and 
1L-6 for 24, 48 and 72 hours. The supernatants were collected to examine 
the synthesis of regulatory complement components by ELISA.
After 72 h stimulation by cytokines, the total cellular RNA was 
isolated as described in section 2.8.1. and Northern blot analysis was 
carried out (see section 2.9.1).
Two sets of endothelial cell cultures stimulated with 10 ng/ml IFNy 
for 24 h were further treated with actinomycin-D as described in section
2.3.7.2. to examine the mRNA stability in IFNy stimulated cell cultures.
2.4.7.4. Mitogens
Three sets of peripheral blood lymphocytes and three sets of 
monocyte depleted peripheral blood lymphocytes were exposed to 
Phytohaemagglutinin (120 pg/ml), Pokeweed mitogen (120 pg/ml) and 
Conca to>»«&ivA (100 pg/ml) separately for 72 hours in order to activate the 
lymphocytes. The supernatants were collected to examine the synthesis of 
regulatory complement components by ELISA.
2.4. GENERAL PROCEDURES INVOLVING NUCLEIC ACIDS
2.4.1. Preparation of the Plasm id DNA
2.4.1.1. Preparation o f competent cells
20 p.1 of glycerol stock of Exoli HB101 were inoculated into 10 ml 
of L-broth and incubated at 37 °C overnight in an orbital incubator. 100 
pi of this culture was added to a tube containing 10 ml of L-broth and 
incubated at 37 °C for further 3 to 4 hours, until the optical density at 
520 nm was approximately 0.6. The culture tube was cooled on ice for 10 
minutes. The cells were pelletted by centrifugation at 2000 rpm, at 4 °C 
for 5 minutes. The supernatant was discarded, the pellet was 
resuspended in 5 ml of ice cold MgCl2 (100 mM). It was incubated on ice 
for 30 minutes and then centrifuged at 2,000 rpm, at 4 °C for 5 minutes. 
The pellet was resuspended in 1 ml of CaCl2 (100 mM), and incubated on 
ice for 40 minutes after which the cells were ready for use in the 
transformation protocol (see below).
2.4.1.2. Transformation o f bacterial cells
Three hundred microlitres of competent cells (section 2.4.1.1.) in 
ice-cold CaCl2 (100 mM) were transferred to microcap tubes and 
approximately 0.5 |ig of plasmid DNA was added. The cells were 
incubated on ice for 30 minutes, 42 °C for 2 minutes (heat-shock) and 
then 5 minutes at 4 °C to recover from the heat-shock. One ml of L-broth 
at 37 °C was then added and the mixture was incubated with shaking for 
1 hour. The cells were centrifuged at 6500 rpm (microfuge) and all but 
100 pi of the medium was removed. The cell pellet was resuspended in
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this residual medium and spread on agar plates containing 100 pg/ml 
ampicillin. The culture was allowed to dry on the agar and was incubated 
overnight at 37°C. Ampicillin-agar plates selected for those clones 
containing closed circular plasmid DNA with an intact ampicillin 
resistance gene. The analysis of recombinant colonies was performed by 
restriction analysis as described in section 2.6.1.
The negative control consisted of an agar plate on which competent 
cells alone were spread .
2.4.2. DNA Purification
2.4.2.1. Sm all scale isolation o f p lasm id  DNA
The glycerol stock of E.coli that had been transformed with the 
appropriate plasmid [Cl-INH (pCl), C4-bp (BP-8), factor I (pSp 64), factor 
H (B38-1), Sp-40,40 (LK107), DAF (pGEM DAF2.1), MCP (MCP-9), CD59 
(YTH 53.1/1), CR1 (pCRl.l)] was plated onto the agar containing 
antibiotic (ampicillin 50 pg/ml or tetracycline 12.5 pg/ml) using a flame- 
sterilized platinum loop. The agar plate was incubated at 37 °C 
overnight. A single colony was picked from the plate and was inoculated 
into a universal container containing 5 ml of L-broth with the appropriate 
antibiotic, and incubated for 4 to 5 hours at 37 °C in an orbital incubator.
An aliquot (1.5 ml) of L-broth culture was transferred to a microcap 
tube and centrifuged at 8000 rpm for 1 minute at room temperature. The 
supernatant was discarded and another 1.5 ml of the culture was added 
and centrifuged as above. After centrifugation, the pellet was 
resuspended in 200 pi lysis buffer and incubated for 5 minutes at room 
temperature, before the addition of 400 pi of freshly prepared alkaline 
solution (NaOH 0.2 M, SDS 1 %, w/v). The mixture was mixed by
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inverting 5 or 6 times and then incubated on ice for 5 minutes. Three 
hundred microliters of 7.5 M ammonium acetate solution (pH 7.8) were 
added and the contents were mixed gently for a few seconds. The 
suspension was kept at 4 °C for 10 minutes to allow the precipitation of 
most of the protein, high molecular weight RNA and chromosomal DNA. 
The tube was centrifuged for 3 minutes at 13,000 rpm in a microfuge and 
the clear supernatant was transferred to the fresh microcap tube. 
Isopropanol (0.6 volume) was added and the tube was incubated at room 
temperature for 10 minutes, prior to centrifugation at 15,000 rpm for 10 
minutes. The supernatant was discarded and the DNA pellet was washed 
with 70 % (v/v) ethanol and air dried, before being dissolved in 100 |il 
Tris.HCl/EDTA (TE). The purified plasmid DNA was digested with 
appropriate restriction enzymes and examined by gel electrophoresis (see 
sections 2.5.1. and 2.5.2).
2.4.2.2. Large scale isolation o f p lasm id  DNA
One mililitre of an overnight culture of E.coli which had been 
transformed with the appropriate plasmid (see small scale plasmid DNA 
preparation in section 2.4.2.1) was added to 500 ml L-broth containing 
requisite antibiotic and incubated overnight at 37 °C in an orbital 
incubator. The culture was transferred to a sterile polycarbonate bottle 
and centrifuged at 5000 rpm for 5 minutes at 4 °C. The supernatant 
was decanted, the pellet was drained and the inside of the bottle was 
dried with a tissue. The pellet was resuspended in 30 ml of GTET 
solution (glucose 8 %, w/v; Tris-HCl 50 mM; EDTA 50 mM; Triton X 100 
0.1 %, v/v) and it was transferred to a sterile 50 ml centrifuge tube. 
Lysozyme (1.2 ml of 50 mg/ml solution) was then added and the solution 
was mixed by gently inverting the tube 5 to 10 times. The solution was
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centrifuged at 12,000 rpm for 15 min and the supernatant was 
transferred to a fresh tube. One hundred microlitres of RNase (10 mg/ml) 
were added and the mixture was incubated at 68 °C for 20 minutes. After 
centrifugation at 10,000 rpm for 15 min at room temperature, the 
supernatant was transferred to a fresh tube and 1.5 ml of CTAB (5 %, 
w/y) was added. After mixing, the solution was centrifuged at 10,000 rpm 
for 15 minutes at 4 °C . The pellet was dissolved in 15 ml NaCl (1.2 M) 
and after the addition of an equal volume of isopropanol and incubation 
at -20 °C for 1 hour, the tube was centrifuged at 10,000 rpm for 10 
minutes at 4 °C. The supernatant was discarded and the pellet was 
washed twice in ice-cold ethanol (10 ml; 75 %, v/v). The pellet was air 
dried and dissolved in TE buffer.
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2.5. GEL ELECTROPHORESIS OF NUCLEIC ACID
2.5.1. Agarose Gel Electrophoresis of DNA
One gram of agarose was dissolved in 100 ml of 1 x TBE buffer in a 
microwave oven for 2 minutes. The solution was removed from the oven 
and allowed to cool to 50 °C. Ethidium bromide (10 pi of a 5 mg/ml 
solution) was added and the mixture was swirled gently, poured into the 
gel mould where it was left to set for 30 minutes at room temperature, 
the comb was removed carefully and then the electrophoresis buffer (1 x 
TBE with 0.5 fig/ml ethidium bromide) was poured into the gel tank.
The DNA (5 pg) sample was mixed with loading buffer (0.25 %, w/v 
bromophenol blue; 50 %, v/v glycerol; 15 % w/v Ficoll in H2O) and was 
heated at 65 °C for 5 min and cooled on ice. DNA samples were loaded 
into the slots of the gel and run at 50 V, 50 mA for 1 hour at room 
temperature. A set of standard markers (1 kb ladder) was also run. ' in 
the same gel, in order to determine the size of DNA being analysed.
2.5.2. Agarose Gel Electrophoresis o f RNA
One gram of agarose was dissolved in 85 ml of water by heating in 
a microwave oven for 2 minutes. The solution was then cooled to 50 °C by 
standing at room temperature, after which 10 ml of 10 x MOPS buffer 
and 5 ml of formaldehyde (37 %, v/v) were added, mixed and immediately 
poured into the gel mould. The gel was left to set for 1 hour at room 
temperature in a fume cupboard.
10 pg of RNA sample was mixed with sample buffer and denatured 
at 65 °C for 15 minutes then cooled on ice for 10 minutes. 3 ml of dye-mix 
was added and the RNA sample was loaded into the slots. The gel was set
8 0
to run at 100 V and at 50 mA for 2 hours. A set of standard markers 
(0.24-9.5 kb) was also run: in the same gel, in order to determined the
s,iz&of mRNA being analysed (Figure 2.1).
Figure 2.1: The RNA size marker.
2.6. PURIFICATION OF DNA RESTRICTION FRAGMENTS
2.6.1. Low M elting Point Agarose Gel Electrophoresis o f DNA
The restriction endonucleases used to excise the cDNA inserts from 
their plasmid vectors*Sre as follows: BarriHI and H indlll for Cl-INH, 04- 
bp, factor H and DAF, EcoRl for factor I, MCP, CR1 and CR2.
The volume of the reaction mixture which contained 20 U of 
suitable restriction enzyme(s), 10 fig of plasmid DNA, 5 pi of spermidine 
(20 mM) and 10 pi of enzyme buffer was adjusted to 100 ml by the 
addition of water. The solution was incubated at 37 °C overnight. Next 
day the solution was heated to 65 °C for 5 min and cooled on ice. 1/10 
volume of dye mix was added.
0.9 % of low melting point (LMP) agarose gel was dissolved in 50 
ml of 1 x TBE by heating in microwave oven for 2 min, 5 pi of ethidium 
bromide (10 mg/ml) was added and left to set in the cold room (4 °C) for 1 
hour.
The DNA samples were loaded in wells and the electrophoresis was 
performed at 4 °C, at 50 V and 50 mA for 2 to 3 hours. The insert was 
purified as described in section 2.6.1
2.6.2. Purification of the DNA from Agarose Gels
Gel electrophoresis was applied to the plasmid DNA as described 
in section 2.6.1. The band of interest was located by using UV light, the 
slice of agarose containing the band excised with a scalpel blade and 
transferred to a microcap tube. Five volumes of sterile water were added 
and the tube was incubated at 65 °C for 5 minutes to melt the agarose.
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An equal volume of phenol was added. The solution was mixed in a 
vortex mixer for 15 seconds. Following 5 minutes of centrifugation at
13,000 rpm at room temperature the aqueous phase was removed. Then it 
was re-extracted once with phenol-chloroform and once with chloroform.
The aqueous phase was transferred to a fresh tube and 1/10 
volume of 3 M sodium acetate (pH 6.0) and 2 volume of ice cold absolute 
ethanol was added prior to incubation overnight at -70 °C.
The tube was centrifuged at 13,000 rpm for 15 min at 4 °C, the 
supernatant was discarded and the pellet was washed twice with ice cold 
75 % (v/v) ethanol. The pellet was then dried under vacuum and dissolved 
in 50 pi of TE buffer.
2.6.3. cDNA Amplification by Polym erase Chain Reaction
The polymerase chain reaction (PCR) was used to amplify the 
cDNA of C4-bp, factor H, S Protein and DAF. The reaction mixture was 
prepared in 0.5 ml microcap tubes. The Gene Amp PCR Reagent Kit 
(Pekin-Elmer Cetus) was used. The composition of the solution is given in 
Table 2.1.
The mixture (100 pi) was added to a microcap tube and overlaid 
with 70 pi of paraffin oil to prevent evaporation. The tube was then 
placed on DNA thermal cycler (Pekin-Elmer Cetus). A negative control 
mixture, which included all the components of the PCR solution except 
the template DNA, and a positive control, which included two control 
primers and a control template DNA, were also used.
The DNA was denatured by heating at 90 °C for 1 minute 
(denaturation), the reaction mixture was then cooled to 42 °C for 2 
minutes to allow the oligonucleotide primers to anneal to their target 
sequence (annealing), then the temperature of the mixture was raised to
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SUBSTANCE VOLUME
FINAL
CONCENTRATION
sterile  w ater 69.5 pi
lOx reaction  buffer 10 \l\ lx
dATP 2 pi 200 mM
dCTP 2 Ml 200 mM
dGTP 2 pi 200 mM
dTTP 2 pi 200 mM
Taq DNA polym erase 0.5 Ml 2.5 U/100 ml
prim er 1 5 pi 1 mM
prim er 2 5 pi 1 mM
cDNA 1 Ml 20 ng
Total volume 100 pi
Table 2.1. Composition of reaction mixture for polymerase chain 
reaction.
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72 °C for 1 min to allow DNA synthesis (extension) to occur. This reaction 
sequence was repeated for 30 cycles. The oligonucleotides used were as 
follows.
For factor H and C4-bp (pAT 153 primers)
5’ -CTC ATG TTT GAC AGC TTA TC- 3’
5' -CAC GAT GCG TCC GGC GTA GA- 3’
For S protein (cDNA)
5' -GCG TCG ACA GAT GGC CAG GA- 3’
5’ -GCG AAT TCA CCG ACT CAA GAA C- 3'
For DAF (pGEM primers)
5’ -CTC ACT ATA GGG AGA CC- 3’
5’ -ACC TTA TGT ATC ATA CAC AT- 3’
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2.7. PREPARATION OF RADIOLABELLED DNA/RNA PROBES
2.7.1. Random Prime Labelling of cDNA
Radioactive labelling of the cDNA probes was performed using the 
Random Primed DNA Labelling Kit. A typical reaction contained 50 ng of 
DNA, 20 nmol of each of unlabelled dATP, dGTP, dTTP, 5pl [a -^ p ]  dCTP 
(specific activity > 3000 Ci/mmol; 10 pCi/pl) and 2 pi Klenow fragment of 
E.coli DNA polymerase (1 U/pl) in a total reaction volume of 20 pi. The 
mixture was incubated at 37 °C for 30 minutes after which the reaction 
was stopped by adding 20 pi of dye-mix. The mixture was applied to a 
small Bio-gel column as described in section 2.7.3. An aliquot (5 pi) of 
the probe was transferred to a tube which contained 5 ml of liquid 
scintillation solution (Ecoscint A) and the radioactivity was counted by 
liquid scintillation spectrometry (1217 Rack Beta). For hybridization 
reactions, the radioactivity level was adjusted to 10® cpm/ml in 
hybridization buffer.
2.7.2. Kinase 5'-end Labelling of the O ligonucleotide
Synthetic oligonucleotides (28 S ribosomal RNA) were end-labelled 
with (y-®2p)ATP. The reaction mixture contained 10 pmol of 
oligonucleotide, 2 pi 10 X bacteriophage T4 polynucleotide kinase buffer 
[0.5 M Tris-HCl (pH 7.6), 1 M MgC^, 50 mM DTT, 1 mM spermidine- 
HC1, 1 mM EDTA (pH 8.0)], 2 pi (y-®^P)ATP (specific activity 5000 
Ci/mmol; 10 pmol) and 1 pi of T4 kinase in a total volume of 10 pi. This 
mixture was incubated at 37 °C for 30 minutes. Ammonium acetate (7.5 
M; 1/10 volume of the mixture) and 2 volumes of ice-cold absolute ethanol 
was added prior to incubation at -70 °C for 30 minutes. The mixture was
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centrifuged at 13,000 rpm for 15 minutes at 4 °C. The supernatant was 
discarded and the pellet was washed twice with ice-cold absolute ethanol. 
The pellet was air dried and dissolved in 100 pi of TE. An aliquot (5 pi) of 
the probe was transferred to a tube which contained 5 pi of liquid 
scintillation solution (Ecoscint A) and the radioactivity was counted by 
liquid scintillation spectrometry (1217 Rack Beta). For hybridization 
reactions, the radioactivity level was adjusted to 10® cpm/ml in 
hybridization buffer.
2.7.3. Column Chromatography
Agarose beads (Bio-gel 1.5, 100-200 mesh) were used for gel 
filtration column chromatography. The lower part of the barrel of a glass 
Pasteur pipette was plugged with a piece of glass wool (about 1 cm long) 
and then filled with Bio-gel 1.5 and washed with 0.1 X (w/v) SSC, 0.1 % 
(w/v) SDS. The labelled probe (20 pi) (see section 2.7.1) was diluted in 
equal amount? of dye mix and layered onto the surface of the gel and 
washed through the column with 0.1 X (w/v) SSC, 0.1 % (w/v) SDS to 
separate the radiolabelled probe from the free radioactivity. The 
radiolabelled probe was collected in a fresh microcap tube and used for 
hybridization (see section 2.10.3).
2.7.4. Nuclear Run-on Assay
Approximately 1 x 10^ cells were pelletted at 2000 rpm in a 
Beckman J-6B centrifuge for 5 minutes at 4 °C. They were washed in ice- 
cold PBS and resuspended in 1 ml of ice-cold lysis buffer and then left on 
ice for 5 minutes. The nuclei were then washed twice in lysis buffer for 5 
minutes at 2000 rpm at 4 °C. The supernatant was removed. The nuclear
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pellet was resuspended in 100 pi ice-cold storage buffer and stored at - 
70°C. Nuclei were thawed and incubated at 30 °C for 30 minutes in 100 
pi reaction mixture [10 mM Tris-HCl (pH 8.0), 5 mM MgCl2 , 100 mM 
KCl, 1 mM ATP, 1 mM CTP, 1 mM GTP, 200 *iCi of [a-32P]UTP (>800 
Ci/mmol), 5 mM dithiothreitol]. The labelled RNA was then isolated from 
the nuclei using the RNAzol method.
RNAzol (1.3 ml) and 130 pi of chloroform were added to the 
reaction mixture,which was then vortexed for 15 seconds and incubated 
on ice for 15 minutes. The lysate was centrifuged for 15 minutes and the 
aqueous phase was transferred to a fresh tube. An equal volume of 
isopropanol was added and incubated at -20 °C for 45 minutes. After 
centrifugation a t 13,000 rpm for 15 minutes at 4 °C, the RNA pellet was 
washed in ice-cold ethanol 75 % (v/v), air dried and dissolved in 200 pi of 
water. An aliquot (2 pi) was added in 5 ml of scintillation solution in 
order to determine the amount of radioactivity incorparated into the 
mRNA transcripts. The concentration of radioactivity was adjusted to 10^ 
cpm/ml in hybridization buffer. The labelled transcripts were then 
hybridized to filters coated with the appropriate single-stranded cDNA at 
65 °C for 72 hours (see section 2.10.3).
5 pg of plasmid DNA was denatured for 5 minutes at 95 °C in 100 
ml water. An equal volume of 20 x SSC was added to each tube and the 
DNA and then it was blotted directly onto a Hybond-N+ membrane. The 
membrane was placed for 1 hour on a filter paper pad which was soaked 
in denaturation solution and then placed (DNA side up) on a filter paper 
pad which was soaked in neutralizing solution for a further 1 minute. The 
membrane was then briefly rinsed in 5 x SSPE and hybridization was 
carried out as described in section 2.10.3.
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2.8. RNA PURIFICATION
2.8.1. Isolation o f the Total Cellular RNA
The RNAzol method was used to isolate cellular RNA 
(Chomczynski and Sacchi, 1979). Monolayers of cells were washed twice 
\ (\ ice-cold PBS prior to lysis by the addition of RNAzol (0.2 ml per 10® 
cells) to each flask. The RNA was solubilized by repeated pipetting of the 
lysate which was then transferred to a microcap tube. Chloroform (1/10 
volume of lysate) was added and the mixture was vortexed for 15 seconds 
and then left on ice for 15 minutes. Prior to centrifugation (13,000 rpm for 
5 minutes at room temperature in a microfuge) the colourless upper 
aqueous phase containing the RNA was transferred to a fresh tube and 
an equal volume of isopropanol was added, after which the tube was 
incubated at -20 °C for 1 hour. After the sample was centrifuged at
13,000 rpm, at 4 °C, for 15 minute in a microfuge, the supernatant was 
removed and the pellet washed twice with ethanol (75 %, v/v). Then the 
pellet was - . dried briefly under vacuum for 10-15 minutes. Finally the
RNA pellet was dissolved in TE (15-50 pi) and the amount of RNA was 
measured by spectrophotometry (see section 2.8.3).
Specimens of synovium were collected at the time of surgery from 
the knee joint of three patients with RA, three with OA and from three 
individuals undergoing meniscectomy who did not have 0A or chronic 
inflammatory joint disease. Immediately after collection the tissue 
specimens were snap-frozen in liquid nitrogen and stored at -70 °C until 
required. Finely ground frozen tissue fragments were homogenised in 
RNAzol (2 ml/100 mg), before adding 1/10 volume of chloroform and 
mixing vigorously for 15 seconds and standing on ice for 15 minutes. The 
suspension was centrifuged (12,000 rpm for 15 minutes at room
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temperature) and the aqueous phase was transferred to a fresh tube to 
which an equal volume of ice-cold isopropanol was added. After standing 
on ice for 15 minutes the tube was centrifuged (13,000 rpm for 15 minutes 
at room temperature), the supeftiatant was removed and the pellet 
washed twice with ice cold 75 % (v/v) ethanol before being dissolved in 
water (100 ml). RNA samples which were contaminated with genomic 
DNA were incubated (5 minutes at 37 °C) with RNase inhibitor (10 
units/mg RNA) prior to incubation (10 minutes at 25 °C) with RNase-free 
DNase I (5 units/100 pi). The samples were then re-extracted with 
RNAzol and chloroform, and precipitated with isopropanol as described 
above.
2.9. QUANTITATION OF DNA/RNA
To quantify the amount of DNA or RNA, readings was taken by 
spectrophotometry (Du-64 spectrophotometer, Beckman) at wavelengths 
of 260 nm and 280 nm. An optimal density (OD) of 1.0 corresponds to 
approximately 50 pg/ml for double-stranded DNA, 40pg/ml for single­
stranded DNA or RNA at 260 nm wavelengths.
1 pi of DNA or RNA was diluted in 1 ml of sterile water and read at 
a wavelengths of 260 nm.
The ratio between the readings at 260 nm and 280 nm was used to 
estimate of the purity of the nucleic acid. A ratio of 1.9 or greater 
indicated a satisfactory degree of purity.
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2.10. ANALYSIS OF mRNA FROM EUKARYOTIC CELLS
2.10.1. Northern Blot Analysis of RNA
For Northern blot analyses, total cellular RNA (10 pg/track) was
fractionated by electrophoresis in 1 % agarose-formaldehyde gels as
described in section 2.5.2. After electrophoresis, the gel was examined
under UV light and photographed. Transcript sizes were determined by
comparing their migrations relative to a RNA ladder which was used as a
size marker (Figure 2.1).
Transfer of the RNA to the Hybond-N+ membranes was performed
by using the alkaline transfer protocol outlined by Amersham
International. The transfer buffer was 0.05 M NaOH and the transfer
was allowed to continue for 2 to 3 hours after which the blot was rinsed in 
V
2 x SSC and kept 4 °C until used.
f
2.10.2. Dot-blot Analysis of RNA
10, 5, 2.5, 1.25, 0.625 and 0.312 pg of total RNA in 5 pi of sample 
buffer were denatured at 65 °C for 15 minutes and cooled on ice. A 
filtration manifold was used to apply the RNA samples onto the Hybond- 
N+ membranes. The membranes were a-tr dried, fixed in 0.05 M NaOH 
for 10 to 20 minutes and then rinsed in 2 x SSC for 5 minutes. 
Hybridization was performed as described in section 2.10.3.
2.10.3. H ybridization Conditions
The protocol applied were set out by Amersham International 
(membrane transfer and detection methods). The hybridization buffer
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consisted of 12.5 ml of 20 x SSPE, 5 ml of 50 x Denhardt's solution, 2.5 ml 
of 10 % (w/v) SDS, 5 ml water, 25 ml of formamide (37 %), 500 |il (10 
mg/ml) of salmon sperm DNA. All prehybridization and hybridization 
reactions were performed overnight at 42 °C in a hybridization oven, 
except those for run-on assay which was prehybridized for 18 hours at 65 
°C, and hybridized for 48-72 hours at 65 °C.
The labelled probe was boiled for 5 minutes and then cooled on ice 
before being added to the hybridization buffer. The labeled probe was 
added at a concentration of 1x10^ cpm/ml.
The filters were washed sequentially in 2 x (w/v) SSC , 0.5 x (w/v) 
SSC, 0.1 x (w/v) SSC each containing 0.1% (w/v) SDS. The first wash was 
performed at room temperature for 30 minutes, followed by three washes 
of 30 minutes each at 65 °C.
The membranes were then covered with Saran-Wrap and Kodak 
XAR-5 film exposed to ian intensifying screens at -70°C. Exposure 
times varied from 1 to 15 days.
2.10.4. Stripping Probes from Nylon Membranes
Filters were washed in 0.1 % (w/v) SDS at 98 °C, allowed to cool to 
20 °C and air dried. To ensure total removal of probe, the stripped 
membranes were subjected^autoradiography. The membranes were stored 
at 4 °C in a sealed plastic envelope until hybridized with another probe.
2.10.5. Scanning of the Autoradiographs
The relative abundance of mRNA species was determined by 
scanning densitometry using a Joyce-Loebl Chromoscan-3 (Joyce-Loebl, 
Gateshead, Tyne and Wear, U.K.). Further analysis was performed by
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using a Molecular Dynamics laser scanner with PDI Quest system 
software running on a Sun-Spare computer.
An arbitrary value of 1.00 was assigned to the control level of 
expression. The abundances of 28S ribosomal RNA was assumed as 
constant. Thus variation in the 28S RNA hybridization signals were 
taken to represent the unequal loading of RNA samples, so the results for 
the expression of other genes were adjusted accordingly.
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2.11. ANALYSIS OF THE SECRETED PROTEINS
2.11.1. Preparation of the Reagents and Buffers
Coating buffer
Sodium bicarbonate (NagCOg, 0.79 g) and 1.46 g of sodium 
hydrogen bicarbonate (NaHCOg) were dissolved in water and the pH was 
adjusted to 9.0. The volume was made up to 500 ml with water and stored 
at 4 °C for up to one week.
PBS-Tween (PBST)
PBS containing 0.05 % (v/v) Tween was prepared by adding 1 ml 
Tween 20 to 100 ml 20 x PBS and making the volume up to 2 litres with 
water.
Blocking buffer
Bovine serum albumin (0.5 g) was dissolved in 500 ml 1 x PBS and 
the final solution was stored at 4 °C for up to 1 week.
Peroxide substrate
Disodium hydrogen phosphate (28 ml, 0.2 M) was added to 44 ml of 
citric acid (0.1 M) and the final pH was adjusted to 5.6 by the dropwise 
addition of one of these solutions. The volume was made up to 100 ml 
with water and the solution was protected from the light. 0- 
phenylenediamine (34 mg) was dissolved in the solution which was then 
kept in the dark. Hydrogen peroxide (40 pi) was added to the solution 
immediately before its use as the substrate.
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2.11.2. Enzyme-linked Immunoadsorbent Assay (ELISA)
A double antibody sandwich ELISA method w ^ 5 used to measure 
the synthesis of complement components by cultured human endothelial 
cells, monocytes, skin fibroblasts, synovial fibroblasts and synovial 
membrane.
ELISA plates were coated with the IgG fraction of goat anti-human 
Cl-INH (10 jig/ml), factor H (5 pg/ml), factor I (10 pg/ml), and the sheep 
anti-human C4-bp (2.5 pg/ml) were used.
The antibody (100 pi) diluted in coating buffer was added to the 
wells of an ELISA plate [Dynatech Immunolon 4 (Cl-INH, H), Corning 
(C4-bp, I)] which were then covered with Saran-Wrap and incubated a t 4 
°C overnight.
The plates were washed five times with PBS containing 0.05 % 
(v/v) Tween, using a Dynatech plate washer; 250 pi of blocking buffer was 
added to each well. The plates were incubated in a moist atmosphere at 
room temperature for 1 hour.
The plates were washed five times with PBS and then 100 pi of 
culture supernatant was added to each well. In the case of synovial 
membrane culture supernatants, multiple dilutions were performed. The 
samples were assayed in duplicate.
A pool of human serum which contained known concentrations of 
complement components was used as a standard. This standard serum 
pool was diluted sequentially in PBS-Tween and 100 pi of each dilution 
was added to a series of wells. All standards were assayed in duplicate. 
The concentrations of complement component covered by each standard 
curve were as follows:
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Cl-INH : (60 ng/ml to 0.06 ng/ml)
C4-bp : (12.5 ng/ml to 0.01 ng/ml) 
factor H: (30 ng/ml to 0.03 ng/ml) 
factor I: (200 ng/ml to 0.19 ng/ml)
The negative controls were culture medium/FCS. The plates were 
incubated in a moist atmosphere a t room temperature for 2 hours, before 
being washed 5 times with PBS-Tween. Biotin-conjugated antibody (100 
pi) was added to each well. The concentrations of the conjugated 
antibodies were:
Cl-INH : 1/5000 
C4-bp : 1/3000 
factor H: 1/4000 
factor 1:1/500
The plates were incubated in a moist atmosphere at room 
temperature for 1 hour.
The plates were washed again five times with PBS-Tween and 100 
pi of avidin-linked horse radish peroxidase (HRP) were added to each 
well. The concentration of the avidin-HRP was 1/5000 for Cl-INH, factor 
H, factor I and was 1/3000 for C4-bp. The plates were incubated in a 
moist atmosphere at room temperature for 1 h.
The plates were washed five times with PBS-Tween^ 100 pi of 
peroxidase substrate (OPD-HC1 2 mg/ml in 0.1 M citrate phosphate pH 
5.6) were added and the plates were left in the dark until the colour 
reaction had developed sufficiently. The reaction was stopped by the 
addition of 25 pi 4 N H2SO4 to each well. The intensity of the colour in 
each well was then measured on a microplate reader (Dynatech MR700).
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A standard curve was constructed for each plate by plotting the 
optical density readings of each standard against the concentration of the 
complement component in that standard. The concentration of each 
complement component in the culture supernatants was determined by 
interpolation from the standard curve. Secretion rates for each 
component were determined from the difference in concerfeation between 
days seven and one.
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2.12. EMMUNOHISTOCHEMICAL DETECTION OF MEMBRANE 
PROTEINS
2.12.1. Fixation of the Cells
Human peripheral blood monocytes, and human synovial 
fibroblasts were grown on glass slides in a petri dish under standard 
culture conditions (see sections 2.3.2. and 2.3.3.). The culture medium 
was removed and the slides were washed twice with PBS. Human 
peripheral lymphocytes slides were prepared by cytospin. The glass slides 
containing monocytes, lymphocytes, fibroblasts and the frozen section of 
synovial membrane were placed in a Coplin jar and fixed in acetone for 5 
minutes. Following a further two washes with PBS, immunostaining was 
carried out as described in section 2 .11.2.
2.12.2. Immunohistochemical Staining
2.12.2.1. Immunoalkaline phosphatase method
Normal swine serum (500 pi) diluted 1:5 in PBS was spread on 
slides and left at room temperature for 5 minutes. The excess serum was 
removed with paper tissue. The primary antibodies against DAF (IA10H6 
monoclonal), MCP (E4.3 monoclonal), CD59 (YTH53.1 monoclonal), CR1 
(E ll monoclonal) were added at 1:10, 1:50, 1:100, 1:1000 dilutions to the 
slides. They were incubated at room temperature for one hour in a moist 
atmosphere. The slides were again placed in a Coplin jar and washed 
with PBS at least 10 times over 30 minutes. Then they were placed in 
O-staining rack and dried with tissue paper. Later alkaline phosphatase 
conjugate! secondary antibodies were applied at a dilution of 1:15. The
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slides were incubated at room temperature for an hour. They were 
washed in PBS 10 times over 30 minutes. The substrate [20 ml veronal 
acetate buffer (pH 9.2), 10 mg fast violet, 5 pg a-naphtol (dissolved in 
dimethyl formamide), 2.5 mg levamisol] was flooded over the slides and 
incubated for 5 minutes at room temperature. The slides were washed 
sequentially using three Coplin jars which contained 1) PBS, 2) tap 
water, and 3) buffered formalin before being rinsed in tap water. The 
slides were placed in a metal slide rack and dipped in haematoxylin for 
15 seconds, rinsed with tap water and then rinsed in PBS as described 
above. The slides were mounted in aquamount and examined by light 
microscopy.
2.12.2.2. Immunoperoxidase m ethod
The technique used was similar to that described for 
immunoalkaline phosphatase except that, as a secondary antibody, 
peroxidase-conjugated swine IgG was used at a dilution of 1:50. The 
substrate applied was diaminobenzine [450 ml Tris buffer (pH 7.4), 50 ml 
imidazole 0.1 M, 250 ml H2O2, 2 ml DAB solution (5 g DAB, 50 ml Tris 
buffer 0.05 M pH 7.4] and the slides were mounted in Histomount.
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2.13. FLOW CYTOMETRIC ANALYSIS
1 x 10® cells were detached from the flasks by the cell scraper and 
washed twice in ice cold PBS/BSA (0.2 %) a t 2000 rpm, at 4 °C. The pellet 
was resuspended in 1 ml of PBS/BSA and 100 pi of suspension was used 
for each experiment. The appropriate monoclonal antibody (5 pi) against 
DAF (CD55, BRIC110, IgGl mouse), MCP (CD46, J4-48, IgGl, mouse), 
CD59 (BRIC 229, IgG2b mouse) and CR1 (CD35, E ll ,  IgGl mouse) was 
added to the each 100 pi of cell suspension and the mixture incubated on 
ice for 40 minutes. The mixture was washed twice with ice-cold PBS/BSA 
at 2000 rpm for 5 minutes at 4 °C. Anti-mouse IgG (100 pi FITC 
conjugated at 1/50 dilution) was added to the resuspended cell pellet 
which was incubated on ice for 30 minutes. Following two further washes 
with PBS/BSA, the pellet was resuspended in 500 pi PBS. The sample 
was then analysed by flow cytometry (Beckman FACS Analyser) which 
was connected to a CONSORT 30 computer with software designed to 
acquire, stoi^and analyse the data.
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CHAPTER 3. RESULTS
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3.1. CHARACTERIZATION OF CELLS
Endothelial cells were isolated from human umbilical cord. Cells 
were cultured until fourth passage and then characterized. In culture, the 
cells formed a monolayer which had a typical cobblestone appearance 
(Figure 3.1). Endothelial cells were also examined by electron microscopy 
and Weibel-Palade bodies were detected (Figure 3.2). Weibel-Palade 
bodies are the rod-shaped organelles in endothelial cells. They containe 
granule membrane proteins-140 (GMP-140). They are important in the 
acute inflammatory response and coagulation. They facilitate the 
adhesion of leucocytes or platelets respectively (Lackie and More, 1992). 
They are an excellent marker for endothelial cells (Gimbrone et al., 1974; 
Zetter, 1981).
Fibroblasts were isolated from human synovial tissue and 
identified by their characteristic fusiform morphology under light 
microscopy (Figure 3.3.). Fibroblasts were also examined by 
immunohistochemistry. They were positively stained with anti-vimentin 
antibody (Figure 3.4) which is expressed in fibroblasts (Freshney, 1987).
Monocytes, isolated from the buffy coats of human blood donations, 
were examined by phase-contrast and light microscopy and were 
identified by their characteristic morphology (Figure 3.5) and by staining 
for non-specific esterase and phagocytosis of latex particles.
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F igu re 3.1: Characteristic cobblestone appearance of endothelial cells in 
culture by light microscopy (x 250).
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F igure 3.2: Endothelial cell analysis by electron microscopy (x 28080) 
Weibel-Palade body indicated with an arrow.
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F igu re 3.3: Characteristic fusiform morphology of fibroblasts 
by light microscopy (x 250).
F igu re 3.4: Immunohistochemical characterization of fibrolla^ts. Cells 
were stained by immunoperoxidase method. Monoclonal mtibody to 
hum an vim entin was used a t 1/50 dilution. Vim entin Lcahzed on 
fibroblasts (brown colour) (x 250).
1 0 7
F igu re 3.5: Peripheral blood monocytes in culture under light microscopy 
(x 250).
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3.2. PREPARATION OF CLONED HYBRIDIZATION PROBES
A human CI-INH cDNA had been cloned into the Puvll site of 
plasmid pAT153/PwuII/8 by Bock et al. (1986). Digestion of the 
recombinant plasmid with BarriHl and Hindlll excised a 1.25 kb 
fragment (Figure 3.6 a, lanes 3 and 4) containing 1250 bp of CI-INH 
cDNA corresponding to the 3' end of the CI-INH gene.
A human C4-bp cDNA had been cloned into the Pvull site of the 
vector pAT153/PimII/8 by Chung et al. (1985). The cDNA of C4-bp was 
amplified by PCR (see section 2.6.2 .). The size of this cDNA was 1.6 kb 
(Figure 3.6 b). Clone pBP8 contains the cDNA between the codon for the 
60^  amino acids of C4-bp and the 8 5 ^  nucleotide in the 3' untranslated 
region of the C4-bp gene.
A human factor H cDNA had been cloned into the Pvull site of the 
vector pAT153/PimII/8 by Ripoche et al. (1988). The cDNA of factor H was 
amplified by PCR (see section 2.6.2.). The size of this cDNA was 1.6 kb 
(Figure 3.6 b) containing 1644 bp of factor H cDNA corresponding to the 
N-terminus one third of factor H.
A human factor I cDNA had been cloned into the Puvll site of 
plasmid pAT153/PttuII/8 by Catteral et al. (1987). Digestion of the 
recombinant plasmid with EcoBl excised a 2.0 kb fragment (Figure 3.6 d) 
containing 2000 bp of factor I cDNA which corresponded to the full-length 
of factor I.
The cDNA of S protein was purchased from Bioquote Ltd. S protein 
cDNA was amplified by PCR (see section 2.6.2.). The size of the cDNA 
was 1.0 kb which corresponded to the 951 bp of the coding region plus a 
portion of the 3' untranslated region S protein (Figure 3.7 a).
A human SP-40,40 cDNA had been cloned into the multiple cloning 
site of plasmid pUC19 by Kirszbaum et al. (1989). Digestion of the
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Figure 3.6: Analyses of cloned cDNAs.
a) Restriction digests of CI-INH by BamHl + H in d lll and of CR1 by Eco 
RI resulted in inserts of 1.25 kb (lanes 3 and 4), and 0.8 kb (lane 1) 
respectively. Remaini/^lanes are irrelevant in th is experiment.
b) C4-bp was amplified by PCR; the size of the cDNA was 1.6 kb (lane 2).
c) Factor H was amplified by PCR; the size of the cDNA was 1.6 kb (lanes 
3 and 4).
d) Restriction digest of factor I by EcoRI resulted &n insert of 2.0 kb (lane
3).
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recombinant plasmid with EcoRl excised a 0.78 kb fragment (Figure 3.7b) 
containing 780 bp of SP-40,40 cDNA corresponding to the 3’ end of the 
SP-40,40 gene.
A human decay accelerating factor (DAF) cDNA had been cloned 
into the .EcoRl site of the plasmid pGEMl by Medof et al. (1987). The 
cDNA of DAF was amplified by PCR (see section 2.6.2.). The size of the 
cDNA was 1.9 kb (Figure 3.7 c) containing 1900 bp of DAF cDNA 
corresponding to the coding region (except the first 3 amino acid in N- 
terminal of DAF) and 3’ untranslated region of DAF gene.
A human membrane cofactor protein (MCP) cDNA had been cloned 
into the multiple cloning site of plasmid pUC19 by Lublin et al. (1988). 
Digestion of the recombinant plasmid with EcoRl excised a 1.6 kb 
fragment (Figure 3.7 d, lane 4) containing 1546 bp of MCP cDNA 
corresponding to the full-length of MCP.
A human homologous restriction factor 20 (CD59) cDNA had been 
ligated into plasmid CDM8 by Davies et al. (1989). Digestion of the 
recombinant plasmid with XbaI excised a 1.2 kb fragment (Figure 3.7 e, 
all lanes) containing 1154 bp of CD59 cDNA corresponding to 1.4 kb 
mRNA species of CD59.
A human complement receptor 1 (CR1) cDNA had been cloned into 
the EcoRl site of plasmid pBR 327 by Wong et al. (1985). Digestion of the 
recombinant plasmid with EcoRl excised a 0.8 kb fragment (Figure 3.6 a, 
lane 1) containing 800 bp of CR1 cDNA corresponding to the 5' end of CR1 
gene.
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F igure 3.7: Analyses of cloned cDNAs.
a) S protein was amplified by PCR; the size of the cDNA was 1.0 kb.
b) Restriction digest of SP-40,40 by EcoRl resulted an inserts of 789 bp 
(all lanes).
c) DAF was amplified by PCR; the size of the cDNA was 1.9 kb.
d) Restriction digest of MCP by EcoRl resulted an inserts of 1.6 kb (lane 
9).
e) Restriction digest of CD59 by Xbal resulted an insert of 1.2 kb (all 
lanes).
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3.3. SYNTHESIS OF COMPLEMENT REGULATORY PROTEINS 
BY SYNOVIAL MEMBRANE
3.3.1. Analysis of Secreted Regulatory Proteins by ELISA.
Fragments of synovial membranes from RA and OA patients and 
from normal individuals were cultured for seven days as described in 
section 2 .2.6 . Culture supernatants were collected at days 1, 3, 5 and 7. 
The samples were assayed for the complement components CI-INH, 04- 
bp, factor H and factor I by ELISA. The results from three separate 
experiments are summarized in Figures 3.8 and 3.9, and the secretion 
rates (calculated as molecule/10 mg tissue/min) in Table 3.1. They show 
that, there was great variation between experiments and, that all the 
components measured accumulated rapidly in the culture medium during 
the first and often the second day of culture. Despite washing the 
synovial membrane pieces five times prior to culture, this pattern of 
component accumulation persisted. Because I was unable to inhibit 
totally or consistanly the accumulation of these components by the 
addition of cycloheximide (2.5 pg/ml) to the culture media, on e must 
conclude that part of each component measured was derived from plasma 
contamination of the synovial membrane fragments. However, the partial 
inhibition observed in some cultures implies that a proportion of the 
components measured in the supernatants had been synthesized locally 
within the synovial membrane.
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F ig u re  3.8: ELISA analyses for a) CI-INH and b) C4-bp secreted by 
synovial membrane in tissue culture from normal (N) individuals, 
osteoarthritis (OA) and rheumatoid arth ritis (RA) patients. The culture 
medium was removed completely at day 1, 3, 5 and 7. The amounts of CI- 
INH and C4-bp secreted into the culture medium a t the indicated days 
was measured. After seven days in culture, the results were plotted as 
cumulative synthesis. Each point represents the mean with the standard 
deviation of three experiments.
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F ig u re  3.9: ELISA analyses for a) factor I and b) factor H secreted by 
synovial membrane in tissue culture from normal (N), osteoarthritis (OA) 
and rheum atoid a rth ritis (RA) patients. The culture medium was 
removed completely a t day 1, 3, 5 and 7. The amounts of factors H and I 
secreted into the culture medium at the indicated days was measured. 
After seven days in culture, the results were plotted as cumulative 
synthesis. Each point represents the mean with the standard deviation of 
three experiments.
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TISSUE CI-INH H I C4-bp
N 1654 ±1239 1252 ±390 398 ±275 1119 ±1065
OA 1427 ± 2  554 ± 198 130 ± 2 351 ±249
RA 1517 ±989 842 ±405 435 ±286 1251 ±639
Table 3.1: Secretion rates of the regulatory fluid-phase complement 
components CI-INH, factor H (H), factor I (I) and C4-bp expressed as 
molecule/10 mg tissue/min in normal (N), osteoarthritis (OA) and 
rheumatoid arthritis (RA) synovial membrane. Figures are the mean ± 
SD of three separate experiments.
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3.3.2. Im munohistochemical Analysis of Membrane Regulatory 
Proteins.
The presence of membrane regulatory proteins of the complement 
system are investigated by immunohistochemistry. Frozen sections of 
synovial membrane obtained from the operation of rheumatoid arthritis 
patients were stained with monoclonal antibodies against DAF (IA10H6) 
(Fig 3.10 b), MCP (E4.3) and CD59 (YTH53.1) (Figure 3.11 a and b), CHI 
(E ll) and MIP (anti-MIP) (Figure 3.12 a and b). DAF, MIP and CD59 
were expressed on most cells, particularly on cells lining the synovium, 
endothelial cells and lymphocytes. MCP was expressed very weakly 
compared to other components examined. CR1 was only expressed on 
macrophages and lymphocytes.
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F igure 3.10: Immunohistochemical analyses of RA synovial membrane. 
Frozen sections were stained by the alkaline phosphatase method, a) 
Mouse IgG was used at 1/80 dilution as control, b) Monoclonal antibody 
to human DAF (IA10H6) was used at 1/80 dilution. DAF localized on cells 
lining the synovium (red colour) (x 250).
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F igure  3.11: Immunohistochemical analyses of RA synovial membrane. 
Frozen sections were stained by the alkaline phosphatase method, a) 
Monoclonal antibody to human MCP (E4.3) was used at 1/80 dilution. 
MCP staining was very weak compared to the other antibodies used (pink 
colour), b) Monoclonal antibody to human CD59 (YTH53.1) was used a t 
1/80 dilution. CD59 localized on cells lining the synovium (red colour) (x 
250).
F ig u re  3.12:Immunohistochemical analyses of RA synovial nembrane. 
Frozen sections were stained by the alkaline phosphatase nethod. a) 
Monoclonal antibody to human CR1 (E ll) was used at 1/80 diution (red 
colour), b) Monoclonal antibody to human MIP (anti-MIP) wis used at 
1/80 dilution. MIP localized on cells lining the synovium (red colour) (x 
250).
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3.3.3. Abundance o f mRNAs Encoding Regulatory Com plem ent 
Proteins.
Since a large proportion of the complement regulatory proteins 
detected by ELISA (CI-INH, C4-bp, factor H and factor I) or by 
immunohistochemical analysis (DAF, MCP, CD59, CR1 and MIP) could 
have been the result of contamination of the synovial membrane 
fragments with plasma proteins, the tissues were analyzed for the 
presence of the mRNAs encoding each of these proteins. Total RNA, 
extracted from synovial membranes from RA and OA patients and normal 
individuals was analyzed by doubling-dilution dot blots hybridized with 
32p_iabelled probes for each of the mRNAs (CI-INH, C4-bp, factor H, 
factor I, S Protein, SP-40,40, DAF, MCP, CD59, and CR1). The dot-blots 
were stripped and rehybridized with a probe for 28S rRNA to allow 
corrections for unequal loading to be made. The results are summarized 
in Figures 3.13, 3.14 and 3.15; the abundances of the mRNAs relative to 
those in normal synovium and corrected for variations in loading are 
summarized in Table 3.2. The data suggest tha t the abundance of the 
mRNAs encoding the secreted proteins (si elevated in RA synovium, as is 
that of CD59 mRNA. Only S protein mRNA is elevated in OA synovium, 
whereas DAF and MCP may be reduced in abundance in both RA and OA 
synovium. However, these data must be interpreted with caution because 
the tissue samples available were small and they may not reflect the 
mRNA abundance in whole synovial membrane. Also, severe limitations 
in the supply of tissue samples precluded confirmation of the differences 
noted by repeated assays.
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F igure  3.13: Dot blot analyses of RNA obtained from synovial 
m em branes from norm al (N) individuals, osteoarthritis (OA) and 
rheum atoid a rth ritis  (RA) patients. The dot blots (5, 2.5, 1.25 and 0.62 pg) 
were hybridized with probes for Cl-INH, C4-bp, factor H (H), factor I (I), 
S protein (S) and SP-40,40 mRNAs.
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Figure 3.14: Dot blot analyses of RNA obtained from synovial 
mem branes form normal (N) individuals, osteoarthritis (OA) and 
rheum atoid a rth ritis (RA) patients. The dot blots (5, 2.5, 1.25 and 0.62 pg) 
were hybridized with probes for DAF, MCP, CD59 and CR1 mRNAs.
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F igure  3.15: Rehybridization of the dot-blots shown in  figures 3.13 and 
3.14 w ith a probe for 28S rRNA. a) Dot blot used for MCP, CD59 and 
CR2, b) factor I, c) CI-INH and factor H, d) C4-bp, S protein and DAF, e) 
SP-40,40.
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COMPONENTS N OA RA
CI-INH* 1.0 1.8 4.4
Factor H* 1.0 1.0 2.0
Factor I* 1.0 0.7 4.3
C4-bp* 1.0 1.1 3.0
S Protein* 1.0 3.2 1.5
SP-40,40* 1.0 0.3 0.9
CD59* 1.0 0.5 2.4
DAF 1.0 ± 1.0 0.4 ±0.3 0.6 ±0.004
MCP 1.0 ±0.03 0.8 ±0.1 0.8 ±0.2
CR1 1.0 ±0.5 1.0 ±0.2 0.9 ±0.2
Table 3.2. Relative abundances of mRNAs for regulatory complement 
components in normal (N), osteoarthritis (OA) and rheumatoid arthritis 
(RA) synovial membranes. The abundance of each mRNA in normal 
synovial membrane was given an arbitrary value of 1 unit. Data for DAF, 
MCP and CR1 are the mean ± SD of three experiments.
* Data from one set of observation.
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Various types of cells such as fibroblasts, endothelial cells, 
macrophages, adipocytes, macrophage-like (type A) and fibroblast-like 
(type B) synoviocytes are present in the synovial membrane. Detection of 
the mRNAs encoding the whole battery of regulatory complement 
proteins in synovial membrane raised the question of which types of cells 
are expressing which complement regulatory proteins in synovial 
membrane. Human synovial fibroblasts, endothelial cells, monocytes and 
lymphocytes were investigated to find an answer to this question.
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3.4. SYNTHESIS OF COMPLEMENT REGULATORY PROTEINS 
BY SYNOVIAL FIBROBLASTS
3.4.1. Analysis of Secreted Regulatory Proteins by ELISA.
Fibroblasts isolated from synovial membranes from RA and OA 
patients and from normal individuals were cultured for seven days as 
described in section 2.3.4. Culture supernatants were collected at days 1, 
3, 5 and 7. The samples were assayed for the complement components CI- 
INH, C4-bp, factor H and factor I by ELISA. The results from three 
separate experiments are summarized in Figures 3.16 and 3.17, and the 
secretion rates (calculated as molecule/cell/min) in Table 3.3.
CI-INH and factor H were detected in the culture supernatants 
from synovial fibroblasts isolated from all RA and OA patients and 
normal individuals. Although factor I was detectable in all normal 
fibroblast cell culture supernatants, only one RA and one OA fibroblast 
culture showed detectable levels of factor I. C4-bp was not detectable in 
any type of fibroblast cell culture supernatants. The secretion of proteins 
was inhibited approximately 80 % by the addition of cycloheximide (2.5 
pg/ml) in the culture medium (data not shown). This result shows that 
the accumulation of complement regulatory proteins in the culture 
supernatants was due to de novo synthesis and not to secretion of 
preformed protein.
The ELISA data indicate that fibroblasts from the synovial 
membrane of RA and OA patients, and from normal individuals, are 
capable of synthesizing and secreting CI-INH, factor H and factor I in 
vitro. The amounts of CI-INH, factor I and factor H secreted increased 
linearly throughout the seven day culture period. Statistical analysis by 
the Mann-Whitney ranking procedure showed significant differences in
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F ig u re  3.16: ELISA analyses for a) CI-INH and b) factor I secreted by 
synovial fibroblast*in culture from normal (N), osteoarthritis (OA) and 
rheumatoid a rth ritis (RA) patients. The culture medium was removed 
completely a t day 1, 3, 5 and 7. The am ount of CI-INH and factor I 
secreted into the culture medium at the indicated days was m easured. 
After seven days in culture, the results were plotted as cumulative 
synthesis (ng/10^ cells). Each point representsthe mean with the standard 
deviation of three experiments.
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Figure 3.17: ELISA analyses for factor H secreted by synovial membrane 
fibroblast in culture from normal (N), osteoarthritis (OA) and rheum atoid 
arthritis (RA) patients. The culture medium was removed completely a t 
day 1, 3, 5 and 7. The amount of factor H secreted into the culture 
medium at the indicated days was measured. After seven days in culture, 
the results were plotted as cumulative synthesis (ng/10^ cells). Each 
point represents the mean with the standard deviation of three 
experiments.
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CELL TYPE Cl-INH H I C4-bp
HUVEC 0 74 ±12 40 ±12 0
MONOCYTE 109 ± 18 65 ± 6 0 23 ±0.3
N (F) 418 ± 80 140 ± 22 39 ±10 0
OA (F) 233 ±80* 79 ±50 16 ±27 0
RA (F) 357 ± 14 143 ± 19 6 ± 1 0 * 0
Table 3.3: Secretion rates of regulatory fluid-phase complement 
components Cl-INH, factor H (H), factor I (I) and C4-bp expressed as 
molecule/cell/min in human umbilical cord endothelial cells (HUVEC), 
monocytes, normal (N), osteoarthritis (OA) and rheumatoid arthritis (RA) 
synovial fibroblasts (F). Each point represents the mean ± SD of three 
experiments. * indicates significant difference (P < 0.05) when compared 
to corresponding normal (F) values.
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secretion rates of factor I between normal and RA fibroblasts (p<0.01), 
and of Cl-INH between normal and OA fibroblasts (p<0.04). The other 
regulatory complement components was not significantly different in RA, 
OA and normal fibroblasts.
3.4.2. Im munohistochemical Analysis of Membrane Regulatory 
Proteins.
The presence of membrane regulatory proteins was investigated by 
immunohistochemical staining. Fibroblasts isolated from synovium from 
normal individuals were grown on glass slides under standard culture 
conditions as described in section 2.3.4. Cells were fixed by acetone 
(section 2.11.1.) and stained with monoclonal antibodies against DAF 
(IA10H6) (Figure 3.18. b), MCP (E4.3) and CD59 (YTH53.1) (Figure 3.19. 
a and b), MIP (anti-MIP) and CR1 (E ll) (Figure 3.20. a and b) by the 
immunoperoxidase method. The staining for DAF and CD59 was strong 
while staining for MIP and MCP was weak. CR1 was not detected on 
fibroblasts.
3.4.3. Abundances o f mRNAs Encoding Regulatory Complement 
Proteins.
A large proportion of regulatory complement proteins (except C4- 
bp and CR1) were detected in synovial fibroblasts. Fibroblasts were 
analyzed for the presence of the mRNAs encoding each of these proteins. 
Total RNA extracted from synovial fibroblasts from RA and OA patients 
and normal individuals was analyzed by Northern blots hybridized with 
^P-labelled probes for each of the mRNAs (Cl-INH, C4-bp, factor H, 
factor I, S Protein, SP-40,40, DAF, MCP, CD59, and CR1). As single
131
AF igure  3.18: Immunohistochemical analyses of normal synovial
fibroblasts. Cells grown on slides were stained by the immunoperoxidase 
method, a) Mouse IgG was used at 1/100 dilution as control, b) 
Monoclonal antibody to hum an DAF (IA10H6) was used a t 1/100 dilution. 
DAF localized on synovial fibroblasts (brown colour) (x 250).
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BF ig u re  3.19: Immunohistochemical analyses of norm al syiovial
fibroblasts. Cells grown on slides were stained by the immunoperoddase 
method, a) Monoclonal antibody to hum an MCP (E4.3) was used ai 1/100 
dilution. MCP staining was very weak compared to the other antbodies 
used (brown colour), b) Monoclonal antibody to hum an CD59 (YTJ53.1) 
was used a t 1/100 dilution. CD59 localized on synovial fibroblasts (irown 
colour) (x 250).
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F igu re  3.20: Immunohistochemical analyses of normal synovial
fibroblasts. Cells grown on slides were stained by the immunoperoxidase 
method, a) Monoclonal antibody to hum an CRl (E ll)  was used at 1/100 
dilution. Staining was negative for CRl. b)  Monoclonal antibody to 
hum an MIP (anti-MIP) was used a t 1/100 dilution. MIP localized on 
synovial fibroblasts (brown colour) (x 250).
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species of mENA were.observed for Cl-INH (2.1 kb), factor I (2.4 kb), S 
Protein (2.8 kb), SP-40,40 (1.8 kb), MCP (4.2 kb) whereas multiple bands 
were observed for factor H (4.3 kb, 1.8 kb), DAF (2.7 kb, 1.5 kb) and CD59 
(2.0 kb, 1.4 kb, 0.8 kb). Although Northern blots were also probed for C4- 
bp and CRl hybridisation signals were not detected. The Northern blots 
were stripped and rehybridized with a probe for 28S rRNA to allow 
corrections for unequal loading to be made. The results are summarized 
in Figures 3.21, 3.22 3.23 and 3.24; the abundances of the mRNAs 
relative to those in normal fibroblast, and corrected for differences in 
loading, are summarized in Table 3 .4 .
The relative abundances of the mRNAs for factor I (p<0.006), factor 
H (4.3 kb species; p<0.04), S protein (p<0.01) and SP-40,40 (p<0.02) were 
significantly different in normal and RA patient fibroblasts. The relative 
abundances were greater for factor H and SP-40,40 but smaller for factor 
I and S protein in RA fibrolasts than in normal fibroblasts. Furthermore, 
the 2.0 kb species of CD59 was greater (p<0.001) in normal fibroblasts 
than OA fibroblasts. Moreover, the relative abundances of the mRNAs for 
factor I (p<0 .002), SP-40,40 (p<0.04), CD59 (2.0 kb species, p<0.01) and 
DAF (2.7 kb species, p<0.001) were significantly different in RA and OA 
fibroblasts. Except for factor I the relative abundances were always 
greater in RA than OA fibroblasts. No significant differences were 
observed in the abundances of Cl-INH and MCP mRNAs in normal, OA 
and RA fibroblasts. The results of the Northern blot analyses showed that 
the only mRNAs present were those for which the protein had been 
detected by ELISA or imiMftohistochemistry.
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Figure 3.21: Autoradiographs of Northern blot analyses of RNA derived 
from cultured synovial fibroblasts from normal individuals (Lanes 1, 2, 3), 
osteoarthritis (Lanes 4, 5) and rheum atoid a rth ritis (Lanes 6 and 7) 
patients. ^^P-labelled a) Cl-INH and b) factor I probes were used for 
hybridisation. The sizes of the mRNAs were: Cl-INH (2.1 kb) and factor I 
(2.4 kb).
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F igure  3.22: Autoradiographs of N orthern blot analyses of RNA derived 
from cultured synovial fibroblasts from norm al individuals (Lanes 1, 2, 3 
in a and  b; Lanes 1, 2 in c), osteoarthritis (Lanes 4, 5 in a and b; Lanes 3, 
4 in  c) and rheum atoid a rth ritis  (Lanes 6, 7 in a and b; Lanes 5, 6 in c) 
patients. ^2P-labelled a) factor H, b) S protein and c) SP-40,40 probes 
were used for hybridisation. The sizes of the mRNAs were: factor H (4.3 
kb, 1.8 kb), S protein (2.8 kb) and SP-40,40 (1.8 kb).
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F igu re 3.23: Autoradiographs of N orthern  blot analyses of RNA derived 
from cultured synovial fibroblasts from norm al individuals (Lanes 1, 2, 3 
in a, Lanes 1, 2 in  b and c), osteoarthritis (Lanes 4, 5 in  a; Lanes 3, 4 in  b 
and c) and rheum atoid a rth ritis  (Lanes 6, 7 in  a; Lane 5 in b; Lanes 5, 6 
in c) patients. ^^P-labelled a) DAF b) MCP and c) CD59 probes were 
used for hybridisation. The sizes of mRNA were; DAF (2.7 kb, 1.5 kb), 
MCP (4.2 kb) and CD59 (2.0 kb, 1.4 kb and 0.8 kb).
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F igu re 3.24: Rehybridization of N orthern  blots shown in  figures 3.21, 
3.22 and 3.23 (in a, b and c) and figure 3.29 (in d and e) w ith a probe for 
28S rRNA. N orthern  blots had previously been hybridized with probes for 
a) C l-IN H , factor I, DAF, MCP and SP-40,40, b) factor H, S protein, c) 
CD59 d) CD59 e) DAF.
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COMPONENTS N OA RA
Cl-INH 1.0 ±0.18 0.8 ±0.06 0.9 ±0.03
FACTOR H
(4.3kb)
(1.8kb)
1.0 ±0.18 
1.0 ±0.42
1.0 ±0.43
1.0 ± 0.001
2.7 ± 1.0 * (+)
1.8 ± 1.75
FACTOR I 1.0 ± 0.20 0.7 ±0.08 0.4 ± 0.005 *(+)
S PROTEIN 1.0 ± 0..20 1.5 ±0.79 0.4 ±0.125*
SP-40,40 1.0 ±0.75 1.3 ±0.78 3.1 ± 0.70 *(+)
DAF
(2.7kb)
(1.5kb)
1.0 ±0.28 
1.0 ± 0.40
0.8 ± 0.05 
0.8 ± 0.03
1.1 ±0.05 (+) 
1.4 ±1.1
MCP 1.0 ±0.47 0.6 ±0.07 0.5 ±0.43
CD59 (2 .0kb) 
(1.4kb) 
(0 .8kb)
1.0 ± 0.10 
1.0 ± 0.10 
1.0 ±0.07
0.5 ±0.06* 
0.9 ±0.57 
1.3 ± 0.86
1.3 ± 0.30 (+) 
1.2 ±0.41 
1.1 ±0.06
Table 3.4: Relative abundances of mRNAs for regulatory complement 
components in normal (N), osteoarthritis (OA) and rheumatoid arthritis 
(RA) synovial fibroblasts. Results represent the mean ± SD of three 
experiments. The abundance of each species of mRNA in normal synovial 
membane was assigned an arbitrary value of 1 unit. * significantly 
different (P < 0.05) from corresponding normal values, (+) sigificantly 
different (P < 0.05) from corresponding OA values.
1 4 0
3.5. SYNTHESIS OF REGULATORY COMPLEMENT PROTEINS 
BY ENDOTHELIAL CELLS
3.5.1. Analysis o f Secreted Regulatory Proteins by ELISA.
Endothelial cells^also present in synovial membrane. Endothelial 
cells were isolated from human umbilical cord and cultured for seven 
days as described in section 2.3.1. Culture supernatants were collected at 
days 1, 3, 5 and 7. The samples were assayed for the complement 
components Cl-INH, C4-bp, factor H and factor I by ELISA. Factor H and 
factor I were detected. Although secretion of Cl-INH by endothelial cells 
has been reported by Schmaier et al. (1989), I could not detect it under 
the unstimulated culture conditions employed. C4-bp was not detected in 
any set of cultures. The addition of cycloheximide (2.5 pg/ml) inhibited 
secretion of proteins approximately 90% by endothelial cells (data not 
shown). This result shows that the accumulation of factors H and I in the 
culture supernatants was due to de novo synthesis and not to secretion of 
preformed protein. The results from three separate experiments are 
summarized in Figure 3.25. and the secretion rates (calculated as 
molecule/cell/min) in Table 3.3. These data indicate that endothelial cells, 
like fibroblasts, are capable of synthesizing and secreting some of the 
regulatory complement proteins in vitro.
3.5.2. Flow-cytometric Analysis of Membrane Regulatory 
Proteins.
The presence of regulatory complement proteins on endothelial 
cells was investigated by flow cytometry. Cells were treated with 
monoclonal antibodies against DAF (BRIC 110), MCP (J4-48), CD59
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F igure 3.25: ELISA analyses for a) factor H and b) factor I secreted by 
endothelial cells. The culture medium was removed completely a t day 1, 
3, 5 and 7. The am ount of factor H and factor I secreted into the  culture 
medium at the indicated days was measured. After seven days in  culture, 
the results were plotted as cumulative synthesis (ng/10^ cells). Each 
point represents the mean with the standard deviation of three 
experiments.
1 4 2
2 0 2
9 .  255
a .  255 
a .  255  
a .  2 5 5
2 .  2 55  
2 .  2 5 5  
2 .  2 55  
2 .  25 5
■pm
“ L I
2 . 2 5 5  
2 . 2 55  
2 . 2 5 5  
2 .  255
3 .  2 55  
a .  2 55  
a .  255 
a .  255
FL 1 FL 1
E
2 2 2
a .  2 5 5
a .  2 5 5
a . 2 5 5
a .  2 5 5
V
1 2 2  i 0 l I Q 2 1 2 2 1 2 4
F ig u re  3.26: Flow-cytometnc analyses of endothelial cells during the 
fourth passage. Cells were treated  with a) BSA (0.2%, w/v) in  PBS as a 
background control b) anti-DAF (BRIC110, IgGl mouse), c) anti-M CP 
( J4-48, IgG l mouse), d) anti-CD59 (BRIC229, IgG2b mouse) and e) anti- 
CR1 ( E l l ,  IgGl mouse) and FITC-conjugated anti-mouse Ig. Fluorescence 
in tensity  is plotted on a logarithmic scale (x-axis), and cell num ber on a 
linear scale (y-axis).
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(BRIC 229) and CRl (E ll) as described in section 2.12. The results 
indicated that DAF, MCP and CD59, but not CRl, were present on 
endothelial cells (Figure 3.26). The fluorescence intensity for CD59 was 
high while that for DAF was relatively low.
3.5.3. Abundances of mRNAs Encoding the Regulatory 
Complement Proteins.
ELISA and flow cytometry analysis showed that endothelial cells 
are capable of secreting factor H and I, and expressing DAF, MCP and 
CD59 on their surfaces. Thus, these cells synthesize the majority of 
regulatory complement proteins. Total cellular RNA was extracted from 
endothelial cells to investigate the mRNAs encoding each of these 
detected proteins, and also those that were not detected by ELISA or flow 
cytometry. Northern blot analyses were performed as described in section
2.9.1. and hybridized with 32p-labelled probes for each of the mRNAs 
(Cl-INH, C4-bp, factor H, factor I, S Protein, SP-40,40, DAF, MCP, CD59 
and CRl). The Northern blots were stripped and rehybridized with a 
probe for 28S rRNA to allow corrections for unequal loading to be made. 
The results are summarized in Figures 3.24, 3.27, 3.28, and 3.29. 
Northern blots hybridized with probes for Cl-INH, C4-bp and CRl did 
not show any signal. A single species of mRNA was observed for factor I 
(2.4 kb), S Protein (2.8 kb), SP-40,40 (1.8 kb), but multiple bands were 
observed for factor H (4.3 kb, 1.8 kb), DAF (2.7 kb, 1.5 kb), MCP (4.8 kb, 
4.2 kb) and CD59 (2.0 kb, 1.4 kb, 0.8 kb). Densitometric analysis enabled 
the ratios of the different species of mRNA to be calculated. The ratios of 
the abundances of the two species of DAF mRNA differ between 
endothelial cells and fibroblasts (Table 3.5) but not between normal, OA 
and RA fibroblasts. The ratios of the abundances of the CD59 mRNAs are
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Figure 3.27: Autoradiographs of Northern blot analyses of RNA derived 
from cultured endothelial cells. The blots were hybridized with probes for 
a) factor H and b) factor I. The sizes of the mRNAs were: factor H (4.3 kb, 
1.8 kb) and factor I (2.4 kb).
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Figure 3.28: Autoradiographs of Northern blot analyses of RNA derived 
from cultured endothelial cells. The blots were hybridized with probes b r 
a) S protein and b) SP-40,40. The sizes of the mRNAs were: S protein (2.8 
kb), SP-40,40 (1.8 kb).
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Figure 3.29: Autoradiographs of N orthern blot analyses of RNA derived 
from cultured endothelial cells. The blots were hybridized with probes 
for a) DAF, b) MCP and c) CD59. The RNAs loaded on Lanes 1 and 3 for 
DAF and Lanes 3 and 5 for CD59 were isolated after treatm ent of the 
cells with cycloheximide (2.5 pg/ml) for 48 hours. The sizes of the 
mRNAs were: S protein (2.8 kb) and SP-40,40 (1.8 kb).
RATIO HUVEC N OA RA
1.5kb/2.7kb 2.0 ±1.0 0.80 ±0.2 0.73 ±0.2 0.90 ±0.6
Table 3.5: The ratio of the abundances of 1.5 kb to 2.7kb species of DAF 
mRNA in human umblical cord endothelial cells (HUVEC) and normal 
(N), osteoarthritis (OA) and rheumatoid arthritis (RA) fibroblasts. Each 
value represents the mean ± SD of three experiments.
summarized in Table 3.6. All the fibroblast RNAs contained a greater 
preponderance of the highest molecular weight mRNA species, in contrast 
to endothelial cells, but again there was no difference between the 
normal, OA and RA fibroblasts. These data suggest that there are cell- 
specific differences in the processing of the mRNAs for these regulatory 
proteins. The same appears to be true for MCP mRNA since this occurs as 
a doublet in RNA from endothelial cells, but not in fibroblast RNA.
The Northern blot data are in agreement with the data obtained 
from ELISA and flow cytometry measurements. In particular, no trace of 
Cl-INH, C4-bp or CRl was found at either the protein or the mRNA 
level.
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RATIO HUVEC N OA RA
1.4kb/2.0kb 1.17 ±0.3* 0.65 ±0.1 0.87 ±0.5 0.78 ±0.2
0.8kb/2.0kb 1.35 ±0.8 0.77 ±0.3 0.90 ±0.9 0.60 ±0.5
Table 3.6: The ratio of the abundances of 1.4 kb to 2.0kb and 0.8 kb to 2.0 
kb species of CD59 mRNA in human umblical cord endothelial cells 
(HUVEC) and normal (N), osteoarthritis (OA) and rheumatoid arthritis 
(RA) fibroblasts. Each value represents the mean ± SD of three 
experiments. * Significantly different than normal (p<0.04).
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3.6. SYNTHESIS OF REGULATORY COMPLEMENT PROTEINS 
BY MONOCYTES
3.6.1. Analysis of Secreted Regulatory Proteins by ELISA
Mononuclear phagocytes are the third type of cell in synovium 
which I have studied by using peripheral blood monocytes prepared from 
human buffy coat preparations of blood donations. Monocytes were 
cultured for seven days as described in section 2.3.2. Culture 
supernatants were collected at the days 1, 3, 5 and 7. The samples were 
assayed for the complement components Cl-INH, C4-bp, factor H and 
factor I by ELISA. Cl-INH, C4-bp and factor H, but not factor I, were 
secreted by monocytes. The results from three separate experiments are 
summarized in Figures 3.30 and 3.31 and the secretion rates (calculated 
as molecule/cell/min) in Table 3.3. These show that monocytes secrete 
about twice as much Cl-INH than factor H and about three times as 
much factor H than C4-bp (Table 3.3.) and they are the only cell type so 
far examined which is capable of synthesizing and secreting C4-bp in 
vitro. The presence of cycloheximide (2.5 fig/ml) inhibited approximately 
80 % of the synthesis of secretory proteins by monocytes (data not shown). 
This result indicates that the accumulation of Cl-INH, C4-bp and factor 
H in the culture supernatants was due to de novo synthesis and not the 
secretion of preformed protein.
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F ig u re  3.30: ELISA analyses for a) C l-IN H  and b) C4-bp secreted by 
monocytes. The culture medium was removed completely a t day 1, 3, 5 
and 7. The am ount of Cl-INH and C4-bp secreted into the culture 
medium a t the indicated days was m easured. After seven days in culture, 
the results were plotted as cumulative synthesis (ng/10^ cells). Each 
point represents the mean with the standard  deviation of three 
experiments.
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Figure 3.31: ELISA analyses for factor H secreted by monocytes. The 
culture medium was removed completely a t day 1, 3, 5 and 7. The am ount 
of factor H secreted into the culture medium a t the indicated days was 
measured. After seven days in culture, the results were plotted as 
cumulative synthesis (ng/10^ cells). Each point represent the mean with 
the standard deviation of three experiments.
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3.6.2. Immunohistochemical Analysis of Membrane Regulatory 
Proteins.
The presence of regulatory membrane proteins was investigated by 
immunohistochemical staining. Monocytes were grown on glass slides in 
a petri dish under standard culture conditions as described in section
2.3.2. Cells were fixed by acetone (section 2.11.1.) and stained with 
monoclonal antibodies against DAF (IA10H6) (Figure 3.32 b); MCP (E4.3) 
and CD59 (YTH53.1) (Figure 3.33 a and b); CRl (E ll) and MIP (anti- 
MIP) (Figure 3.34 a and b) by the alkaline phosphatase method. Intensity 
of staining for DAF, CD59 and MIP was stronger than for MCP and CRl. 
Positive staining of monocytes for CRl is in contrast to fibroblasts and 
endothelial cells which were negative.
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BFigure 3.32: Imunohistochemical analyses of monocytes. Cells grown on 
glass microscope slides were stained by the alkaline phosphatase method,
a) Mouse IgG was used a t 1/100 dilution as control, b) Monoclonal 
antibody to hum an DAF (IA10H6) was used at 1/100 dilution. DAF 
localized on monocytes (red colour) (x 250).
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F ig u re  3.33: Immunohistochemical analyses of monocytes. Cells grown 
on glass microscope slides were stained by the alkaline phosphatase 
m ethod, a) Monoclonal antibody to hum an MCP (E4.3) was used at 1/100 
dilution, b) Monoclonal antibody to hum an CD59 (YTH53.1) was used at 
1/100 dilution. MCP and CD59 localized on monocytes (red colour) (x 
250).
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AF igu re  3.34: Immunohistochemical analyses of monocytes. Cells grown 
on microscope slides were stained by the alkaline phosphatase method, a) 
Monoclonal antibody to hum an CR1 (E ll)  was used a t 1/100 dilution, 
localized on monocytes (pink colour) b) Monoclonal antibody to human 
MIP (anti-M IP) was used a t 1/100 dilution. MIP localized on monocytes 
(red colour) (x 250).
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3.6.3. Abundances of mRNAs Encoding the Regulatory 
Complement Proteins.
To investigate further the synthesis of complement regulatory 
proteins, monocytes were analyzed for the presence of mRNAs encoding 
each of these proteins. Total cellular ENA extracted from cultured 
monocytes was analyzed by Northern blots and dot-blots hybridized with 
32p-iabelled probes for each of the mRNAs (Cl-INH, C4-bp, factor H, 
factor I, S Protein, SP-40,40, DAF, MCP, CD59 and CR1). The results are 
summarized in Figures 3.35, 3.36 and 3.37.
A single species of mRNA was observed for Cl-INH (2.1 kb), C4- 
bp (2.5.kb) and SP-40,40 (1.8 kb), whereas two bands were observed for 
factor H (4.3 kb, 1.8 kb). In monocytes factor H mRNA could not be 
detected unless cycloheximide (2.5 (ig/ml) was present in the cultures. 
Due to the scarcity of RNA, dot-blots were used for the hybridization with 
probes for DAF, MCP, CD59 and CR1 mRNAs and positive signals were 
detected for all of these regulatory membrane proteins. Factor I and S 
protein mRNAs were not detected on Northern blots of monocyte RNA.
Northern and dot blot data and the data obtained from ELISA and 
immunohistochemical staining were in agreement in showing that C4-bp 
and CR1 were expressed in monocytes but not in fibroblasts or 
endothelial cells.
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Figure 3.35: Autoradiographs of Northern blot analyses of RNA derived 
from cultured monocytes. The blots were hybridized with probes for a) 
Cl-INH and b) C4-bp. The sizes of the mRNA were: Cl-INH (2.1 kb) and 
C4-bp (2.4 kb)
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Figure 3.36: Autoradiographs of Northern blot analyses of RNA derived 
from cultured monocytes. The blots were hybridized with probes for a) 
factor H (total RNA was isolated after treatm ent of the cells with 
cycloheximide (2.5 pg/ml) for 48 hours) and b) SP-40,40. The sizes of the 
mRNAs were: factor H (4.3 kb, 1.8 kb) and SP-40,40 (1.8 kb).
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F igure  3.37: Autoradiographs of dot blot analyses of RNA (5 pg) deived 
from cultured monocytes. The blots were hybridised with probes fir a) 
DAF; b)MCP; c) CD59 and d) CR1 mRNAs.
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3.7. SYNTHESIS OF REGULATORY COMPLEMENT PROTEINS 
BY LYMPHOCYTES
3.7.1. Analysis of the Secreted Regulatory Proteins by ELISA.
3.7.1.1. Peripheral blood lymphocytes cultured under standard  
culture conditions.
Lymphocytes are a fourth cell type in synovium and the last one 
investigated in this thesis in order to understand the regulation of 
complement activation at sites of inflammation. Lymphocytes were 
isolated from human bufly coat and were cultured for seven days under 
standard culture conditions as described in section 2.3.3. Culture 
supernatants were collected at days 1, 3, 5 and 7. The samples were 
assayed for the complement components Cl-INH, C4-bp, factor H and 
factor I by ELISA. Cl-INH, factor H and factor I were detectable at very 
low levels after one day. The supernatants which were collected at days 3, 
5 and 7 were negative for all components (Cl-INH, C4-bp, factor H and 
factor I). The results from three separate experiments were calculated as 
molecule/cell/min and summarized in Table 3.7.
It was thought that the proteins detected previously may due the 
monocytet contamination in the lymphocyte culture or perhaps monocyte- 
derived cytokines may have stimulatelthe lymphocytes to secrete these 
components. So lymphocyte preparations were depleted of monocytes by 
preincubation in a culture flask at 37°C three to four hours. Then non­
adherent cells were transfer! to a fresh culture flask and cultured as 
before. Similar experiments were done with monocyte-depleted 
lymphocyte cultures. Except for factor H none of the regulatory proteins 
were detected in the monocyte-depleted lymphocyte culture supernatants
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CONTROL PHA PWM Con A
Cl-INH 2.7 ±1.5 3.3 ±0.5 1.6'±01 2.4 ±0.9
C4-bp 0 0 0 0.9 ±0.8
Factor I 1.2 ±0.4 0 1.2 ±0.7 31.0 ±12.0
Factor H 2.5 ±1.1 1.4 ±0.6 4.0 ±0.1 1.4 ±0.5
Table 3.7. Secretion rates of fluid-phase regulatory complement proteins 
Cl-INH, C4-bp, Factor H and Factor I (molecule/cell/min) in lymphocytes 
cultured under standard condition (control) and stimulated by 
Phytohaemagglutinin (PHA), Pokeweed mitogen (PWM) and Concaivcwalu 
A (Con A). Each value represents the mean ± SD of three experiments.
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under unstimulated conditions (Table 3.8). Factor H was not detectable 
after one day.
The failure to detect any regulatory complement component in the 
supernatants after one day of culture led us to stimulate the lymphocytes 
with mitogens like phytohaemagglutinin (PHA), Pokeweed mitogen 
(PWM) and Conca^ ayoM* A (Con A). Mitogen treatment inducesmitosis and 
proliferation and may stimulate the cells to synthesize complement 
proteins.
3.7.1.2. Peripheral blood lymphocytes stim ulated w ith mitogens.
Lymphocyte cultures were stimulated with phytohaemagglutinin 
(PHA) (120 pg/ml) for 72 hours, culture supernatants were collected after 
1, 3, 5 and 7 days and the samples were assayed for the complement 
components Cl-INH, C4-bp, factor H and factor I by ELISA. The results 
from three separate experiments were calculated as molecule/cell/min 
and summarized in Table 3.7. Cl-INH and factor H were detected after 
one day at very low levels. The stimulation with PHA did not increase the 
amounts significantly. Factor I was not detectable in PHA stimulated 
lymphocytes.
Similar experiments were done with lymphocytes stimulated with 
Pokeweed mitogen (PWM) (100 pg/ml) for 72 hours and Concavalin A 
(Con A) (100 Jig/ml) for 72 hours, and the culture supernatant assayed by 
ELISA. The results, calculated as molecule/cell/min and summarized in 
Table 3.7. These show that although treatment with PWM did not 
increase the amounts of proteins significantly, following the stimulation 
with Con A the synthesis of factor I was increased around 25-fold which 
suggst> that Con A upregulates synthesis and secretion of factor I by 
peripheral blood lymphocytes.
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COMPONENTS CONTROL PHA PWM Con A
Cl-INH 0 0 0 11.0
C4-bp 0 0 0 10.0
Factor I 0 0 0 10.0
Factor H 7.2 15.5 3.9 7.1
Table 3.8. Secretion rates of fluid phase regulatory complement proteins 
of Cl-INH, C4-bp, factor H and factor I (molecule/cell/min) in monocyte 
depleted lymphocytes cultured under standard condition (control) and 
stimulated with Phytohaemagglutinin (PHA), Pokeweed mitogen (PWM) 
and Conca AavjcvU A (Con A). These values are from a single experiment.
Monocyte depleted lymphocyte cultures were stimulated with the 
same mitogens at the same concentrations. The supernatants were 
examined for secreted Cl-INH, C4-bp, factor H and factor I by ELISA. 
Only factor H was detected in the monocyte depleted lymphocyte culture 
supernatants even after stimulation with PWM and PHA (Table 3.8). 
Interestingly all the secreted regulatory proteins were detected following 
the stimulation with Con A (100 pg/ml) (Table 3.8.).
These data suggested that although complement proteins 
disappear after monocyte depletion Con A stimulates the synthesis of 
secreted proteins (Cl-INH, C4-bp, factor H and factor I) by lymphocytes. 
Perhaps lymphocytes secrete those proteins a t very low levels and ELISA 
is not sensitive enough to detect them or lymphocytes may only begin to 
synthesize those proteins following the stimulation by Con A or possibly 
cytokines released at site of inflammation by monocytes and other cell 
types.
3.7.2. Immunohistochemical Analysis of Membrane Regulatory 
Proteins.
Lymphocytes were isolated from buffy coats and resuspended in 
PBS. Cytospin preparations were fixed on glass slides with acetone (see 
section 2.11.1.) and reacted with monoclonal antibodies against DAF 
(IA10H6) (Figure 3.38 b), CD59 (YTH53.1) and MIP (anti-MIP) (Figure 
3.39 a and b), and against MCP (E4.3) and CR1 (E ll)  (Figure 3.40 a and
b). Although the cells did not react very satisfactorily for DAF, CD59, 
MCP and CR1, they did give weak positive results. Lymphocytes stained 
strongly for MIP.
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AFigure 3.38: Imunohistochemical analyses of lymphocytes. Cytospin 
preparations of cells were fixed and stained by the immunoperoxidase 
method, a) Mouse IgG was used at 1/100 dilution as control, b) 
Monoclonal antibody to hum an DAF (IA10H6) was used a t 1/100 dilution. 
DAF localized on lymphocytes (brown colour), x 250
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Figure 3.39: Immimohistochemical analyses of lymphocytes. Cytospin 
preparations of cells were fixed and stained by the immunoperoxidase 
method, a) Monoclonal antibody to hum an CD59 (YTH53.1) was used at 
1/100 dilution. CD59 localized on lymphocytes (brown colour), b) 
Monoclonal antibody to hum an MIP (anti-MIP) was used a t 1/100 
dilution. MIP localized on lymphocytes (brown colour) (x 250).
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F ig u re  3.40: Immunohistochemical analyses of lymphocytes. Cytospin 
preparations of cells were fixed and stained by the alkaline phosphatase 
mtethod. a) Mouse IgG was used at 1/100 dilution as control, b) 
Monoclonal antibody to hum an MCP (E4.3) was used a t 1/100 dilution 
(piink colour), c) Monoclonal antibody to hum an CR1 (E ll)  was used at 
1/100 dilution (pink colour) (x 250).
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3.7.3. Abundance of mRNAs Encoding Regulatory Proteins.
Total cellular RNA extracted from lymphocytes was almost always 
degraded. Using the RNA immediately after extracting it, and treating 
the solutions and equipment with diethyl pyrocarbonate (DEPC), did not 
alter the result. Northern blots were performed as described in section
2.9.1. with the best preparations of RNA. Blots were hybridized with 32p_ 
labelled probes for Cl-INH, C4-bp, factor H and factor I mRNAs but none 
of them gave positive signals. Although smears were detected on the blots 
hybridized with probes for factor H and Cl-INH, it may be deceptive to 
comment about these data and further investigation is necessary.
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3.8. EFFECT OF CYTOKINES ON ENDOTHELIAL CELLS
3.8.1. Analysis of Secreted Regulatory Proteins by ELISA in  
Endothelial Cells Following Cytokine Stimulation
Cytokines are cell-derived mediators of acute and, particularly, 
chronic inflammation. Interferon y (IFNy) is important in macrophage 
activation. Interleukin 1 (IL-1) is essential for lymphocyte proliferation in 
response to antigens; it stimulates fibroblast proliferation and is 
responsible with interleukin 6 (IL-6) for increased hepatic protein 
synthesis during the acut phase response. Cells a t sites of chronic 
inflammation are subject to the effects of cytokines.
Endothelial cells were treated with IFNy, IFNa, IL-1 and IL-6 to 
better understand the events occurring at sites of inflammation. These 
cytokines were added to the endothelial cell culture medium at 0.01 ng/ml 
and 10 ng/ml. The supernatants were collected 24, 48 and 72 hours later. 
The samples were assayed for the complement components Cl-INH, 04- 
bp, factor H and factor I by ELISA. The results from three separate 
experiments are summarized in Figures 3.41 and 3.42 and the secretion 
rates (calculated as molecule/cell/min) are summarized in Table 3.9. The 
amounts of factor H secreted were increased following the stimulation 
with IFNy. Furthermore, although secretion of Cl-INH was not detected 
under standard culture conditions, Cl-INH became detectable following 
stimulation by IFNy. Addition of IL-1 and IL-6 into the culture medium 
did not upregulate the secreted complement regulatory proteins; in 
contrast, a slight suppression was observed. Similarly, following the 
stimulation of endothelial cells with IFNa, a slight decrease was observed 
in the amount of secreted factor H. As found with IFNy, IFNa-treated 
endothelial cells also secreted Cl-INH (35 molecule/cell/minute) at 24, 48
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F ig u re  3.41: ELISA analyses for factor H secreted by endothelial cells. 
The culture medium was removed completely at 24, 48 and 72 hours. The 
am ount of factor H secreted into the culture medium a t the indicated 
hours was measured. After three days in culture, the results were plotted 
as (molecule/cell/min). Untreated endothelial cells (open circles), 
endothelial cells treated with IFNy (10 ng/ml) (solid circles). Each point 
represents the mean with the standard deviation of three experiments.
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F ig u re  3.42: ELISA analyses for Cl-INH secreted by endothelial cells. 
The culture medium was removed completely a t 24, 48 and 72 hours. The 
amount of Cl-INH secreted into the culture medium a t the indicated 
hours was measured. After three days in culture, the results were plotted 
as (molecule/cell/min). U ntreated endothelial cells (open circles), 
endothelial cells treated with IFNy (10 ng/ml) (solid circles). Each point 
represents the mean with the standard deviation of three experiments.
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CONTROL 0.01 ng/ml 10 ng/ml
IFNy 53.0 ± 19.0 65.0 ± 25.0 89.0 ±52.0
IFNa 53.0 ± 19.0 32.0 ± 8.0 39.0 ± 17.0
IL-ip 39.0 ± 22.0 24.0 ± 13.0 30.0 ±9.4
IL-6 39.0 ± 22.0 17.2 ±2.8 23.0 ± 19.0
Table 3.9. Secretion rates of factor H expressed as molecule/cell/min in 
endothelial cells treated with 0.01 ng/ml and 10 ng/ml of IFNy, IFNa, IL- 
lp and IL-6 for 24 hours. Each ocAu<l represents the mean ± SD of three 
experiments.
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and 72 hours. C4-bp not detected in the supernatants of cytokine treated 
cells.
These data suggested that IFNy upregulates secreted regulatory 
proteins in endothelial cells in both the classical (Cl-INH) and the 
alternative (factor H) pathway. Moreover, the secretion of some 
components like Cl-INH becomes detectable only after stimulation with 
IFNy. The upregulation observed is dose dependent and the effect 
develops after 24 hours stimulation by IFNy. Furthermore, the study 
made in our laboratory showed that IFNy also upregulates the 
transcription rate of the Cl-INH and factor H genes in endothelial cells 
(Lappin et al., 1992). Unlike IFNy, the other cytokines tested (IL-1 and 
IL-6) did not upregulate complement regulatory proteins, and although 
IFNa upregulates Cl-INH it did not upregulate factor H. As a result i , it 
was decided to concentrate on a study of the effects of IFNy on the 
synthesis of regulatory membrane proteins by endothelial cells.
3.8.2. Analysis of IFNy-stimulated Membrane Regulatory Proteins 
by Flow Cytometry.
Endothelial cells were grown until the fourth passage and 
confluent cells were treated with 10 ng/ml of IFNy. IFNy-treated 
endothelial cells becdme fusiform in contrast to the characteristic 
cobblestone appearance of untreated endothelial cells (Figure 3.43). One 
group of cells was stimulated with IFNy for 24 hours and the other group 
used as a control. Cells were prepared for flow cytometry as described in 
section 2.12. They were treated with monoclonal antibodies against DAF 
(BRIC 110), MCP (J4-48), CD59 (BRIC 229) and CR1 (E ll). The results 
are summarized in Figure 3.44.
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AF ig u re  3.43: a) Characteristic cobblestone appearance of endothelial cells 
grown under standard culture conditions, b) Following INFy (10 ng/ml) 
treatm ent endothelial cell morphology changed and cells were showoxf 
a . fusiform appearence. Photographs were taken under light microscopy (x 
250).
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F igure  3.44: Flow-cytom etric analyses of endo thelia l ceils during th e  
fourth  passage. D otted lines rep resen t untreateu control group, 
continuous lines re p re se n t ceils tre a te d  w ith  INFy (10 ng/ml) for 24 
hours. B oth group of ceils w ere tre a te d  w ith  a) BSA (0.2%, w/v) in PBS as 
a  background control b) anti-D A F (BRIC110, IgGl mouse), c) anti-MCP 
(J4-48. IgG l mouse), d) anti-C D 59 (BRIC229, IgG2b mouse) and e) anti- 
CH I ( E l l ,  Ig G l mouse) and  FITC -conjugatea an ti-m ouse Ig. Fluorescence 
in ten sity  is p lo tted  on a  logarithm ic scaie (x-axis), a n d  cell number on a 
lin ea r scaie (y-axis).
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The data suggested that there were no differences in the number of 
DAF molecules on the majority of the cells after stimulation by IFNy. 
However, a small proportion of the cells showed a sharp peak in the 
fluorescence pattern, which indicates the presence of a sub-set of 
endothelial cells that upregulate DAF in response to IFNy. This might be 
related to the age of the endothelial cells, since this sub-set was absent in 
higher passages of cells. The fluorescence intensity with anti-MCP was 
slightly higher in the control group compared to that in IFNy-stimulated 
cells. Unlike the secreted regulatory proteins, MCP was downregulated 
by IFNy. Nevertheless, although there was no increase in the fluorescence 
intensity with anti-CD59, the number of cells displaying CD59 on their 
surfaces was greater in the IFNy-stimulated cultures. CR1 was not 
detectable in control or IFNy-treated cells.
3.8.3. Abundances of mRNAs Encoding Membrane Regulatory 
Proteins
The effects of IFNy treatment on protein levels differed between 
different membrane proteins, as described previously. To investigate if 
these differences are reflections of the mRNA abundances, total cellular 
RNA was assayed from control and IFNy-stimulated endothelial cells.
Endothelial cells in their fourth passage were, treated with 0.01, 10 
and 100 ng/ml of IFNy for 24 hours. Total cellular RNA wcxs extracted, 
and subjected to Northern blot analysis. The blots were hybridized with 
32p-labelled probes for the mRNAs encoding DAF, MCP, CD59 and CR1. 
Multiple bands were observed for DAF (2.7 kb, 1.5 kb), MCP (4.8 kb, 4.2 
kb) and CD59 (2.0 kb, 1.4 kb, 0.8 kb). Although similar blots were also 
probed for CR1 no signals were detected. The Northern blots were 
stripped and rehybridized with a probe for 28S rRNA to allow corrections
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for unequal loading to be made. The results are summarized in Figures 
3.45, and 3.46; the abundances of the mRNAs relative to those in 
unstimulated endothelial cells and corrected for loading errors are 
summarized in Table 3.10.
These data indicate that the abundance of CD59 mRNA increased 
after IFNy stimulation. The increment was not great. The data are in 
agreement with the flow cytometry results since the number of cells 
displaying CD59 on their surfaces was more in the IFNy-stimulated 
cultures. The abundance of MCP mRNA in IFNy-treated cultures was 
slightly decreased compared to untreated cells, also in agreement with 
the flow cytometry results. A slight increase in mRNA (2.7 kb species) 
abundances were also observed for DAF in IFNy-treated cells. The small 
proportion of responsive cells detected by flow cytometry (see Figure 3.44) 
seems inadequate to make a difference in mRNA abundances.
3.8.4. The Effect o f IFNy Stim ulation on Transcription Rates.
The nuclear extracts were isolated from untreated and IFNy- 
treated (10 ng/ml for 24 hours) endothelial cells as described in section
2.7.4. The nascent transcripts were elongated for 30 minutes in vitro in 
the presence of [a-^P]UTP. The labelled RNA was then isolated from the 
nuclei by RNAzol (see section 2.7.4.). Equal amounts of DAF, MCP and 
CD59 and vector pUC19 DNAs were immobilized on nylon membranes 
(see section 2.9.3.). Hybridization with labelled transcripts w&& carried 
out as described in section 2.9.4. The results from two experiments are 
summarized in Figure 4.47.
The data indicate that the transcription rates were increased 60 % 
for DAF, 90 % for MCP and 3.4 fold for CD59 by IFNy stimulation. The 
increase in transcription rates did not correspond with the changes in
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F igure 3.45: Autoradiographs of Northern blot analyses of RNA derived 
from cultured endothelial cells. The blots were hybridized with ^2p_ 
labelled probes for:
a) DAF (lane 1 control; lanes 2, 3 and 4; 0.01, 1 and 10 ng/ml INFy 
treated  cells RNA respectively).
b) MCP (lane 1 control, lane 2, 10 ng/ml INFy treated cells RNA).
c) CD59 (lane 1 control, lane 2 and 3; 1 and 100 ng/ml INFy treated cells 
RNA). The sizes of mRNA were; DAF (2.7 kb, 1.5 kb), MCP (4.8 kb and
4.2 kb) and CD59 (2.0 kb, 1.4 kb and 0.8 kb).
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F ig u re  3.46: Rehybridization of Northern blots shown in Figure 3.45 (in 
a, b and c) with a probe for 28S rRNA. N orthern blots had previously 
been hybridized with probes for a) DAF, b) MCP and c) CD59.
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CONTROL 10 ng IFNy
CD59
DAF
MCP
2.0 kb 1.0 ±0.50 1.48 ±0.89
1.4 kb 1.0 ± 0.48 1.36 ±0.1
0.8 kb 1.0 ± 0.43 1.67 ± 1.0
2.7 kb 1.0 ±0.25 1.10 ±1.0
1.5 kb 1.0 ±0.27 0.70 ±0.36
4.8 kb 1.0 ± 0.35 0.95 ± 0.33
4.2 kb 1.0 ± 0.40 0.97 ± 0.38
Table 3.10. Relative mRNA abundances for CD59, DAF and MCP in 
IFNy-treated (lOng/ml for 24 hours) and untreated endothelial cells. The 
abundance of each mRNA in untreated cells was given an arbitrary value 
of 1 unit. Each representsthe mean ± SD of three experiments.
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F igure 3.47: T ranscriptional activity of regu latory  m em brane protein  
genes. Endothelial cells were incubated w ith  INFy for 24 hours. 
Subsequently nuclei were isolated for run-on experim ents. 32p-labelled 
transcrip ts  were hybridized to immobilized DNAs, bound to nylon 
m em brane. P lasm ids containing the  following DNA fragm ents were used 
1) DAF (in A and  B); 2) MCP (in A and B); 3) CD59 (in A and B); 4) SP- 
40,40 (in A), vector DNA pUC19 (in B); 5) vector DNA p u c l9  in  A. In  the  
left lane nuclei of u n trea ted  endothelial cells, in  th e  rig h t lane nuclei of 
endothelial cells trea ted  w ith INFy (10 ng/ml).
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mRNA abundances and protein concentration as shown by the Northern 
blot and flow cytometry data. It is possible that changes in mRNA 
stabilities might be an explanation for this discrepancy.
3.8.5. The Effect o f IFNy Stim ulation on mRNA Stability.
Endothelial cells were grown until fourth passage. One group of 
cells were treated with IFNy for 24 hours and one group used as a control. 
Both group of cells were treated with Actinomycin D (5 |ig/ml), which 
prevents RNA synthesis, for different times (0,1, 2, 4, 6, 8, and 24 hours) 
as described in section 2.3.7.2. Total cellular RNA was extracted and 
blotted on Hybond N+ membranes as described in section 2.9.2. Dot blots 
were hybridized with ^P-labelled probes for the mRNAs of DAF, MCP 
and CD59, then stripped and rehybridized with a probe for 28S rRNA to 
allow corrections for unequal loading to be made. The half-lives of DAF, 
MCP and CD59 mRNAs were calculated to compare their stabilities in 
untreated and IFNy-treated cells. The results are summarized in Table 
3.11.
These data suggested that CD59 mRNA has^Ionger half-life than 
MCP and DAF. IFNy-treatment did not made great differences in the 
half-lives of membrane regulatory proteins. DAF and CD59 mRNA half- 
lives showed 25% and 10% decrease respectively wheras MCP mRNA 
half-life did not change. Although small decreases was observed in mRNA 
half-lives following IFNy this is not enough to explaine the contradiction 
between the increase in transcription rates and the changes in mRNA 
abundances and protein concentration. A block in the transcription of the 
membrane regulatory genes may cause the contradiction observed. The 
increase in transcription rate of DAF, MCP and CD59 following IFNy- 
'■('necM^eAf maY depend of\ some transciptionally active initial exons.
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DAF MCP CD59
IFNy (-) 2.1 1.7 3.9
IFNy (+) 1.6 1.6 3.5
Table 3.11. The effects of IFNy (10 ng/ml for 24 hours) on mRNA half- 
lives (in hours) of DAF, MCP and CD59 in endothelial cells. These values 
are from a single experiment.
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I ^However, in the later part of those genes- transcription rate may reduce,
thus run-on transcription assays shows increase transcription but the 
mRNA abundances remain steady. Similar observation reported for c- 
myc (Eick and Bomkamm, 1986) and c-myb (Reddy and Reddy, 1989) 
gene expressions. Further studies 6n transcription rate of DAF, MCP and 
CD59 by using a number of probes along these genes needs to be done.
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CHAPTER 4. DISCUSSION
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4.1. EXTRAHEPATIC COMPLEMENT SYNTHESIS
Activation of the complement system plays a major role in the host 
defence against infections and in inflammatory responses. Rheumatoid 
arthritis (RA) is a classical example of chronic inflammation. Local 
complement activation occurs in RA joints as witnessed by increased 
levels of activation products including C3dg and C5b-9 membrane attack 
complex in synovial fluid (Mollnes et al., 1986). These data show that C3 
and C5 convertases are formed and that the terminal part of the 
complement cascade is also involved in activation.
Although the liver is the major site of synthesis for most 
circulating complement components, it is now well established that other 
cells including monocytes, macrophages (Littman and Ruddy, 1977, 
Whaley, 1980), fibroblasts (Katz and Strunk, 1988a, 1988b, 1989a), 
endothelial cells (Ripoche et al., 1988) and intestinal epithelial cells 
(Colten, 1976) synthesize complement components. In vitro studies of 
synovial fluid macrophages and adherent synovial membrane cells 
showed that they synthesize complement components (De Ceulaer et al., 
1980). Moreover, metabolic studies with radiolabelled 125j_C3 showed 
that approximately 50 per cent of the intra-articular C3 in the RA joint 
was synthesized locally (Ruddy and Colten, 1974). Katz and Strunk 
(1988a) established that complement protein synthesis is a constitutive 
function of fibroblasts from normal^osteoarthritis (OA) and RA synovial 
membranes and thus showed that the capacity to synthesize complement 
does not require the presence of inflammation. Later studies revealing 
the presence of mRNAs encoding C4, C2, C3, factor B and Cl-INH in
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synovial membrane from normal joints as well as OA and RA joints have 
provided conclusive evidence that synthesis of these complement 
components occurs locally within normal and inflamed synovium in vivo 
(Moffat et al., 1989). However, the purpose of local synthesis of 
complement components is unknown. In normal tissues it may play a role 
in the host defence whereas in inflamed tissues it may contribute to the 
inflammatory process.
At the time of starting the work described in this thesis, there was 
abundant evidence that complement activation occurred in RA joints and 
that some complement components were synthesized locally. In this 
potentially cytolytic environment, regulation of complement activation is 
essential for the protection of host cells. The present study is the first 
thorough investigation of the synthesis of secreted and all the regulatory 
membrane-bound complement proteins involved in the regulation of 
complement activation in synovial tissue from normal individuals, and 
patients with RA and OA. The contributions of some of the different types 
of cell, which are present in synovium, were also studied using cultures of 
endothelial cells, fibroblasts, monocytes and lymphocytes, in order to 
extend the understanding of regulation of complement activation in 
normal and inflamed synovial membrane.
Complement activation occurs in a cascade manner, and each step 
is controlled by regulatory proteins in both the classical and the 
alternative pathways and in the membrane attack sequence. In total 
there are eleven regulatory proteins either in the fluid-phase or on cell 
membranes. Cl-INH, C4-bp and factor I control the classical pathway in 
the fluid-phase. Factor H and factor I are also fluid-phase proteins which 
are responsible for alternative pathway regulation. Membrane attack
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sequence regulatory proteins are S protein and SP-40,40 (Choi et al., 
1989).
The membrane-bound regulatory proteins DAF, MCP and CR1 
affect either the assembly or stability of C3/C5 convertases in both 
classical and alternative pathways, whereas CD59 and MIP prevent the 
insertion of membrane attack complexes into cell membranes (Lachmann, 
1991).
4.2. COMPLEMENT SYNTHESIS IN SYNOVIAL TISSUE
4.2.1. Dot-blot Analysis of mRNA abundances
In this study the synthesis of regulatory complement proteins was 
based upon the detection of specific mRNAs by dot-blot analysis. This 
technique was used as the complement mRNAs were found to be degraded 
when analyzed by Northern blot analysis. Thus, quantification of the 
relative abundances of these mRNAs could not be assessed by Northern 
blotting. Similar technical problems were previously reported by Moffat 
(1989). However, he concluded that the mRNAs which code for the 
complement components are unstable in synovial tissue in vivo since the 
probing of the Northern blots with p2-microglobulin and actin cDNAs 
showed these mRNAs to be undegraded. Another difficulty of studying 
the synovial tissue was the synovial membrane tissue samples were 
limited and the amount of each available tissue sample was small. This 
limited the number of experiments which could be performed.
Human cDNA probes were used throughout the dot-blot analysis. 
A determination of the size of the mRNAs was not possible with dot-blots,
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but non-specific hybridization was eliminated by washing the filters to 
high stringency (0.1 x SSC containing 0.1 % SDS at 65°C for 30 minutes), 
which should only allow the formation of specific DNA-RNA hybrids on 
the filters.
Densitometric analysis of the dot-blot autoradiographs for DAF, 
MCP and CR1 did not show significant differences in the abundances of 
mRNAs from normal synovial membrane compared to OA and RA 
synovial membrane. This may indicate that these membrane-bound 
proteins, which are effective on the early steps of complement activation, 
do not really play a vital role for the inhibition of complement activation 
in inflamed synovium.
The abundances of the mRNAs encoding the classical and 
alternative pathway secreted proteins were elevated in RA synovium, as 
was that of CD59 mRNA. These increases might be related to increased 
synthesis of these regulatory proteins in an attempt to regulate the 
activation of complement at the early stages of both the classical and 
alternative pathways. Thus^cells in synovium protect themselves from the 
lytic attack of complement by increasing the fluid-phase secreted 
regulatory proteins rather than the membrane-bound regulatory proteins.
Increased abundance of CD59 mRNA in synovial membrane from 
RA patients might also show that, if some activated components escape 
from the inhibition in the fluid-phase, increased synthesis of CD59 on cell 
membrane might prevent the formation of MAC. This indicates that the 
cells a t sites of inflammation might be well protected against homologous 
complement attack. However, the data on the secreted regulatory 
proteins and CD59 must be interpreted cautiously as only one assay for
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mRNA abundance could be determined in each type of tissue due to the 
limited amount of tissue available.
The presence of SC5b-9 complex in the synovial fluid of RA 
patients and in cultured synovial cells has been reported (Morgan et al., 
1988a and 1988b). Although S protein and SP-40,40 act on the soluble 
C5b-7 complex to prevent its insertion into cell membranes, there was not 
a significant increase in the abundances of their mRNAs in contrast to 
that of CD59 mRNA. However, it must be remembered that the rate of 
translation, and so the amount of protein secreted can be increased even 
when the abundance of the mRNA is unaltered.
Membrane-bound proteins generally protect only those cells on 
which they are expressed (Oglesby et al., 1992, Wing et al., 1992). In 
contrast, all the cells in the inflammatory zone can benefit from the 
regulatory effects of fluid-phase proteins. Synovial membrane contains 
different typesof cell each of which secretes a different range of the control 
proteins of the classical and alternative pathways (see sections, 3.4., 3.5, 
3.6., 3.7.). Thus} complete regulation of activation of the early stage in the 
fluid-phase depend upon mononuclear phagocytes (Cl-INH, C4-bp, factor 
H), fibroblasts (Cl-INH, factor H, factor I), endothelial cells (factor Hf*i <J 
factor I). However, regulation of complement at the convertase levels is 
not completely effective so that regulation of the membrane attack 
complex on the cell membrane is also required. Thus, elevated levels of 
secreted classical and alternative pathway proteins and CD59 in RA 
synovium might provide a broad spectrum of protection for the cells at 
both the early and at the late stages of complement activation a t sites of 
inflammation.
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Although the dot-blot analyses demonstrated that the mRNAs
in normal, RA and OA synovial membranes, many mRNAs are subject to 
translational control and thus the presence of mRNA may not necessarily 
indicate synthesis of protein. For instance, in unfertilized sea urchin eggs 
maternal mRNAs are stored as translationally repressed mRNPs
(Grainger and Winkler, 1987). Also, as the tissue samples were small,
they might only reflect the local changes in mRNA abundances and not 
the abundances in the whole synovial membrane.
4.2.2. Analysis o f Culture Supernatants
Synthesis of Cl-INH, C4-bp, factor I and factor H in synovial 
membranes from normal individuals and patients with RA and OA was 
also investigated by studying the accumulation of the proteins in tissue 
culture supernatants. There was great variation between experiments, 
but all the components measured accumulated rapidly in the culture 
medium during the first and often the second day of culture. After the 
second day the rate of accumulation of each components decreased as 
has been reported for C3 and C4 previously (Moffat, 1989). It is possible 
that a feed-back inhibition mechanism could be responsible for the 
decreased synthesis in the later stages of culture as has been suggested 
for C4 synthesis by guinea pig peritoneal macrophages (Auerbach et al., 
1983). Addition of cycloheximide caused variable, but incomplete 
inhibition of proteins. So, part at least of regulatory complement protein 
accumulation in medium probably due* to release of protein absorbed from
encoding for all the known complement regulatory proteins were present
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plasma in vivo. Washing was not effective to change the accumulation 
pattern in medium.
The partial inhibition of protein accumulation in culture 
supernatants observed in some cultures implies that a proportion of the 
components measured had been synthesized locally by synovial 
membrane indicating that, in some circumstances at least, the regulatory 
complement protein mRNAs are translated in cultured fragments of 
synovial membranes.
4.2.3. Immunohistochemical Analysis
Immunohistochemical staining of frozen sections of synovial 
membrane from RA patients showed that CD59, MEP and DAF were 
expressed on most cells, particularly on cells lining the synovium, 
endothelial cells and lymphocytes. Staining of the synovial lining cells for 
CD59 and MIP was very strong. The high expression of these membrane- 
bound proteins may protect these cells from cytolysis and this could help 
explain their survival despite complement activation in the synovial 
membrane in the adjacent synovial fluid. The importance of CD59 in the 
protection of cells against complement attack is demonstrated by the 
severe complement-mediated haemolysis which occurs in patient with 
paroxysmal nocturnal haemoglobinuria. These patients have a defect in 
forming phosphatidyl glycolipid anchors and so lack membrane CD59 
(Holguin et al., 1989; Pangburn et al., 1983).
In keeping with the finding of increased abundance of CD59 mRNA 
on dot-blot analysis of RA synovium, immunohistochemistry results also 
showed abundant CD59 in synovial lining cells. These observations also
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suggest that increased expression of CD59 may be involved in cytolysis in 
inflamed joints.
It has been reported that DAF is expressed^only a small extend in 
hyperplastic and multilayered synovial lining cells in RA synovitis 
whereas it is expressed highly in normal synovium (Itoh et al., 1991). In 
contrast, I have found a wide DAF expression in cells lining the RA 
synovium. Moreover, in the same study Itoh et al. (1991) HRF20 (CD59) 
and CR1 were not detected in either the flat or hyperplastic synovial 
lining cell while I have found a high concentration of CD59 in synovial 
lining cells. Immunohistochemical studies of cells lining normal and 
inflamed hyperplastic synovium showed that the degree of hyperplasia 
varied considerably in different specimens of RA synovium and that the 
synovial membrane hyperplasia in OA patients was patchy (Athanasou et 
al., 1988). These observations might explain some of the contradictions 
between the results of my study and those reported by Itoh et al. (1991). 
However, I can not explain the deficiency of CD59 reported in normal and 
inflamed tissue by Itoh et al. (1991). Since cells lining the synovium 
include two major cell types the macrophage-like (A type) and the 
fibroblast -like (B type) (Graabek, 1984), and CD59 is widely expressed 
on peripheral blood monocytes (Philbrick et al., 1990), one would expect 
this protein to be expressed on A type cells. Furthermore, CD59 mRNA 
was detected by Northern blotting of fibroblast RNA and membrane 
expression of CD59 was detected by immunohistochemistry in this study 
(see sections 3.4.2., 3.4.3.).
Immunohistochemical analysis of normal and OA synovial 
membrane in addition to RA synovial membrane may clarify any 
differences in the distribution and the level of expression of membrane-
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bound complement regulatory proteins. However, it is clear that cells in 
synovial membrane are capable of expressing membrane-bound 
regulatory complement proteins in vivo (3.3.2.).
4.3. CELLS RESPONSIBLE FOR COMPLEMENT REGULATORY 
PROTEIN SYNTHESIS IN SYNOVIAL MEMBRANE
There are various cell types in synovial membrane which could be 
responsible for extrahepatic synthesis of complement regulatory proteins. 
These cells are fibroblasts, endothelial cells, mononuclear phagocytes, 
lymphocytes and macrophage-like (type A) arid fibroblast-like (type B) 
synovial lining cells *
Two approaches could be applyoJ to determine the range of 
regulatory complement components synthesized by each of these cells. 
First is isolation of these cells directly from synovial membrane. This 
is technically possible. Isolation of synovial fibroblasts (Dayer et al., 
1976), synovial membrane macrophages (De Ceulaer et al., 1980) and 
synovial microvascular endothelial cells (Jackson et al., 1989) has been 
reported. However, as mentioned before, the availability of the synovial 
membrane tissue samples was very restricted and isolation of all the cell 
types from synovium was not practical. Instead, fibroblasts were isolated 
from synovial membrane and model cell cultures chosen for the other cell 
types.
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4.3.1. Complement Regulatory Protein Synthesis by Fibroblasts
Fibroblasts were isolated from synovial membrane from normal 
individuals and patients with OA and RA and the cells were cultured and 
passaged until sufficient number was obtained to perform the 
experiments.'Drawback to this multiple passages may select a sub­
population of cells that is not representative of the fibroblasts of synovial 
membrane; again lack of the material dictated this c
4.3.1.1. mRNA analysis
All regulatory protein mRNAs, except for C4-bp and CR1, were 
detected in RNA from fibroblasts from all three types of synovial 
membrane. These findings support the suggestion that complement 
protein synthesis is a constitutive function of fibroblasts and that the 
capacity to synthesize these proteins does not require the presence of 
inflammation (Katz and Strunk, 1988a). However, all^ctata show is that 
genes encoding regulatory complement proteins are transcribed and the 
synovial membrane fibroblasts contain mature mRNAs encoding these 
proteins in vitro.
This is the first report of the detection of factor I mRNA in 
fibroblasts. The abundance of this mRNA was found to be significantly 
low in RA fibroblasts compared to normal fibroblasts. It is not known if 
there is a decrease in the transcription rate of the factor I gene in RA 
fibroblasts or a decreased stability of its mRNA. As with the factor H 
mRNA findings, these results imply a persistence of the in vivo 
phenotype in cultured cells. Factor I levels are reduced in RA synovial
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fluid (Whaley et al., 1975) whereas levels of factor H are not reduced. 
These data were originally interpreted in terms of the catabolism of these 
components, whereas my data suggest that changes in synthesis might 
play a role in producing these alterations. Reduction of factor I levels in 
synovial tissue might be expected to result in increased complement 
activation because of reduced inactivation of C3b and C4b. Failure to 
inactivate C3b may result in its binding to host cells, with alternative 
pathway activation occurring unless the membrane regulatory proteins 
(DAF and MCP) can cope with this increased demand (reviewed in 
Parker, 1992). If not chronic tissue damage will result.
Factor H mRNA abundance was significantly higher in RA 
fibroblasts than in normal or OA fibroblasts. However, caution must be 
excersed in the interpretation of these data as they imply that some of the 
phenotypic characteristics that fibroblasts express in inflamed synovial 
membrane persist in culture in vitro. Furthermore, the secretion of factor 
H was not significantly increased in RA synovial fibroblasts (see 4.3.1.2.). 
There was no difference in Cl-INH mRNA abundance between normal, 
RA and OA synovial fibroblasts; C4-bp does not appear to be synthesized 
by these cells.
Previously biosynthetic labelling experiments showed that synovial 
fibroblasts synthesize seven complement components including Cl-INH 
(Katz and Strunk, 1988a). Later, ELISA analysis of synovial membrane 
fibroblast culture supernatants confirmed the synthesis of Cl-INH in 
these cells (Moffat, 1989). Recently, the occurrence of Cl-INH and factor 
H mRNAs in, and secretion of the proteins from skin fibroblasts have 
been reported (Lappin et al., 1992).
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A strong association between the presence of SP-40,40 and 
membrane attack complex (MAC) occurs in glomeruli in which 
immunoglobulin deposits are present, and investigators suggested that 
MAC found in the absence of SP-40,40 is cytolytically active (French et 
al., 1992). In RA fibroblasts the abundance of SP-40,40 mRNA is 
increased (section 3.4.3.). The presence of the TCC (the soluble form of 
the C5b-9 MAC which contains S protein and/or SP-40,40) in RA joints 
has also been reported (Mollnes et al., 1986; Morgan et al., 1988a). Thus, 
up-regulation of SP-40,40 synthesis may prevent the formation of the
lytic MAC and so protect the host cells against homologous complement 
attack.
Apart from its cytolytic activity, non-lethal amounts of MAC 
stimulate the production of oxygen metabolites from cultured human 
synoviocytes (Morgan et al., 1988b). Thus, sub-lethal amounts of MAC 
stimulate the formation of these toxic metabolites which could contribute 
to tissue damage. The abundance of the mRNA for the other MAC 
regulatory protein (S protein) was reduced in RA synovial fibroblasts. 
Assuming that the relative abundances of S protein and SP-40,40 mRNAs 
reflect the synthetic rates of these two proteins, it is possible that 
increased synthesis of SP-40,40 could compensate for decreased S protein 
synthesis.
The relative abundances of the mRNAs for membrane regulatory 
proteins DAF, MCP and CD59 in OA, RA and normal synovial membrane 
fibroblasts were not different. However, there were differences in the 
distribution of the different species of CD59 mRNA in the three types of 
fibroblasts. The relative abundance of the 2.0 kb species of CD59 mRNA 
in OA was significantly lower than in RA or normal fibroblasts. However,
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the functional significance of this is unclear as it has been suggested that 
the higher molecular-weight bands simply represent relatively stable, 
albeit nonfunctional, processing intermediates (Philbrick et al., 1990). If 
this conclusion is correct, the decreased abundance of this mRNA species 
may not necessarily cause a deficiency in CD59 expression on the cell 
surface and thus may not cause a functional defect. Cell-specific 
expression of different mRNA species of CD59 were also detected in 
fibroblasts and endothelial cells and will be discuded in more detail in 
section 4.5. Recently, tissue-specific expression of CD59 mRNA species 
was also reported in liver, brain, lung tissues and placenta (Kumar et al., 
1993). Whether these differences are related to differences in the 
abundance of protein is unknown. Although CD59 was isolated as a 
complement regulatory protein, there are reports which suggest that 
CD59 participates in a transmembrane signalling pathway which results 
in cell activation (reviewed in Lublin, 1992). Moreover, CD59 with MIP 
have been reported to be stress proteins (Schiren et al., 1991). Further 
investigations are required on the level of expression of the membrane 
regulatory proteins and their functional activity in the three types of 
fibroblasts and the significance, if any, of relative abundances of the 
different mRNA species of CD59.
4.3.I.2. Analysis o f culture supernatants
Analysis of culture supernatants from synovial fibroblasts derived 
from three normal, three RA and three OA patients indicated that these 
fibroblasts synthesize Cl-INH, factor H and factor I. The secretion of 
proteins increased linearly throughout the seven-day culture period.
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Addition of cycloheximide to culture media inhibited the synthesis of 
these proteins. This indicates de novo synthesis of the secreted regulatory 
proteins in cell culture.
There was no difference in the amounts of Cl-INH secreted by 
normal and RA synovial membrane fibroblasts. This is in agreement with 
the finding of similar abundances of Cl-INH mRNA in normal and RA 
fibroblasts. However, Cl-INH secretion was significantly lower from OA 
fibroblasts compared to normal fibroblasts. Although Cl-INH mRNA 
abundance was also lower in OA than normal fibroblasts, the difference 
was not statistically significantly.
Despite the increased abundance of factor H mRNA in RA 
fibroblasts, there were no significant differences in the amounts of factor 
H secreted from normal, RA and OA fibroblasts. It is possible that in RA 
fibroblasts the mRNA encoding factor H is masked by proteins in stable 
ribonuclear particles which protect them against degradation, but which 
also prevent translation. If this is the correct explanation then the in 
vitro culture conditions must not allow the unmasking of mRNAs,, possibly 
because of the absence of a factor which stimulates translation and which 
is only present in vivo. The occurred CCof such masked mRNAs has 
previously been shown to explain events during, for the example, the 
fertilization of sea urchin eggs (Grainger and Winkler, 1987).
There was a good agreement between the abundance of factor I 
mRNA and the excretion of this protein. As mentioned above, the 
abundance of factor I mRNA was lower in RA fibroblasts than in normal 
synovial fibroblasts. In fact, although the secretion of factor I was 
detected in all normal synovial fibroblast cell culture supernatants, I
detected factor I in only one of the three RA fibroblast culture
2 0 1
supernatants. Statistical analysis of the data showed significant 
differences between normal and HA fibroblasts in the amounts of factor I 
secreted. Furthermore, the secretion rate of factor I in fibroblasts was 
very low compared with those of Cl-INH and factor H.
The double-antibody ELISA assays performed with anti-S protein 
antibody did not give satisfactory results as considerable amounts of S 
protein bound non-specifically to the plastic surface despite the use of 
blocking agents and detergents. Similar problems have been reported by 
other investigators (Hogasen et al., 1991). This problem occurred even 
^Uxlifferent types^SLISA plates were used and suggest that the adhesion 
properties of S protein (vitronectin) may be involved. SP-40,40 antibody 
was not available. Thus the secretion rates of these two proteins could not 
be determined.
4.3.1.3. Immunohistochemical analysis
Normal synovial fibroblasts stained positively for DAF, MCP, 
CD59 and MIP. CD59 and MIP showed^strongest staining while MCP 
was weakest. It is unknown what is the relative contributions of CD59 
and MIP for protection against complement-mediated damage as 
compared with DAF and MCP. Functional comparison studies need to be 
performed. If the expression pattern observed is correct it would appear 
that protection against insertion of the MAC is more important than 
protection at the level of the C3 and C5 convertases. Expression of MCP, 
CD59 and MIP has been reported previously in skin and synovial 
fibroblasts (McNeamey et al., 1989, Schieren et al., 1991). These data are 
in agreement with those in section 3.4.2. of this thesis.
2 0 2
Because of lack of time staining was not performed on RA and OA 
fibroblasts. Also it is known that the presence of inflammatory mediators 
modulate the expression of membrane-bound proteins, e.g. IFNy, 
upregulates MIP and CD59 in fibroblast (Schieren et al., 1991). So, 
additional tissue sections from intact synovial membrane, which include
O 'the connective tissue, rather than isolated fibroblast, may give better idea 
for the expression pattern of membrane-bound proteins in normal and 
inflamed tissue synovial fibroblasts.
4.3.2. Complement Regulatory Protein Synthesis by M onocytes
Monocytes/macrophages are a major source of extrahepatic 
complement protein as they synthesize more complement components 
than any cells apart from hepatocyteJ They are the only cell type 
examined in this study that synthesize C4-bp. Although they do not 
synthesize factor I, they do synthesize Cl-INH, so they secrete all of the 
regulatory components of the classical pathway, which may be important 
in the regulation of the complement activation in the normal synovial 
joint, and in the synovial joint affected by OA and RA.
Although factor H secretion was detected in monocyte culture 
supernatants, factor H mRNA was not detectable by Northern blot 
analysis of RNA from monocytes. This failure to detect factor H mRNA 
was probably due to its instability in monocytes. Factor H mRNA was 
detected when the cells had been cultured in the presence of 
cycloheximide, which selectively stabilizes mRNAs by arresting their 
translation on ribosomes (Alberts et al., 1989). The half-life of factor H 
mRNA in monocytes was found to be very short (12 minutes) compared
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with over 3 hours in fibroblasts and endothelial cells (Lappin et al., 1992). 
These cell-specific differences in mRNA stability could be due to a labile 
destabilizing factor, such as that described for c-myc mRNA (Brewer and 
Ross, 1989). It is probable that the instability of factor H mRNA in 
monocytes contributes to the low secretion rate of this protein from these 
cells.
It has also been reported that IFNy or synthetic glucocorticoids 
(dexamethasone) increase factor H mRNA abundance in monocytes 
(Lappin et al., 1992) and endothelial cells (Dauchel et al., 1990) probably 
by stabilizing factor H mRNA. It is possible that the therapeutic effects of 
both glucocorticoids and IFNy in rheumatoid arthritis patients (Sanz and 
Alboukerk, 1991; Machold et al., 1992) may partially due to the increased 
synthesis of factor H by the cells in synovial membrane which would 
regulate complement activation at the level of the alternative pathway C3 
convertase and/or at the level of the C5 convertase of the classical and 
alternative pathways.
Neither factor I protein nor factor I mRNA were detected in 
monocytes. Previously^ the ability of monocyte-conditioned media to 
inactivate C3b was taken as evidence of the synthesis and secretion of 
factor I by monocytes (Whaley, 1980). However, my data suggest that such 
C3b inactivation is due to a protease(s) other than factor I.
Using Western blotting and ELISA, S protein has been 
demonstrated in the supernatants of monocytes and alveolar and 
peritoneal macrophages cultured in serum-free medium (Hetland et al.,
1989). However, I was unable to detect S protein mRNA in Northern 
blots. A low transcription rate or short half-life or both may be the reason 
for my failure to detect S protein mRNA by Northern blots. Measures to
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increase S protein mHNA abundance could have been taken. These 
include the addition of cytokines to increase transcription of the S protein 
gene and/or cycloheximide to stabilize S protein mRNA. These measures 
have been used successfully to detect factor H mRNA in monocytes 
(section 3.6) and Cl-INH secretion in endothelial cells (section 3.8).
As well as showing for the first time that monocytes expressed SP- 
40,40, my data confirm previous observations on the ability of monocytes 
to synthesize Cl-INH (Yeung-Laiwah et al., 1985), C4-bp (Lappin and 
Whaley, 1990), factor H (Whaley, 1980), DAF (Kinoshita et al., 1985), 
MCP (Seya et al., 1988), CD59 (Hideshima et al., 1990) and CR1 (Fearon, 
1980).
4.3.3. Complement Regulatory Protein Synthesis by Lym phocytes.
In this study human peripheral blood lymphocytes were used as a 
model cell. Although Cl-INH, factor H and factor I secretion was detected 
in culture supernatants from peripheral blood lymphocytes by ELISA, 
following monocyte depletion onlyismall amount of factor H was present. 
Thus it is probable that most of the complement components detected 
were synthesized by contaminating monocytes. It is known that addition 
of antigen-stimulated lymphocyte culture supernatants to monocyte 
cultures increases C2 synthesis (Littman and Rudy, 1977). Similar 
factors present in the culture supernatant may stimulate lymphocytes to 
secrete complement regulatory proteins in the presence of monocytes. 
Although phytohaemagglutinin and concam\|olhA stimulate human T 
cells, and pokeweed mitogen stimulates both human T and B cells 
(Lydyard and Grossi, 1990), only c o n c u rs  I>'iA treatment significantly
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stimulated factor I synthesis in lymphocyte cultures. Factor I synthesis 
by lymphocytes has been reported previously (Lambris et al., 1982). 
Several attempts to detect complement mKNAs in lymphocyte RNA were 
unsuccessful, which could have been due to the degradation of the 
mKNAs during extraction or their low abundance as a result o f ; their 
instability in vivo. Further studies are required to resolve this issue.
Although complement regulatory proteins might not be secreted by 
lymphocytes, these cells could contribute to the regulation of complement 
in inflamed sites by secreting cytokines (e.g. IFNy) which would act on 
other cell types to up-regulate the synthesis of regulatory components. 
Therefore, lymphocytes might play an indirect regulatory role in 
complement synthesis at sites of inflammation.
4.3.4. Complement Regulatory Protein Synthesis by Endothelial 
Cells.
Angiogenesis, the process of generation of new blood vessels, is an 
important feature, not only of normal phenomena such as embryonic 
development and wound healing, but also pathological states such as 
tumour growth and chronic inflammation (Folkman, 1985). In 
immunogenically mediated chronic inflammation such as RA synovitis, a 
significant increase in the number of capillaries and postcapillary venules 
has been observed (Folkman et al., 1985). The vessel wall is frequently 
exposed to proteolytic enzymes that are generated in plasma and within 
vascular tissue at site?of inflammation. Protection of endothelial cells 
depends upon the production and/or expression of inhibitors of proteolytic 
enzymes. Despite complement activation at sites of inflammation
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endothelial cells are well protected against homologous attack by 
complement.
In this study, human umbilical vein endothelial cells were 
characterized and used as a model to investigate the regulation of 
complement activation.
4.3.4.I. mRNA analysis
Analysis of Northern blots indicated that unstimulated endothelial 
cells do not express. any classical pathway regulators. However, IFNy 
stimulates Cl-INH synthesis in endothelial cells (see section 3.8.1.). This 
suggests the occurrence of a fine regulation of complement regulatory 
protein synthesis at sites of inflammation. Previously, Schimaier et al. 
(1989) reported the expression of Cl-INH in endothelial cells. However, 
although they detected the mRNA by slot blotting, the message was not 
apparent on their Northern blots.
Messenger RNAs for all the membrane regulatory proteins except 
CR1 were detected by Northern blotting of endothelial cell KNA. 
Interestingly, cell-specific differences 1V1 the abundance of different mRNA 
species were observed, and they are discussed in section 4.5.
To my knowledge, this (section 3.5.3) is the first report of the 
detection of the mRNAs for S protein and SP-40,40 in endothelial cells. 
The synthesis of S protein from endothelial cells has been detected 
previously by radioimmunoassay using a combination of monoclonal and 
polyclonal S-protein antibodies (Berge et al., 1992).
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4.3.4.2. Analysis o f culture supernatants
Synthesis of factor H and factor I by endothelial cells was 
confirmed by the detection of these proteins in culture supernatants 
(section 3.5.1). The secretion rate of factor H was twice than of factor I. As 
endothelial cells are in contact with the blood their ability to synthesize 
complement components could be important in vivo as such synthesis 
could contribute to the circulating plasma levels. However, it is more 
probable that the purpose of the release of factor H and factor I by 
endothelial cells in vivo is to produce a local increase in their 
concentrations close to the endothelial cell surface, so that these proteins, 
together with the membrane-bound molecules DAF, MCP and CD59 
protect endothelium from complement-mediated damage.
Although I did not detect Cl-INH in culture supernatants from 
unstimulated endothelial cells, the secretion of Cl-INH by endothelial 
cells has been reported by Schmaier et al. (1989). This could be explained 
by a possible difference in the sensitivity of ELISA assays and by the use 
of conditioned media in that study which could lead to the accumulation 
of synthesized protein into the culture supernatant. However, treatment 
of endothelial cells with IFNy stimulated Cl-INH synthesis and revealed 
the protein in culture supernatants (see section 3.8.1.). This suggestgthat 
in inflammation endothelial cells contribute to the early stages of 
classical pathway activation (Cl activation) as well as to the later stages 
of the alternative and classical pathways (C3 and C5 convertases).
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4.3.4.3. Flow cytometric analysis
DAF, MCP and CD59 were detected on the surfaces of endothelial 
cells. The intensity of tlie signal from the CD59 antibody was higher than 
from the DAF and MCP. Although a sub-population of cells responsive to 
IFNy for DAF expression was detected by flow cytometry at the fourth- 
passage of endothelial cells, unstimulated cells did not show such sub­
population for any membrane-bound regulatory complement protein. It is 
not known if this sub-population also express CD59 and MCP. Also it is 
not known if they possess any functional significance against complement 
attack. Further studies need: to be performed to bring answers to these 
questions. IFNy-responsive sub-population of endothelial cells are 
discussed more in section 4.4.1.
These data suggest that, in addition to S protein and SP-40,40, 
CD59 also plays a role in the control of the membrane attack sequence. 
Tight control of this lytic sequence is required to protect endothelial cells 
from the lytic attacks of complement activation.
In the early studies of endothelial cells, expression of MCP 
(McNeamey et al., 1989), DAF (Asch et al., 1986) and CD59 (Hamilton et 
al., 1990; Brooimans et al., 1992) was shown. Biosynthetic studies of 
endothelial cells have shown that CR1 is not present on endothelial cells 
(Julen et al., 1992).These data are in agreement with those in section 3.5.
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4.4. THE EFFECTS OF CYTOKINES ON ENDOTHELIAL CELLS
The expression of secreted complement regulatory proteins in 
synovial membrane was demonstrated at the mKNA level (dot blots) and 
some of the cells which could be responsible for this synthesis were 
identified by studying different cell types in culture. Cytokines are likely 
4o play a role in the pathogenesis of RA (Arend and Dayer, 1990). Synovial 
tissue and synovial fluid are rich sources of these mediators and ample 
data have accrued supporting the notion that cytokines can account for 
some of the functional properties of cells in synovium (Firestein et al.,
1990). One of these is the modulation of the synthesis of complement 
components.
It was feasible to study only one cell type in detail so I 
concentrated on endothelial cells for the following reasons:
1) They form the interface between blood and tissues and are therefore 
key cells in the inflammatory response.
2) Control of complement in the immediate vicinity of the endothelial 
cells is essential to protect the endothelial cells from the powerful 
cytolytic effects of complement.
3) There is little information available on complement synthesis in these 
cells.
I selected to study the cytokines IFNy, IFNa, IL-1 and IL-6 as they 
are known to be present at sites of inflammation and they regulate the 
synthesis of complement components in some cells.
Preliminary studies showed that IFNy and IFNa increased the 
synthesis of the secreted regulatory complement proteins in endothelial 
cells. It has been reported previously that treatment with IFNy increases
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the secretion and the mRNA abundances of factor H and factor I (Ripoche 
et al., 1988) and Cl-INH (Lappin et al., 1992). This report show that the 
increased synthesis of Cl-INH was due to increase in transcriptional 
rate. I detected an inhibition in factor H protein levels in the presence of 
IL-ip or IL-6 (section 3.8.1). The inhibitory effect of IL-1 on factor H has 
been reported previously by Broomimans et al. (1990). The opposing 
effects of IFNy and IL-l/IL-6 on the secretion of fluid-phase regulatory 
proteins indicates that the relative concentrations of these cytokines in 
the immediate vicinity of endothelial cells affect the level of synthesis of 
the complement proteins and might either amplify or down-regulate the 
inflammatory response.
4.4.1. The Effect of IFNy on Membrane Protein synthesis
The production of mRNA in eukaryotic cells is a complex process 
involving both transcriptional and post-transcriptional mechanisms. 
Modulation of the abundances of mRNAs can occur as a result of 
regulation at a number of stages, though changes in rates of gene 
transcription and mRNA turnover and translation appear to have the 
greater effects (Darnell, 1982).
This part of the study was therefore undertaken to determine the 
effects of IFNy on the transcription of the genes encoding DAF, MCP and 
CD59 in endothelial cells, to investigate the effects of IFNy on the 
stability of the mRNA encoding DAF, MCP and CD59, and to determined 
the effects of IFNy on the expression of these proteins on the cell surface.
IFNy increased the rate of transcription of genes encoding DAF, 
MCP and CD59 (section 3.8.4). Many studies have shown that IFNy
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stimulated the transcription of a large number of genes (Lamer et al., 
1986), including complement regulatory genes Cl-INH, factor H and C4- 
bp (Lappin et al., 1992). The DNA sequences involved in the regulation of 
transcription by IFNy are thought to be principally located in the regions 
upstream from the coding sequence of IFN-responsive genes. A computer 
search for conserved sequences in the upstream region of human 
interferon-sensitive genes has identified interferon-stimulated response 
elements (ISRE) which are located in the flanking regions of these genes 
(Levy et al., 1988, Shirayashi et al., 1988) including the factor B gene (Wu 
et al., 1987). The role of such consensus sequences in the action of 
interferons on the transcription of DAF, MCP and CD59 genes is unclear. 
However, there are no published data regarding the presence of IFNy 
response elements in DAF, MCP and CD59 genes. There are controversial 
reports about the inducibility of CD59 expression with IFNy. Philbrick et 
al. (1990) found no effect of IFNy on CD59 message levels in transformed 
cell lines of lymphoid origin and T cells. In contrast, Tandon et al. (1992) 
showed that the expression of CD59 in human thyroid cells is enhanced 
by IFNy.
Although IFNy induced increases in the rates of transcription of 
the genes encoding DAF and MCP, it had no effect on the abundances of 
these mRNAs. Moreover, a 3-fold increase in the rate at which the CD59 
gene was transcribed effected . no more than a 50% increase in 
mRNA abundance. However, increased transcription in response to IFNy 
was associated with a reduction in the half-lives of DAF and CD59 
mRNAs. Though, the reduction was insufficient to explain the 
discrepancy between transcription rate and mRNA abundance. An arrest 
in transcription may explain this discrepancy. If this speculation is
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correct, hybridization of the labelled RNA to dot blots containing cloned 
fragments of different regions of the genes would indicate the site of the 
arrest. A block to transcription elongation has previously been reported 
for the c-myc (Eick and Bronkamm, 1986) and for c-myb genes (Redy and 
Redy, 1989).
A sub-population of cells responsive to IFNy for DAF expression 
was detected by flow cytometry of fourth-passage endothelial cells. It is 
unlikely that these cells arose solely as an artefact. Such an artefact 
would have affected the expression of the other regulatory components in 
IFNy-treated cells, since cells harvested from the same culture flask and 
then subjected to antibodies against membrane-bound regulatory 
proteins and this sub-population was only present for DAF. Moreover, 
there was not such sub-population in control cells. This sub-population 
might arise from expansion of inherently IFNy-sensitive cells that 
normally are present in low numbers. However, my data showed that 
some endothelial cells are responsive to IFNy-stimulation for DAF 
expression. Interestingly, this sub-set disappeared after several more 
passages of the cells. It is not known if the proportion of cells that is 
sensitive to IFNy is greater during the first passage. It has been reported 
that prolonged cell culture causes a significant reduction in 
immunogenicity in endothelial cells (Dhesi et al., 1992), and the secretion 
of factor H by endothelial cells was reduced when endothelial cells were 
passaged repeatedly (Brooimans et al., 1989). This could be due either to 
a change in phenotype as cells proliferate in vitro, or to the IFNy- 
responsive cells being at a proliferative disadvantage. These observations 
indicate one of the problems of using in vitro culture to draw conclusions 
regarding events in vivo.
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After treatment of endothelial cells with IFNy there was an 
increase in the proportion of cells expressing CD59, but again this only 
seen at low passage numbers.
These results suggest that IFNy upregulates secretion of fluid- 
phase regulatory complement proteins and, possibly, the expression of the 
membrane-bound regulatory proteins. As IFNy induces remission in some 
RA patients (Machold et al., 1992), there is the possibility that increased 
synthesis of fluid-phase complement proteins could contribute to this by 
down-regulating complement activation. (This point has been discussed 
previously). It is interesting that, although cells responsible for the 
production of IFNy are present in RA synovial joint, previous studies have 
shown that, cultured synovial tissue fragments produce very little IFNy 
(Firestein and Zvaifler, 1987). Furthermore, the quantitative analysis of 
cytokine gene expression in RA by in situ hybridization showed that, in 
contrast to high levels of IL-lp, IL-6 and TNFa mRNs in synovial tissue, 
there was little or no IFNy mRNA detected (Firestein et al 1990). Since 
IFNy favours the synthesis of the regulatory proteins of complement 
(section 3.8.1), and suppres; the synthesis of C3 (Lappin et al., 1990), the 
key activation component in both classical and alternative pathways, the 
absence of IFNy synthesis in RA synovium might favour activation of 
complement, therefore leading to chronicity of the inflammation.
Further studies are required to investigate the effect of IFNy on 
the expression of the membrane-bound regulatory proteins and the ability 
of IFNy-treated cells to resist complement attack. Also, the role of 
interferon-responsive elements in the regulation of transcription of these 
interferon-sensitive genes, and the mechanisms by which IFNy modulates
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the stabilities of the mRNAs encoded by Cl-INH, factor H, DAF, MCP 
and CD59 genes, should be investigated.
4.5. CELL-SPECIFIC EXPRESSION OF THE REGULATORY 
COMPLEMENT PROTEINS
Several of the complement regulatory proteins, DAF, MCP, CR1, 
factor H and C4-bp constitute the regulators of the complement activation 
(RCA) gene family and are located a t a single chromosomal site (reviewed 
in Hourcade et al., 1989). Although no detailed analysis is yet available of 
the nucleotide structure of the promoter and enhancer elements of the 
cluster of RCA genes, immunohistochemical means of detection of the 
gene products suggest that there is cell- and tissue-specific regulation of 
their expression. However, the ubiquitous tissue expression of
DAF and MCP are also shown (McNearney et al., 1989; Kinoshita et al., 
1985; Asch et al., 1986). It is clear that gene duplication has played an 
important part in the evolutionary development of the RCA cluster 
(Hourcade et al., 1989), and homologies in the transcriptional regulatory 
regions might also be found among the RCA family members.
In my study, cell-specific differences were detected in a number of 
the complement regulatory proteins secreted. Cell-specific differences in 
the secretion rates of some proteins were also observed. Cl-INH secretion 
was much higher from fibroblasts than from monocytes, and the secretion 
of Cl-INH was only detectable in the presence of IFNy in endothelial 
cells. Furthermore, factor H was very low in monocytes compared with 
fibroblasts. However, factor H was the only regulatory complement 
protein to be secreted by all cells under standard culture conditions.
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Despite these differences, DAF, MCP, CD59 and MIP were always 
present on the membranes of the fibroblasts, endothelial cells, monocytes 
and lymphocytes.
Cell-specific differences in the stabilities of the mRNAs for C2, 
factor B, C3, C4-bp, Cl-INH and factor H in Hep G2 cells, monocytes, 
skin fibroblasts and endothelial cells have been reported by Lappin et al. 
(1992). It was thought that these differences might derive from cell- 
specific expression of a labile destabilizing factor, such as that described 
for c-myc mRNA (Brewer and Ross, 1989).
In addition to these, cell-specific differences in the relative 
abundances of the various species of mRNAs for DAF, MCP and CD59 
mRNAs were seen in endothelial cells and fibroblasts. Fibroblasts from 
normal and inflamed synovium expressed a greater preponderance of the 
highest molecular size CD59 mRNA species than endothelial cells. In 
contrast, endothelial cells expressed a greater relative abundance of the 
lower molecular size species of DAF mRNA than fibroblasts. 
Furthermore, MCP occurs as a doublet in RNA from endothelial cells but 
not in fibroblast RNA. These data suggest that there are cell-specific 
differences in the processing of the pre-mRNAs encoding these regulatory 
proteins. Tissue-specific polymorphism of MCP has been demonstrated 
and shown to be due to differential splicing (Russel et al., 1992). It is not 
known whether the larger mRNA species have to be processed further 
before being translated, or they are translated both give rise to the same 
protein, or to give different proteins. Therefore, it has
yet to be determined whether the tissue-specific differences in the 
abundances of the various mRNA species for DAF, MCP and CD59 have 
an effect on the expression or the activity of the protein products. It will
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be important to sequence the different mRNA species for each of these 
proteins in order to gain some insight into the nature of each of them.
Recently, investigators have shown that the abundances of the 
various species of CD59 mRNA differ between brain, liver, lung and 
placenta (Kumar et al., 1993). In the same study they also suggested an 
exclusive relationship between the expression of SP-40,40, CD59 and 
DAF in normal tissues: tissues showing abundant SP-40,40 mRNA had 
low abundances of CD59 and DAF mRNAs, and vice versa. There may be 
a positive or negative feed-back mechanism between cells controlling the 
expression of different regulatory complement proteins. Cells may 
interact with each other to obtain the levels of regulatory proteins 
sufficient to protect themselves and surrounding cells in the tissue from 
the lytic activation of complement system. Further studies need to be 
performed to determine interactions among cells for the expression of the 
complement regulatory proteins.
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4.6. GENERAL CONCLUSIONS
The results obtained in this study indicated that tissues from 
synovial membrane from normal individuals, osteoarthritis and 
rheumatoid arthritis patients synthesize all regulatory complement 
proteins: Cl-INH, C4-bp, factor H, factor I, S protein, SP-40,40, DAF, 
MCP, CD59 and MIP. This shows:
1) Locally synthesized complement regulatory components could regulate 
complement activation in normal and inflamed synovial joints.
2) Complement regulatory protein synthesis is a constitutive function of 
cells and such synthesis does not require the presence of inflammation.
Membrane-bound proteins DAF, MCP, CD59 and MIP were 
expressed in all cells. Thus^even when activation may not be inhibited in 
the fluid-phase, the ubiquitous presence of these membrane regulatory 
proteins should provide a tight control of complement activation.
IFNy regulates the control of complement activation by increasing 
secretion of the fluid-phase proteins although further work must be 
undertaken to confirm this observation.
The extrahepatic synthesis of complement regulatory proteins at 
sites of inflammation may play a major role the protection of host cells
from the lytic attack of complement. Furthermore, manipulation of the 
expression of the genes encoding the regulatory proteins by IFNy may be 
helpful in down-regulating inflammation and reducing tissue damage.
However, the results obtained in my experiments were determined 
under in vitro conditions and may not necessarily reflect the in vivo 
situation.
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The work described in this thesis contributes to the understanding 
of the regulation of Complement system in normal and inflamed tissues. 
The following studies should be undertaken as a continuation of this 
work.
1. In situ hybridization and immunohistochemistry of normal and 
rheumatoid synovial tissues to show which cells synthesize the 
complement regulatory proteins in vivo.
2. Studies of the cell-specific differences in the expression of the different 
mRNA species for DAF, MCP and CD59 should be performed in order to 
understand the processing of each of these mRNAs and in order to 
determine whether differences in the structure, level of expression and 
function of the protein are dependent on the cell-specific differences in 
the relative abundances of different mRNA species
3. In terms of understanding the regulation of the expression of the 
complement genes the transcriptional and post-transcriptional effects of 
cytokines on each gene in different cell types must be evaluated.
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